Oregon’s ‘Operation Table Rock’ busts hemp operators growing marijuana

Oregon’s ‘Operation Table Rock’ busts hemp operators growing marijuana
Oregon’s ‘Operation Table Rock’ busts hemp operators growing marijuana

Oregon regulators say more than 110 licensed hemp operations were found to be illegally growing high-THC marijuana after a recent crackdown in Jackson and Josephine…

Read More


#CBD #Hemp

Oregon’s ‘Operation Table Rock’ busts hemp operators growing marijuana


September 28, 2021 9:44 am

Hemp Oil Entry Deleted from the EU Feed Materials Catalog

Hemp Oil Entry Deleted from the EU Feed Materials Catalog

Hemp oil entry is deleted from the European catalog of feed materials, while hemp seed oil and hemp silage definitions are included. The Catalogue now also includes an entry for hemp products derived from any part of the plant except the flowering tops.

The European Commission’s Standing Committee on Plants, Animals, Food and Feed (SCOPAFF), representing EU governments and public authorities has discussed the entries in the European catalog of feed materials. As a result, the entries have been updated.

As reported by the EIHA in their newsletter, the Member States decided to take a precautionary approach in particular with regards to hemp oil, to avoid the marketing of feed materials with a possible functional effect. Hence, all products issued from flowering tops, flowers, buds, and blossoms are excluded from the Catalogue.

The placing on the market and use of feed is regulated at the EU level by regulation 767/2009. This regulation establishes the Catalogue as a tool to improve the labeling of feed materials and compound feed. It is meant to facilitate the exchange of information on the product properties and list feed materials in a non-exhaustive manner. The use of the Catalogue by the feed business operators is voluntary. However, the name of a feed material listed in the Catalogue may be used only on the condition that all relevant provisions of the Catalogue are complied with.

The newly included entry for hemp products derived from any part of the plant except the flowering tops is very general and broad, the EIHA concludes. The comparative table of the entries before and after the changes can be found here.

The topic will be further discussed in the Working Group on food and food supplements on October 7th.

Hemp webpage

Also, hemp now has its page on the European Commission’s website, which EIHA greets as another step towards the full normalization of the plant as an agricultural crop in Europe and higher visibility for the sector.

According to the European Commission, the area dedicated to hemp cultivation has increased significantly in the EU from 19,970 hectares (ha) in 2015 to 34,960 ha in 2019 (a 75% increase). In the same period, the production increased from 94,120 tonnes to 152,820 tonnes (a 62.4% increase). France is the largest producer, accounting for more than 70% of EU production, followed by the Netherlands (10%) and Austria (4%).

Considering the growing interest in hemp fiber, the Commission will propose a comprehensive EU strategy for sustainable textiles aiming to create a more sustainable, innovative, circular economic model.

Furthermore, on its new webpage, the Commission states that only de-hulled seeds serve as food for human consumption, while whole seeds should be used as feed for animals.

Improving energy efficiency in the building sector will play a key role in achieving carbon-neutrality by 2050, a goal set out in the European Green Deal. Hemp can play a significant role in reaching this objective, states the Commission.

Hemp could be used to produce paper, acknowledges the Commission. There are multiple advantages to using hemp fiber to make paper: hemp stalks only take up to five months to mature, the paper does not necessarily require toxic bleaching chemicals and it can be recycled seven to eight times.

As for CBD products, the Commission places them in the ‘Other uses’ section, recognizing the interest in production and marketing due to its multiple uses in cosmetics, health, and food. The Commission recognizes the decision of the Court of Justice of the European Union, which determined that the marketing of legally produced CBD is permitted under EU law.

The post Hemp Oil Entry Deleted from the EU Feed Materials Catalog appeared first on ilesol.


#CBD #Hemp

Hemp Oil Entry Deleted from the EU Feed Materials Catalog


September 27, 2021 11:32 am

Hemp Oil Entry Deleted from the EU Feed Materials Catalog

Hemp Oil Entry Deleted from the EU Feed Materials Catalog

Hemp oil entry is deleted from the European catalog of feed materials, while hemp seed oil and hemp silage definitions are included. The Catalogue now also includes an entry for hemp products derived from any part of the plant except the flowering tops.

The European Commission’s Standing Committee on Plants, Animals, Food and Feed (SCOPAFF), representing EU governments and public authorities has discussed the entries in the European catalog of feed materials. As a result, the entries have been updated.

As reported by the EIHA in their newsletter, the Member States decided to take a precautionary approach in particular with regards to hemp oil, to avoid the marketing of feed materials with a possible functional effect. Hence, all products issued from flowering tops, flowers, buds, and blossoms are excluded from the Catalogue.

The placing on the market and use of feed is regulated at the EU level by regulation 767/2009. This regulation establishes the Catalogue as a tool to improve the labeling of feed materials and compound feed. It is meant to facilitate the exchange of information on the product properties and list feed materials in a non-exhaustive manner. The use of the Catalogue by the feed business operators is voluntary. However, the name of a feed material listed in the Catalogue may be used only on the condition that all relevant provisions of the Catalogue are complied with.

The newly included entry for hemp products derived from any part of the plant except the flowering tops is very general and broad, the EIHA concludes. The comparative table of the entries before and after the changes can be found here.

The topic will be further discussed in the Working Group on food and food supplements on October 7th.

Hemp webpage

Also, hemp now has its page on the European Commission’s website, which EIHA greets as another step towards the full normalization of the plant as an agricultural crop in Europe and higher visibility for the sector.

According to the European Commission, the area dedicated to hemp cultivation has increased significantly in the EU from 19,970 hectares (ha) in 2015 to 34,960 ha in 2019 (a 75% increase). In the same period, the production increased from 94,120 tonnes to 152,820 tonnes (a 62.4% increase). France is the largest producer, accounting for more than 70% of EU production, followed by the Netherlands (10%) and Austria (4%).

Considering the growing interest in hemp fiber, the Commission will propose a comprehensive EU strategy for sustainable textiles aiming to create a more sustainable, innovative, circular economic model.

Furthermore, on its new webpage, the Commission states that only de-hulled seeds serve as food for human consumption, while whole seeds should be used as feed for animals.

Improving energy efficiency in the building sector will play a key role in achieving carbon-neutrality by 2050, a goal set out in the European Green Deal. Hemp can play a significant role in reaching this objective, states the Commission.

Hemp could be used to produce paper, acknowledges the Commission. There are multiple advantages to using hemp fiber to make paper: hemp stalks only take up to five months to mature, the paper does not necessarily require toxic bleaching chemicals and it can be recycled seven to eight times.

As for CBD products, the Commission places them in the ‘Other uses’ section, recognizing the interest in production and marketing due to its multiple uses in cosmetics, health, and food. The Commission recognizes the decision of the Court of Justice of the European Union, which determined that the marketing of legally produced CBD is permitted under EU law.

The post Hemp Oil Entry Deleted from the EU Feed Materials Catalog appeared first on ilesol.


#CBD #Hemp

Hemp Oil Entry Deleted from the EU Feed Materials Catalog


September 27, 2021 11:32 am

PubMed: Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms

PubMed: Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms

Cannabis Cannabinoid Res. 2021 Sep 27. doi: 10.1089/can.2021.0058. Online ahead of print.

ABSTRACT

Introduction: Cannabigerol (CBG), and its precursor before decarboxylation, cannabigerolic acid is sometimes labeled the “mother of all cannabinoids.” The purpose of the present study was to investigate reasons for use and self-reported therapeutic effects in CBG-predominant cannabis users. Usage patterns and adverse effects, including withdrawal symptoms were also explored. Methods: Cannabidiol-predominant cannabis users were recruited online to complete an online survey assessing CBG use patterns, conditions treated with CBG-predominant cannabis (containing >50% CBG), perceived efficacy, associated adverse events, and withdrawal symptoms. One hundred twenty-seven eligible participants (U.S. residents ages 21+ who reported using CBG-predominant cannabis in the past 6 months) completed the survey. Results: Most of the samples (n=65; 51.2%) reported use of CBG-predominant products solely for medical purposes (n=46; 36.2% reported use for medical and recreational purposes; n=8; 6.3% reported recreational use only, and n=8 were missing). The most common conditions the complete sample reported using CBG to treat were anxiety (51.2%), chronic pain (40.9%), depression (33.1%), and insomnia/disturbed sleep (30.7%). Efficacy was highly rated, with the majority reporting their conditions were “very much improved” or “much improved” by CBG. Furthermore, 73.9% claimed superiority of CBG-predominant cannabis over conventional medicines for chronic pain, 80% for depression, 73% for insomnia, and 78.3% for anxiety. Forty-four percent of CBG-predominant cannabis users reported no adverse events, with 16.5% noting dry mouth, 15% sleepiness, 11.8% increased appetite, and 8.7% dry eyes. Around 84.3% reported no withdrawal symptoms, with sleep difficulties representing the most frequently endorsed withdrawal symptom (endorsed by two respondents). Conclusions: This is the first patient survey of CBG-predominant cannabis use to date, and the first to document self-reported efficacy of CBG-predominant products, particularly for anxiety, chronic pain, depression, and insomnia. Most respondents reported greater efficacy of CBG-predominant cannabis over conventional pharmacotherapy, with a benign adverse event profile and negligible withdrawal symptoms. This study establishes that humans are employing CBG and suggests that CBG-predominant cannabis-based medicines should be studied in randomized controlled trials.

PMID:34569849 | DOI:10.1089/can.2021.0058

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34569849/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210928065915&v=2.15.0 September 27, 2021 10:00 am

PubMed: A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?

PubMed: A Systematic Review of Fibromyalgia and Recent Advancements in Treatment: Is Medicinal Cannabis a New Hope?

Cureus. 2021 Aug 20;13(8):e17332. doi: 10.7759/cureus.17332. eCollection 2021 Aug.

ABSTRACT

Fibromyalgia syndrome (FMS) is a pain disorder characterized by chronic widespread pain, fatigue, and sleep disturbance, in the absence of any well-defined underlying organic disease. The exact pathophysiology and the mechanism which links different factors related to the disease is still unknown. Due to unknown precise pathogenesis, the coexistence of other diseases, and overlapping clinical features, FMS diagnosis may be laborious. Various treatment strategies are used, only a few Food and Drug Administration (FDA) approved, still we are facing challenges regarding effective treatment. Recently, medicinal cannabis has proven to be effective in chronic pain conditions such as osteoarthritis, neuropathic pain, and other non-cancer chronic pain. However, further research is needed about how the cannabinoid system works with the pain pathway. Using the fact that medicinal cannabis is effective in the treatment of chronic pain and certain rheumatic diseases, in this review, we aim to analyze the role of the cannabinoid system in fibromyalgia syndrome. We followed Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines in searching PubMed, MEDLINE (through PubMed), PubMed Central, and Google Scholar using keywords “fibromyalgia, chronic pain, cannabis, cannabinoids, pharmacotherapy, alternative therapy” and Medical Subject Heading (MeSH) words. After applying inclusion/exclusion criteria and checking for the quality assessment, 22 articles were retrieved and used for the analysis of the role of cannabis in the treatment of fibromyalgia. The two main compounds of cannabis with analgesic and anti-inflammatory properties are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), and their ratio determines the effect on various symptoms of FMS. We included studies regarding the use of cannabinoids in the treatment of fibromyalgia, investigating the use of nabilone, dronabinol (a synthetic analog of THC), Bedrocan (22.4 mg THC, <1 mg CBD), Bediol (13.4 mg THC, 17.8 mg CBD), and Bedrolite (18.4 mg CBD, <1 mg THC). In the era of the coronavirus disease 2019 (COVID-19) pandemic and opioid crisis, many adverse outcomes are observed in the patients suffering from FMS due to lack of any definitive treatment and promising outcomes from the known treatment options, which led to the need for effective and safer treatment alternatives. Although the studies reviewed in this article suggest that medical cannabis is a safe and effective treatment for fibromyalgia pain, several limitations regarding dosage, length of treatment, adverse effects, long-term follow-up, and dependence needs further investigation.

PMID:34567876 | PMC:PMC8451533 | DOI:10.7759/cureus.17332

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34567876/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210927065837&v=2.15.0 September 27, 2021 10:00 am

Marijuana policy reading

Marijuana policy reading

Drafting a pamphlet: “What North Carolinians Need To Know About Marijuana Money.” Here’s what I’m thinking for background reading references:  

For marijuana issues generally, I don’t know a better place to start than Mark Kleiman’s Marijuana Legalization:  What Everyone Needs to Know (2d ed. 2016, with Caulkins and Kilmer, under $20), which inspired the title here.  A more technical 2015 analysis by Kleiman and others for the State of Vermont is in the public domain at https://www.rand.org/pubs/research_reports/RR864.html.

Kleiman’s work is a little dated; a recent multi-author issue of the B.U. Law Review provides a good update in the public domain. https://www.bu.edu/bulawreview/2021/07/14/volume-101-number-3-may-2021/.

For an ideological prohibitionist view, the group Smart Approaches to Marijuana, https://learnaboutsam.org, provides online material and offers a book for sale.  

An anti-prohibition view is thought through in a free online book by the U.K. Transform Drugs Foundation: https://transformdrugs.org/publications/how-to-regulate-cannabis-a-practical-guide


#CBD #Hemp
Marijuana policy reading
September 25, 2021 2:25 pm

PubMed: The Current and Potential Application of Medicinal Cannabis Products in Dentistry

PubMed: The Current and Potential Application of Medicinal Cannabis Products in Dentistry

Dent J (Basel). 2021 Sep 10;9(9):106. doi: 10.3390/dj9090106.

ABSTRACT

Oral and dental diseases are a major global burden, the most common non-communicable diseases (NCDs), and may even affect an individual’s general quality of life and health. The most prevalent dental and oral health conditions are tooth decay (otherwise referred to as dental caries/cavities), oral cancers, gingivitis, periodontitis, periodontal (gum) disease, Noma, oro-dental trauma, oral manifestations of HIV, sensitive teeth, cracked teeth, broken teeth, and congenital anomalies such as cleft lip and palate. Herbs have been utilized for hundreds of years in traditional Chinese, African and Indian medicine and even in some Western countries, for the treatment of oral and dental conditions including but not limited to dental caries, gingivitis and toothaches, dental pulpitis, halitosis (bad breath), mucositis, sore throat, oral wound infections, and periodontal abscesses. Herbs have also been used as plaque removers (chew sticks), antimicrobials, analgesics, anti-inflammatory agents, and antiseptics. Cannabis sativa L. in particular has been utilized in traditional Asian medicine for tooth-pain management, prevention of dental caries and reduction in gum inflammation. The distribution of cannabinoid (CB) receptors in the mouth suggest that the endocannabinoid system may be a target for the treatment of oral and dental diseases. Most recently, interest has been geared toward the use of Cannabidiol (CBD), one of several secondary metabolites produced by C. sativa L. CBD is a known anti-inflammatory, analgesic, anxiolytic, anti-microbial and anti-cancer agent, and as a result, may have therapeutic potential against conditions such burning mouth syndrome, dental anxiety, gingivitis, and possible oral cancer. Other major secondary metabolites of C. sativa L. such as terpenes and flavonoids also share anti-inflammatory, analgesic, anxiolytic and anti-microbial properties and may also have dental and oral applications. This review will investigate the potential of secondary metabolites of C. sativa L. in the treatment of dental and oral diseases.

PMID:34562980 | DOI:10.3390/dj9090106

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34562980/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210926065914&v=2.15.0 September 25, 2021 10:00 am

Hemp Cake As An Alternative Ingredient For Sustainable Meat?

Hemp Cake As An Alternative Ingredient For Sustainable Meat?

The hemp plant is one of the most versatile plants on earth, with humans having made use of the hemp plant for centuries for many purposes.

As hemp advocates will be quick to point out, the hemp plant has the ability to clothe, feed, and in many cases heal. It’s a truly amazing crop.

Hemp grows much faster than most trees and can even be used to decontaminate soil, especially soil that is contaminated with heavy metals.

Food-products made from hemp are particularly popular among consumers, including hemp milk and hemp seed. 

The results of a recent study could one day lead to hemp being in even more things that we eat.

Evolving Consumer Demands

Many consumers are becoming more conscious about what they eat, and understandably so. What we eat plays a very important role in our overall health.

Sustainability is another major concern, and so it is no coincidence that consumers are increasingly looking for sustainable meat products.

Sustainable meat is specifically created via regenerative practices and processes with the goal of lowering meat’s carbon footprint.

Producing sustainable meat involves the addition of various ingredients for storage purposes to help preserve the meat, among other things. Hemp is one of those ingredients.

Hemp Cake As A Sustainable Meat Ingredient?

Researchers recently conducted a study in which they examined hemp cake, a by-product of cold pressing oil from hemp seeds, as an alternative ingredient in sustainable meat.

They specifically looked at hemp cake’s impact “on the physicochemical and textural properties, oxidation, and sensory acceptance of cooked and vacuum-packed meatballs during refrigerated storage”

“The addition of 7.4% hemp cake enhanced the amount of dry matter and reduced the content of water. Lightness (L*) and redness (a*) values reduced significantly with higher levels of hemp supplementation.” the researchers stated.

“The results indicate that hemp cake, a material considered mainly as waste, may be destined for food purposes and be an alternative ingredient for the production of sustainable meat products.” the authors concluded.


#CBD #Hemp
https://cannatechtoday.com/hemp-cake-as-an-alternative-ingredient-for-sustainable-meat/
September 24, 2021 11:00 am

PubMed: Synthesis, characterization and stress-testing of a robust quillaja saponin stabilized oil-in-water phytocannabinoid nanoemulsion

PubMed: Synthesis, characterization and stress-testing of a robust quillaja saponin stabilized oil-in-water phytocannabinoid nanoemulsion

J Cannabis Res. 2021 Sep 23;3(1):43. doi: 10.1186/s42238-021-00094-w.

ABSTRACT

BACKGROUND: This study describes the design, optimization, and stress-testing of a novel phytocannabinoid nanoemulsion generated using high-pressure homogenization. [Formula: see text], a plant-derived commercial emulsifier containing quillaja saponin, was used to stabilize the lipid phase droplets in water. Stress-testing was performed on this nanoemulsion in order to evaluate its chemical and colloidal stability under the influence of different environmental factors, encompassing both physical and chemical stressors.

METHODS: Extensive optimization studies were conducted to arrive at an ideal nanoemulsion formulation. A coarse emulsion containing 16.6 wt% CBD-enriched cannabis distillate and 83.4 wt% carrier (soybean) oil dispersed in 10 wt% [Formula: see text] (1.5 wt% quillaja saponin) solution after 10 homogenization cycles at a pressure of 30,000 psi produced a stable nanoemulsion. This nanoemulsion was then subjected to the stress studies.

RESULTS: The optimized nanoemulsion had an average droplet diameter of ca. 120 nm and average droplet surface ζ potentials of ca. -30 mV. It was imaged and characterized by a variety of protocols. It proved to be stable to droplet agglomeration and phase separation upon storage under ambient conditions for 6 weeks, as well as under a variety of physical stressors such as heat, cold, dilution, and carbonation. pH values ≤2 and moderately high salt concentrations (> 100 mM), however, destabilized the nanoemulsion, eventually leading to phase separation. Cannabis potency, determined by HPLC, was detrimentally affected by any changes in the nanoemulsion phase stability.

CONCLUSIONS: Quillaja saponin stabilized cannabidiol(CBD)-enriched nanoemulsions are stable, robust systems even at low emulsifier concentrations, and are therefore significant from both a scientific as well as a commercial perspective.

PMID:34556180 | DOI:10.1186/s42238-021-00094-w

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34556180/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210924065841&v=2.15.0 September 24, 2021 10:00 am

Danish agro operators join to pursue expansion in hemp foods

Danish agro operators join to pursue expansion in hemp foods
Danish agro operators join to pursue expansion in hemp foods

Two Danish farming enterprises have agreed to join forces, hoping to capitalize on hemp’s potential in the rapidly-growing plant-based foods sector. Denmark-based international farming co-op…

Read More


#CBD #Hemp

Danish agro operators join to pursue expansion in hemp foods


September 23, 2021 7:33 am

Lean Management in a Cannabis Lab

Lean Management in a Cannabis Lab

Lean management or Lean thinking is a process for continuous improvement that can be applied to any business. Most frequently Lean is attributed to the manufacturing sector due to its origins in Japan at the Toyota Motor Company. Lean originated in post-war Japan where resources were scarce as the country rebuilt itself after World War II. The scarcity of resources forced the Japanese to do more with less which manifested itself within the Toyota organization as the Toyota Production System from which Lean originated.

Today, Lean thinking is being applied to every industry and we believe that the cannabis industry, and in particular laboratories, can benefit tremendously from its principals.

What Is Lean and How Does it Apply to Cannabis?

Lean thinking is a set of powerful tools for any business or organization that wants to be the best in their industry and deliver superior value their customers. This is especially relevant to the fast-growing cannabis and hemp testing industry where customers demand fast turnaround times and error-free results.

The reason that Lean applies to all businesses and especially the cannabis industry is because of its focus is on eliminating waste. Waste comes in many forms including defects, waiting time, extra motion, excess inventory, transportation, over production, over processing and underutilized talent.

Companies that adopt Lean management eliminate waste using a wide variety of tools that help surface issues and eliminate the root causes. When companies eliminate waste, they simultaneously improve both their speed and quality, two attributes that customers really care about. Given the fast-changing nature of the cannabis industry and differences state by state, we believe that using Lean thinking to eliminate waste is critical to being a top performing business in the cannabis industry.

One important tool that many businesses begin with is known as 5S or 6S. At our laboratory we recently implemented 6S to organize both our office and laboratory spaces. 6S is a process improvement tool that stands for Sort, Set in Order, Shine, Standardize, Sustain and Safety. The process involves each technician or analyst assessing their areas and asking critical questions such as: Can I easily reach everything I need for this test or process? Is there wasted motion due to the placement of items within the lab? Can I easily tell how much consumable inventory I have on hand at a glance?

This process also helps improve safety because the workspace is better organized, easier to navigate and designed with safety in mind. Each person is responsible for maintaining their workspace and regular audits by rotating teammates, helping drive continuous improvement to our 6S. It is a fundamental process for any business starting to adopt Lean thinking.

Another very helpful process that any cannabis business can implement is the Gemba walk. Gemba is the Japanese word for “actual place” and refers to the place in a business where value is created for the customer. Value in our cannabis business is created in our testing lab. By improving everything in our testing lab we improve our quality and speed for our customers. In our laboratory we begin the Gemba walk as a team reviewing our key performance indicators (KPIs). From there, the management team visits each station to review additional KPIs and discuss any issues that group may be having. We try to surface issues, however small they may be, so that they are solved and hopefully eliminated. This process is key to helping us keep a pulse on the lab, engaging employees and better understand the improvements that need to be made.

How to Implement Lean Processes

labsphoto
Without quality results, a testing laboratory does not really have a product or service to offer

Lean thinking is a very accessible set of tools. Unfortunately, it is quite difficult to implement because of the dedication that it requires. Implementing Lean and changing the culture requires a significant amount of time, investment in training and management commitment. Time and capital for training can be scarce at some businesses in the cannabis industry. For the businesses with capital, it is extremely important that management commit to implementing Lean and changing their culture. Without the support of the executive team most businesses stop implementing new procedures and revert to how they are used to operating. It is also common for changes in management to result in lean becoming deprioritized in place of a new initiative.

If the executive team is inexperienced in Lean management, it will be important to find a Lean consultant that can guide the training and events. A Lean consultant should be able to provide you with thorough training on each tool and help your business implement them in real time to improve the business. The training and knowledge gained during these events are extremely valuable and practical tools that every employee can use.

Results From Implementing a Lean Organization

If a business is able to successfully implement Lean management the results for their customers can be dramatic. In the laboratory setting, turnaround times will be reduced, and more importantly, will remain consistent despite fluctuations in sample volume. Faster turnaround times for cannabis companies means that they can bring inventory to market faster which can be critical for supply constrained businesses.

Additionally, implementing Lean helps reduce the number of errors, rework and retests so the quality of the results for the customer is dramatically improved. Root cause issues are solved, processes are updated and then shared with the entire team so that everyone can learn and benefit from the improvement. Without quality results, a testing laboratory does not really have a product or service to offer so it is critical to get it right every time.

All areas of the cannabis industry are becoming more competitive, and it is important for every business to make sure they can stay competitive considering changing market dynamics. Lean management has helped businesses in other industries stand apart from the rest and we believe that the cannabis industry will be no different. Academic literature has studied and documented the positive impact that Lean has on businesses globally. Lean management has repeatedly shown that businesses that can truly implement Lean thinking in everything that they do will have an inherent advantage because they’ll be faster, more agile, higher quality, more efficient and focused entirely on creating value for their customer.

The post Lean Management in a Cannabis Lab appeared first on Cannabis Industry Journal.


#CBD #Hemp

Lean Management in a Cannabis Lab


September 22, 2021 3:41 pm

Native American alliance hopes to spark cannabis on tribal lands

Native American alliance hopes to spark cannabis on tribal lands
Native American alliance hopes to spark cannabis on tribal lands

The Native American Cannabis Alliance (NACA) said it signed memoranda of understanding with indigenous farmers from three Native American tribes as it looks to spur…

Read More


#CBD #Hemp

Native American alliance hopes to spark cannabis on tribal lands


September 21, 2021 11:40 am

Now Seeking Leaders in Sustainability

Now Seeking Leaders in Sustainability

There’s no argument that the cannabis industry has made some serious global strides in the past few years. 

For many people, the act of purchasing cannabis out in the open in dispensaries that resemble Apple stores is still hard to comprehend. 

While it’s an exciting time, it’s an industry that needs sustainable solutions for many of its sectors. Cultivation, packaging, and retail businesses all have room to improve their environmental stewardship.

Fortunately, the cannabis industry is still fairly young. According to research conducted by New Frontier Data, the legal cannabis market will continue to grow and is expected to reach $43 billion by 2025. 

This industry is only going to get larger, which means there’s an opportunity to make positive, sustainable changes that will impact the world. 

Seeking Sustainable Leaders

The cannabis plant is incredibly eco-friendly, so how can we reflect that with more responsible production practices? One company working for change is Tiny E Paper Company.

Tiny E Paper produces 100% pure hemp paper from hemp stalks and pre- and post-extraction waste from CBD. During a presentation at the Emerge Virtual Cannabis Conference, Founder and CEO Erica Halverson emphasized the importance of sustainable leadership.

“We have a really awesome opportunity and responsibility right now, and we cannot squander that by doing it the wrong way. We have a chance to really be a model for the world right now in what sustainability means, and what it means in practice, rather than just saying it,” said Halverson. 

We are still very much a budding industry. By carrying out sustainable practices we can help build global trust and cleaner medicine, while also helping the world.

The 2021 Sustainable Leadership Awards

Cannabis & Tech Today partnered with Regennabis for this year’s Sustainable Leadership Awards to highlight individuals and businesses making sustainable practices foundational for their work in the industry.

We’re using the United Nation’s Sustainable Development Goals as a guide to help define what it means to build a sustainable business model.

The awards are seeking applicants using sustainable practices in several sectors, from water conservation and eco-friendly packaging to social impact and the cannabis event with the smallest carbon footprint. 

Nine different categories showcase how broad the term sustainability is and how a company can make an impact in a variety of ways. 

Categories include: water conservation, energy use, innovation, packaging, stewardship, event impact, ESG, social impact, and SDGs. Learn more with this link.

Companies Changing the Game

Since starting the Sustainable Leadership Awards in 2019, we have showcased innovative, game-changing companies, taking what it means to “go green” to another level. 

During the 2019 award ceremony, which took place MJBizCon in Las Vegas, Cannabis & Tech Today CEO Charles Warner explained why the awards were created.

“We realized that sustainability is something that is incredibly important for this burgeoning industry and it’s up to us to take charge and lead the way, because if we don’t do it, it’s going to be forced upon us in regulations. It’s our sandbox to really push the envelope towards sustainability,” said Warner. 

We have had a lot of amazing winners over the years, many of whom have continued to excel since being awarded their custom engraved plaque. 

Companies like LumiGrow, Surna Packaging, Polyscience, and Solar Therapeutics – just to name a few.

If those names look familiar, it’s because not only are they doing amazing work, they’ve been featured in an issue of Cannabis & Tech Today, another prize awarded to each award winner. 

Solar Therapeutics Director of Marketing and Communications Derek Gould offered advice to operators looking to become more sustainable after the company’s win. If overwhelmed, take it step-by-step. 

“You don’t have to go all-in on sustainability right off the bat. There’re a lot of low-hanging fruit and very easily implemented, inexpensive ways, and procedures that can make your facility at least start to be a little bit more sustainable. It’s imperative we start really considering this approach to cultivating cannabis,” said Gould. 

How to Apply

If your company deserves to be recognized for mastering eco-friendly practices, giving back to your community, or being an example of conservation, we would love to learn more about you. 

Any cannabis business operating in accordance with state and local regulations in North America may apply. 

All applications must be submitted by October 10, 2021. Apply here.

Each entry is $199. One entry per category. 

Winners will be awarded a custom plaque, a profile in Cannabis & Tech Today, and a spotlight session at our Emerge Virtual Cannabis Conference & Expo. 

Being sustainable is a team effort and the pandemic only made it more evident how well this industry works together.

We can’t wait to see which inspiring companies will apply for this year’s Cannabis & Tech Today Sustainable Leadership Awards. Sign up for the Cannabis & Tech Today newsletter to stay up to date.


#CBD #Hemp
https://cannatechtoday.com/cannabis-techs-sustainability-leadership-awards-taking-applications/
September 21, 2021 11:00 am

Ilesol Pharmaceuticals Launches New Cosmetics Line Skin Greens

Ilesol Pharmaceuticals Launches New Cosmetics Line Skin Greens

Ilesol Pharmaceuticals is launching a new cosmetics line Skin Greens.

Skin Greens is a product collection for healthy and natural skin nutrition based on CBD and high-quality natural herbal active ingredients in functional pharmaceutical formulations.

Skin Greens are formulated to be used daily for healthier, smoother, and more beautiful skin. And beyond.

Ilesol Pharmaceuticals is GMP certified for cosmetics – ISO 22716 and holds ISO 9001 certificate.
The company is in the process of implementing Hazard analysis and critical control points (HACCP) and HRN EN ISO 22000:2018 Food safety management systems. We are putting quality first. Food certification is in our focus, since we are very close to Novel food approval in the UK, and in the process of registration in the EU.

Our mission is the highest quality in CBD production and control in every stage of the production process. We control the full production process from biomass to ingredient and final product, which is done in our facility in Varazdin. We guarantee transparency and full traceability throughout our production process. We provide top-quality products using interprocess analytics and highly regarded third-party testing.

Skin Greens

Until recently the company has been more focused on bulk and white-labeled products. We have launched our cosmetic line Skin Greens, under our brand.

The Skin Greens line includes After Shave & Face Cream, Face Cream, After Depilation Lotion, and Body Lotion.

The following products are in our coming soon category: CBD Muscle & Joint Thermal Gel, CBD Muscle & Joint Cooling Gel, and Ultra-Relief CBD Salve.

Skin Greens Face Cream combines a high concentration of cannabidiol and MSM for a moisturizing, balancing, and stimulating effect. Enriched with jojoba oil, shea butter, panthenol, allantoin, and aloe vera, the cream deeply hydrates and nourishes the skin, prevents drying, and contributes to the revitalization of skin firmness and natural glow.

Skin Greens Body Lotion combines cannabidiol, arnica montana flower extract, and MSM for moisturizing, energizing, and stimulating effects. The rich, nourish#ing formula with extra virgin olive oil, almond and sunflower oils, as well as shea butter absorbs into the skin with ease, deeply nourishes, and provides an extremely relaxing effect on muscles and joints.

Skin Greens 2-in-1 After Shave & Face Cream combines a high concentration of cannabidiol, arnica montana flower extract, and MSM for a soothing, revitalizing, and stimulating effect. It is enriched with extra virgin olive oil, almond oil, shea butter, and glycerin, which simultaneously soothes the skin after shaving, hydrates, nourishes, and restores the skin’s natural healthy glow.

Skin Greens After Depilation Lotion combines a high concentration of cannabidiol, arnica montana flower extract, and MSM for soothing, revitalizing, and stimulating effect. The light texture of the lotion easily applies to the skin, quickly absorbs, and soothes redness and irritation after depilation.

Extra virgin olive oil, almond oil, shea butter, and glycerin deeply nourish the skin, restore the necessary skin moisture, protect from drying out and stimulate regeneration.

Skin Greens products are dermatologically tested by an independent third-party laboratory. The products are formulated with plant-based ingredients only that have not been tested on animals by a supplier, producer, or any third-party entity.

Besides cosmetics, we produce a wide range of CBD/CBG products and ingredients.
So far, our best-selling products are Natural CBD Oils ranging from 2.5 to 20% CBD. The wax removal process used in Ilesol Pharmaceuticals’ natural oil formulations distinguishes us in quality of product from the majority of the market.

Our offer also includes Natural CBG oils, Purified CBD/CBG oils, Pure CBD/CBG oils, CBD/CBG Purified Extract, High Terpenes CBD extract, CBD/CBG isolate, CBD/CBG Crumble, CBD/CBG Terpsolate, and CBD E-Liquid base.

We provide private label services, with our CBD oils and other products made exclusively for specific clients. Our company is open to custom-made business solutions, and we have broad experience in various formulation production.

About Ilesol Pharmaceuticals

Ilesol Pharmaceuticals is an industrial scale producer of full-spectrum CBD and non-detectable THC products. The company was founded in 2017 by two experts in pharmaceutical process engineering and optimization, medicinal plants extraction methods, active compounds isolation, hemp processing, cultivation, breeding, and optimization. In the first year, we were providing services for big industry players. We launched our first products in early 2018. From the start, we are committed to providing our clients with specifically formulated products. This business model made us 1st European cannabinoid à la carte company.

Our revenue in 2019, the pre-COVID year, was 3.6 M €, which made us one of the fastest-growing companies in Croatia.

In 2019 we have acquired a new production facility of 3.400 m2 in Varazdin, Croatia, where we have set up our proprietary and novel production process.

We are primarily focused on b2b sales and contract manufacturing.

Our policies are close cooperation with partners, full reliability and transparency, total commitment to quality and production.

The post Ilesol Pharmaceuticals Launches New Cosmetics Line Skin Greens appeared first on ilesol.


#CBD #Hemp

Ilesol Pharmaceuticals Launches New Cosmetics Line Skin Greens


September 21, 2021 8:52 am

Leaders in Cannabis Formulations: Part 4 – LifeTonic

Leaders in Cannabis Formulations: Part 4 – LifeTonic

Russell is the CEO of NES Technology Holdings, a technology development and marketing company that operates Vapor Distilled and LifeTonic Brands. NES Technology Holdings has invented a technology portfolio of more than 160 granted and pending patents that cover inventions across several high-value industries, including cannabis, beverage, fragrance and nutraceuticals. The company is currently in license acquisition diligence processes with 7 of world’s 10 largest fragrance companies and has received a joint venture offer from a $3 billion fragrance company to produce perfumes with its extraction technology. It is also launching ionized cannabis beverage products that provide effects as quickly as alcohol in Nevada and Colorado this fall.

Vapor Distilled invented and commercialized an evaporative extraction process with 40 international patents granted and pending that, along with CO2 extraction, is one of only two fundamentally new extraction processes invented in the last 50 years. Instead of using solvents or hydrocarbons to extract oils from plants, evaporative extraction directly evaporates essential oils from plants and condenses the evaporated compounds into an extract. The process takes less than two seconds to complete and extracts higher levels of volatile terpenes than existing extraction methods. Vapor Distilled has built a fleet of commercial-scale extraction machines and has supplied some of the cannabis industry’s largest brands. The company is currently licensing its evaporative extraction technology within the perfume industry and is marketing an aroma hop extract to replace the dry hopping step when making beer.

LifeTonic invented a drug delivery technology with 56 patents pending and granted, that turns oil-based plant compounds like CBD and THC into electrically charged cannabinoid ions that dissolve completely in water without emulsifiers or additives. When cannabinoids are ionized, absorption is significantly enhanced and their effects can be felt in minutes. The effects of a LifeTonic ionized CBD beverage can be felt by most people in less than 5 minutes, whereas the effects of a LifeTonic ionized THC beverage can be felt by most people in less than 8 minutes. For reference, typical onset times for cannabis beverages are 30 minutes or longer. LifeTonic beverage technology will allow cannabis beverages to work as quickly as alcohol, enabling cannabis to become a social drink.

Russell Thomas, CEO of Vapor Distilled and LifeTonic

We spoke with Russell Thomas, CEO of Vapor Distilled and LifeTonic about his cannabinoid evaporation process and rapid onset beverage technologies. Thomas is a career entrepreneur and inventor with 21 years of experience inventing and protecting intellectual property. Russell’s team has generated more than 160 granted and pending patents. Prior to entering the cannabis industry, Thomas worked in the cleantech industry.

Aaron Green: How did you get involved in the cannabis industry?

Russell Thomas: I came to the cannabis industry from the cleantech industry where I worked on technologies that improved the fuel economy of vehicles. I saw opportunities in the cannabis industry to improve cannabis extraction, which was one of the most important supply chain verticals in cannabis. Every product, from edibles to beverages and vape products, requires a cannabis extract. Any product that needs to be accurately dosed requires an extract. The old way of making edible products with cannabis butter was simply not viable as the industry matured, and most people were rapidly moving away from smoking cannabis and embracing vape products. Even with the entire industry almost completely dependent on extraction, no fundamental innovation was occurring. The primary ways that cannabis was being extracted were chemically intensive. The cleaner methods, such as CO2 extraction, were slow and expensive for terpene recovery. I saw this as a great opportunity to provide a better solution within a primary funnel of the cannabis supply chain.

We commercialized an extraction technology that evaporates cannabinoids directly from plant material in the form of vapor, and then recondenses that vapor back into an essential oil. The entire process takes less than two seconds to complete and preserves fragile terpenes. That technology, called Evaporative Extraction, is the foundation of Vapor Distilled.

Green: What timeframe was that roughly?

Thomas: We capitalized our company in 2015 and began selling wholesale extracts in 2017.

Green: Can you talk more about the evaporative extraction process?

Thomas: Our process works in a similar way to a cannabis vaporizer, but on a massive scale. Our extract is literally recondensed cannabis vapor. In one step, we extract, refine, and activate cannabinoids. On one end, plant material goes in the machine, and on the other end, extract and depleted plant material comes out. Our total extraction time is less than two seconds if you measure the time from when the plant material goes into the extractor and when the extract is condensed.

The LifeTonic logo

A continuous feed of dry plant material is introduced into a heated air stream. The air stream pneumatically conveys the plant material through a series of turbulent, heated evaporation chambers. Upon entering the evaporation chambers, volatile plant compounds are instantaneously distilled from the plant material. A centrifugal separator removes the depleted plant material from the air stream. The air stream is rapidly cooled, causing the volatile plant compounds to condense into an essential oil.

We achieve nearly total activation of THCA to THC simultaneously during extraction and, on average, we extract approximately two to four times more terpenes than a conventional extraction process. The cannabis industry is rampant with exaggeration about terpenes, but we are the only cannabis company negotiating a joint venture with a $3 billion fragrance company to produce perfumes, and I think that says a lot about our process.

Green: Is the extract coming out then as an oil?

Thomas: Our extract comes out of our machines as a fully-activated, high-terpene content, full spectrum oil. Unlike the THC crude that emerges from other processes, our extract requires no further distillation, activation or refinement. You can put it straight into a product.

Green: How about terpene recovery?

Thomas: This is by far what we do best. We excel with the recovery terpenes and volatile compounds from plant material. From day one, we noticed that our evaporative extraction process yields about two to four times more terpenes by mass compared to traditional extraction methods.

While we started as a cannabis company, we recently received a compelling joint venture offer from a $3 billion fragrance company to produce perfume products with our technology. We are also under NDA with 7 of the world’s 10 largest fragrance companies to complete diligence processes to license our extraction technology.

As part of our licensing diligence process, we are performing paid fragrance extraction research for three multi-billion-dollar fragrance companies. Our evaporative extracted fragrance extracts are presenting a broader and more complete range of volatile compounds compared reference samples. We are also seeing substantially improved yield of volatile fragrance compounds. Combined, this gives us the advantage of being able to produce more extract at a lower cost, while also producing a superior product. This combination is how licensees can take market share away from any fragrance company that does not have access to our technology, and it is why we are seeing so much rapid traction in this area.

We have also extracted hops with our technology. If you’ve ever smelled a traditional hops resin, it smells good, but the smell doesn’t fill the room. If you put just a drop of our hops extract on any surface, the entire room will smell strongly of a premium IPA beer. It’s so potent you don’t want to get it on your hands or clothes because you will smell like beer for hours. It’s powerful and wonderful stuff!

Green: What is your business model?

Thomas: At our core, we are a technology development and licensing company. We first identify what we believe to be critical verticals and bottlenecks in high-value industries, then we develop and patent highly differentiated and disruptive technology solutions that we believe exist nowhere else. We then demonstrate both market fit and viability at scale through proof-of-concept sales of branded and high-profile, white-labeled products produced with our unique technologies. Finally, we systematically license and exit the various portions our IP portfolio though the orchestration of highly competitive bidding processes that promote both defensive and strategic acquisitions of our technologies. We are currently at the final phase of our model with licensing our extraction technology, and we are receiving offers as part of a competitive bidding process.

Green: Okay, let’s change gears here and start talking more about LifeTonic and your cannabinoid ionization technology. Can you talk high level about the onset times of cannabinoids in different matrices and media?

Thomas: Through LifeTonic, we invented 56 international patents granted and pending cannabinoid ionization technology that compresses the normal onset time of cannabis beverages from 30 minutes down to just a few minutes. Our cannabinoid ionization technology can also be used as a rapid onset vape alternative when sold in a breath spray format. We are currently selling hemp-based versions of these products through LifeTonic.com, and we are bringing THC versions of these products to market in Nevada and Colorado this fall and winter under the brand name LifeTonic.

All conventional and even nano-emulsified cannabis edibles and beverages take a long time to work. A cannabis chocolate can take 45 minutes to two hours before the effects kick in. Cannabis gummies are faster, but it still takes half an hour to 45 minutes to feel the effects. The very best nano-emulsified cannabis beverages take about a half an hour to work on average, if you are lucky. That long of a time delay effectively eliminates the social aspect of consuming cannabis, so most people instead choose to vaporize or smoke cannabis.

If you look at the largest investments that have been made across cannabis, some of the most prominent have been made by alcohol companies. Constellation Brands invested nearly $4 billion into Canopy Growth, with a mission to find an alternative to alcohol in cannabis. Molson Coors has partnered with Hexo and AB InBev has partnered with Tilray, both with that same mission. Even after all this effort and investment, cannabis beverages represent just a sliver of the market because current cannabis-based beverages take too long to work. The fastest ones on the market, on average, take around a half hour to kick in.

Imagine going to a bar and knowing that every time you got a shot of tequila or a shot of whiskey it’s going to take thirty minutes or more for the effects to even begin to kick in. That would be terrible. That would be the end of social drinking. Unfortunately, that is how a conventional cannabis beverage works.

You can’t really get a social drinking experience with cannabis yet, so most people vape it because it’s fast. But a lot of people don’t want to smoke something; in fact, they don’t want to inhale at all. So, we saw beverages as a huge opportunity. How do we make cannabis beverages work as fast as alcohol? That’s what our ionization technology delivers. From all the people we’ve surveyed – hundreds of people – they say that they reliably feel an onset within about seven to eight minutes with our technology. That is just about as fast as a shot of tequila or whiskey.

“With our partners, we will be featuring LifeTonic beverage products on tap in a cannabis cocktail lounge right off the Las Vegas strip, where social consumption rules are welcoming.”What we’ve done is very different from available nanoemulsion technologies. All those technologies try to mix oil and water, and oil and water don’t mix. In a nanoemulsion, you mix cannabis, a carrier oil, an edible detergent and water, and then you run it all through an ultrasonic homogenizer that breaks the cannabinoids and oil into microscopic droplets suspended in water. There are a lot of styles of nanoemulsions, from spray-dried nanoemulsions to liquid liposomal encapsulations, and they all confer certain absorption benefits when compared to straight-up oil absorption. But still, even the microscopic oil droplets suspended in water are quite large compared to what we have done, and still take quite a long time to digest.

We looked at the cannabis molecule and we said, “You know what? If we can put a strong negative charge on it, if we can ionize it, then we can make it behave more like a dissolvable salt instead of an oil.” When we treat it this way, the cannabis molecule dissolves completely in the water without emulsifiers or additives. When something is dissolved, there is no nano-emulsion droplet size. It is single molecules dissolved water. A single ionized cannabinoid molecule is about 1,000 times smaller than an average nano-emulsion droplet – and this greatly enhances absorption. The onset speed of ionized cannabinoids compared to nanoemulsions is measurable as just a few minutes instead of a half hour or more.

We have 56 granted and pending patents on LifeTonic’s ionization technology. We can ionize THC, CBD, CBG and CBD – most cannabinoids are compatible. There are also several herbal products that are compatible with our ionization technology, like the curcuminoids in turmeric, which are normally very hard to get into water. We can also ionize the eugenol that is in cloves. Ionized eugenol is an intoxicant, so we have big plans for alcohol alternatives outside of cannabis.

We’re using this technology to enter the Nevada cannabis market with one of the largest dispensary chains and cannabis product manufacturers in Nevada. With our partners, we will be featuring LifeTonic beverage products on tap in a cannabis cocktail lounge right off the Las Vegas strip, where social consumption rules are welcoming. We’ll craft every kind of cocktail you can imagine, only without alcohol. All these beverages will work in a matter of minutes to provide the first true social drinking experience with cannabis. After you enjoy a beverage, you may purchase a package of ionized THC beverage powder sachets in the cannabis cocktail lounge or at any of the dispensaries within our distribution network. You can pour the powder into any beverage, and it becomes a friendly, fast-acting THC beverage that will get you high, but not leave you with a hangover. We will also be selling a breath-spray format that works almost as quickly as vaping.

Green: What kind of validation studies have you done?

Thomas: We have conducted several broad market studies for our ionized products and almost all people report a profound onset within a few minutes. We have not completed a formalized clinical trial, but we are closing a major funding round that will allow us to do so. We plan to begin controlled pre-clinical trials focused mainly on ionized CBD because it’s far easier to get FDA approval for clinical trials on CBD than for THC. Our studies will monitor a couple dozen volunteers with a functional MRI and watch the change in the brain using our oral spray and beverage products compared against a standard CBD tincture control. We know that we’re going to see fast action because everybody who uses it says that a feeling develops in minutes.

Green: What geographies are you active in and exploring?

Thomas: CBD and hemp products from our extraction technology have been sold in every US state and parts of Europe. Additionally, hemp-based CBD and CBG versions of our ionized products and ionized turmeric products have been sold in several states through our LifeTonic.com, our ecommerce site. We have also sold white labeled versions of our ionized products through partner brands. We will be launching THC versions of our ionized products with our partners Nevada this fall. We expect THC versions to also be available in Colorado this winter.

Green: So, you are creating the powders on site?

Thomas: Yes. We manufacture ionized CBD, CBG, eugenol and turmeric beverage powders on site. We also manufacture and fast acting ionized sprays. These products are sold through our own retail site and we white label for other brands. Per our long-term licensing strategy, these sales establish market viability through sales. Selling products and establishing market viability prior to licensing significantly increases the value of our licenses and exits. It’s very important to answer the question: Do people buy it and do people love it? So far, we like the feedback!

On the THC side, we manufacture ionized products through partners in each cannabis state that we enter. We manufacture the ionizing base here in Colorado, then we ship it to other states where our partners add the THC and package it in LifeTonic-branded packaging. The analogy is that we sell a proprietary Coca-Cola formula without the caffeine, then our partners add the caffeine and bottle it in Coca-Cola branded bottles. In this way, we ensure that the hardest part of our process is controlled house to ensure consistency and quality across all states. It also allows us to be a non-plant touching business, since we only sold upstream base products that did not contain THC. We pick the best manufacturing and distribution partner in each cannabis state and grow from there.

Green: What’s the one thing you’re most interested in learning about?

Thomas: Increasing the bioavailability of cannabis. I have been most passionate about making cannabis work as quickly as alcohol and giving people an alternative to inhaling it through smoking or vaping. That’s definitely what we’ve been most excited about as a company.

Green: Okay, great. That concludes the interview!

Thomas: Thank you Aaron!

The post Leaders in Cannabis Formulations: Part 4 – LifeTonic appeared first on Cannabis Industry Journal.


#CBD #Hemp

Leaders in Cannabis Formulations: Part 4 – LifeTonic


September 20, 2021 8:48 pm

PubMed: Molecular and Biochemical Insights Into Early Responses of Hemp to Cd and Zn Exposure and the Potential Effect of Si on Stress Response

PubMed: Molecular and Biochemical Insights Into Early Responses of Hemp to Cd and Zn Exposure and the Potential Effect of Si on Stress Response

Front Plant Sci. 2021 Sep 3;12:711853. doi: 10.3389/fpls.2021.711853. eCollection 2021.

ABSTRACT

With the intensification of human activities, plants are more frequently exposed to heavy metals (HM). Zinc (Zn) and cadmium (Cd) are frequently and simultaneously found in contaminated soils, including agronomic soils contaminated by the atmospheric fallout near smelters. The fiber crop Cannabis sativa L. is a suitable alternative to food crops for crop cultivation on these soils. In this study, Cd (20 μM) and Zn (100 μM) were shown to induce comparable growth inhibition in C. sativa. To devise agricultural strategies aimed at improving crop yield, the effect of silicon (Si; 2 mM) on the stress tolerance of plants was considered. Targeted gene expression and proteomic analysis were performed on leaves and roots after 1 week of treatment. Both Cd- and Zn-stimulated genes involved in proline biosynthesis [pyrroline-5-carboxylate reductase (P5CR)] and phenylpropanoid pathway [phenylalanine ammonia-lyase (PAL)] but Cd also specifically increased the expression of PCS1-1 involved in phytochelatin (PC) synthesis. Si exposure influences the expression of numerous genes in a contrasting way in Cd- and Zn-exposed plants. At the leaf level, the accumulation of 122 proteins was affected by Cd, whereas 47 proteins were affected by Zn: only 16 proteins were affected by both Cd and Zn. The number of proteins affected due to Si exposure (27) alone was by far lower, and 12 were not modified by heavy metal treatment while no common protein seemed to be modified by both CdSi and ZnSi treatment. It is concluded that Cd and Zn had a clear different impact on plant metabolism and that Si confers a specific physiological status to stressed plants, with quite distinct impacts on hemp proteome depending on the considered heavy metal.

PMID:34539703 | PMC:PMC8446647 | DOI:10.3389/fpls.2021.711853

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34539703/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210921065914&v=2.14.5 September 20, 2021 10:00 am

3 Tips for Partnering With a Hemp Inspection Lab

3 Tips for Partnering With a Hemp Inspection Lab

After spending their early careers in a third-generation, family-owned testing laboratory for commodity grains, Kia Adams-Mikesh and Mark Adams, along with their father and grandfather, Mike and Steve Adams, turned their attention toward hemp.

They realized there was a need for unbiased third-party testing laboratories and decided to bring their expertise to the budding hemp industry.

The brother-sister team launched Adams Independent Testing (AIT) in 2019 with a focus on providing Certificates of Analysis (COAs) to buyers and sellers of hemp, testing for potency, pesticides, heavy metals, mycotoxins, terpenes, microbials, and more. 

Especially in the hemp industry, quick turnaround times and attention to customer service are essential.

Existing wait times for results were often between one and four weeks — unacceptable for formulators, processors, and farmers who cannot afford to let biomass languish in a barn or warehouse, waiting for their COA.

When preparing for your hemp inspection, here are three things to look for:

Understand your state’s regulations.

Buyers and sellers of any commodity often choose to pursue certificates to prove their product is free from contaminants such as pesticides, heavy metals or mold.

The USDA has laid the foundation for hemp regulation, such as making sure the THC level is below 0.3%.

Still, variances are common when it comes to state regulations. Some states only have regulations for finished products, while others only regulate smokable hemp.

Other states have no regulations at all.

In such a new industry, the rules are always changing. Choosing to test for as many contaminants as possible helps ensure the highest quality product from start to finish.

Sample your product correctly.

While there are standard regulations for grain sampling, hemp sampling best practices lag behind.

One common example has to do with biomass stored in large plastic totes.

Many people will simply scoop biomass from the top of one tote, which does not give a representative sample.

Instead, use a probe or other sampling apparatus to get all the way to the bottom of the tote, then the middle, and finally the top.

The other key is to sample from multiple totes, which might represent different fields or strains.

This “bottom, middle, top” method works for extracts, too.

Know how to read your COA.

It’s one thing to receive a COA and another thing to decipher it. There’s no governing standard for consistency among testing results, and different labs handle and represent data differently. 

Hemp buyers and sellers must look at the “limits of quantification,” which refers to how closely laboratories test for particular analytes, such as THC.

One lab may set 0.01% as the limit of quantification, while another may use 1% for the same analyte.

The second lab wouldn’t detect a reading for anything under 1%, even if the THC measured above the USDA’s limit of 0.3%.

The test isn’t technically fraudulent, but it’s a red flag.

Cannabis labs, for example, likely don’t usually set limits of quantification as low as 0.3%.

In this type of situation, partnering with an unbiased third-party lab offers an important advantage. ϖ

Learn more at https://hempinspection.com or follow on Instagram at @hempinspection.


#CBD #Hemp
https://cannatechtoday.com/3-things-to-know-when-partnering-with-a-hemp-inspection-lab/
September 17, 2021 11:00 am

Czech Republic Sets 1% THC Limit

Czech Republic Sets 1% THC Limit

On September 14, Czech MEPs adopted an amendment to the law on addictive substances, accepting 1% THC in hemp products, reported Magazin Konopí. The amendment got support from more than 101 MPs, which was more than required. It will come into effect on 1 January next year.

“Thank you all for your support and don’t worry: We won’t forget about psychoactive cannabis for the personal needs of adults. We will fight for its availability in the next election period, no matter how the elections turn out”, commented Tomáš Vymazal, Member of the Parliament of the Czech Republic and Deputy of the Pirate Party, who supported the amendment.

After Switzerland, Czech Republic is the first European country to legalize 1%THC in hemp.

“Many countries are 1% already, including Switzerland and Australia. Europe is ready for 1%, that’s why I saw as a waste of political capital for EIHA to push for 0.3%, desperate for an easy win to prove relevance. Not testing THC for approved varieties is what I’ve been advocating for years, since government certification should count for SOMEthing”, commented Richard Rose, Legend Hemp and Vegan food pioneer.

The original version of the bill will now be submitted to President Miloš Zeman for his signature. If he approves the amendment, it will take effect on Jan. 1, 2022.

“This is a package of pragmatic measures, free from dogmatism and stereotyping, which are unfortunately still fundamental obstacles for Czech policy in the field of addictive behavior”, Vymazal stated on the party website, reported 420Intel.

He said that growers will not have to worry about criminalization due to nice weather and other growing conditions, as the THC level in the final product cannot be predicted in advance.
“Farmers growing varieties of industrial hemp from the common European catalog will not have to prove the THC content of hemp plants – they will only submit a certificate of origin,” he said.

The daft of the amendment sent to the president states that hemp extracts and tinctures containing up to 1 percent THC will not be regarded as an addictive substance.

“All cannabis extracts that have a THC content of up to 1 percent by weight and which at the same time do not have narcotic effects will be completely exempted from the substance abuse regime,” Vymazal stated.

“This means that, for example, an ointment made from a non-narcotic variety of cannabis will no longer be an addictive substance, although it contains THC and although the original cannabis plant may have exceeded 1 percent THC. Due to the dilution of the active substances during the production of the ointment, an extract is created, which will not be an addictive substance in the sense of the law,” he added.

The post Czech Republic Sets 1% THC Limit appeared first on ilesol.


#CBD #Hemp

Czech Republic Sets 1% THC Limit


September 17, 2021 7:20 am

5 Cosas que Debe Saber Sobre el Delta-8 Tetrahidrocannabinol – Delta-8 THC

5 Cosas que Debe Saber Sobre el Delta-8 Tetrahidrocannabinol – Delta-8 THC 5 Cosas que Debe Saber Sobre el Delta-8 Tetrahidrocannabinol – Delta-8 THC Anonymous (not verified) Thu, 09/16/2021 – 12:02

Detailed Description
Los productos de Delta-8 THC no están aprobados por la FDA y pueden ponerle en riesgo.

Audience

Topics
Public Awareness

English

El delta-8 tetrahidrocannabinol, también conocido como Delta-8 THC, es una sustancia psicoactiva que se encuentra en la planta de Cannabis sativa, de la que la marihuana y el cáñamo son dos variedades. El Delta-8 THC es uno de más de 100 cannabinoides producidos naturalmente por la planta de cannabis, pero no se encuentra en cantidades significativas en la planta de cannabis. Por ello, las cantidades concentradas de Delta-8 THC se fabrican normalmente a partir de cannabidiol (CBD) derivado del cáñamo.

Es importante que los consumidores sepan que los productos de Delta-8 THC no han sido evaluados ni aprobados por la FDA para su uso seguro en ningún contexto.  Pueden comercializarse de forma que ponen en peligro la salud pública y, sobre todo, deben mantenerse fuera del alcance de los niños y las mascotas. 

A continuación, se presentan 5 cosas que debe saber sobre el Delta-8 THC para mantenerse a usted y a sus seres queridos protegidos de productos que pueden suponer graves riesgos para la salud:

1. Los productos de Delta-8 THC no han sido evaluados ni aprobados por la FDA para su uso seguro y pueden comercializarse de forma que ponen en riesgo la salud pública.

La FDA está consciente de la creciente preocupación sobre los productos de Delta-8 THC que se venden actualmente en línea y en las tiendas. Estos productos no han sido evaluados ni aprobados por la FDA para su uso seguro en ningún contexto. Algunas de las preocupaciones incluyen la variabilidad en las formulaciones y las etiquetas de los productos, el contenido de otros cannabinoides y terpenos, y las concentraciones variables de Delta-8 TCH. Además, algunos de estos productos pueden estar etiquetados simplemente como “productos de cáñamo”, lo que puede confundir a los consumidores que asocian “cáñamo” con “no psicoactivo”. Además, la FDA está preocupada por la proliferación de productos que contienen Delta-8 THC y se comercializan para usos terapéuticos o médicos, aunque no hayan sido aprobados por la FDA. La venta de productos no aprobados con afirmaciones terapéuticas sin fundamento no sólo constituye una infracción de la ley federal, sino que también puede poner en riesgo a los consumidores, ya que no se ha demostrado que estos productos sean seguros o eficaces. Esta comercialización engañosa de tratamientos no probados plantea importantes problemas de salud pública porque los pacientes y otros consumidores pueden utilizarlos en lugar de las terapias aprobadas para tratar enfermedades graves e incluso mortales.

2. La FDA ha recibido informes de eventos adversos relacionados con productos que contienen Delta-8 THC.

Desde diciembre de 2020 hasta julio de 2021, la FDA recibió informes de eventos adversos tanto de consumidores como de las fuerzas policiales que describían a 22 pacientes que consumieron productos con Delta-8 THC; de ellos, 14 se presentaron en un hospital o sala de emergencias para recibir tratamiento después del consumo. De los 22 pacientes, 19 experimentaron efectos adversos tras consumir productos alimenticios que contenían Delta-8-THC (por ejemplo, brownies, gomitas). Los eventos adversos incluyeron vómitos, alucinaciones, problemas para mantenerse en pie y pérdida de conciencia.  

Los centros nacionales de control de envenenamiento recibieron 661 casos de exposición a productos con Delta-8-THC entre enero de 2018 y el 31 de julio de 2021, 660 de los cuales ocurrieron entre el 1 de enero de 2021 y el 31 de julio de 2021. De los 661 casos de exposición:

  • El 41% implicó una exposición no intencional al Delta-8-THC y el 77% de estas exposiciones no intencionales afectaron a pacientes pediátricos menores de 18 años.
  • El 39% afectó a pacientes pediátricos menores de 18 años.
  • El 18% requirió hospitalizaciones, incluyendo niños que requirieron ingreso en la unidad de cuidados intensivos (ICU, por sus siglas en inglés) tras la exposición a estos productos.

3. El Delta-8 THC tiene efectos psicoactivos y embriagantes.

El Delta-8 THC tiene efectos psicoactivos y embriagantes, similares a los del Delta-9 THC (es decir, el componente responsable del “subidón” que pueden experimentar las personas al consumir cannabis). La FDA está al tanto de los informes de los medios de comunicación sobre productos con Delta-8 THC que hacen que los consumidores estén “drogados”.  La FDA también está preocupada por el hecho de que los productos con Delta-8 THC probablemente expongan a los consumidores a niveles de la sustancia mucho más elevados que los que se dan de forma natural en los extractos crudos de cáñamo. Por lo tanto, no se puede confiar en el uso histórico del cannabis para establecer un nivel de seguridad para estos productos en los seres humanos.   

4. Los productos de Delta-8 THC a menudo implican el uso de productos químicos potencialmente dañinos para crear las concentraciones de Delta-8 THC que se afirman en el mercado.

La cantidad natural de Delta-8 THC en el cáñamo es muy baja, y se necesitan productos químicos adicionales para convertir otros cannabinoides del cáñamo, como el CBD, en Delta-8 THC (es decir, conversión sintética). Las preocupaciones con este proceso incluyen:

  • Algunos fabricantes pueden utilizar productos químicos domésticos potencialmente nocivos para fabricar Delta-8 THC mediante este proceso de síntesis química. Se pueden utilizar productos químicos adicionales para cambiar el color del producto final. El producto final de Delta-8 THC puede tener subproductos potencialmente dañinos (contaminantes) debido a los productos químicos utilizados en el proceso, y hay incertidumbre con respecto a otros contaminantes potenciales que pueden estar presentes o producirse dependiendo de la composición de la materia prima inicial. Si se consumen o inhalan, estas sustancias químicas, incluidas algunas utilizadas para fabricar (sintetizar) el Delta-8 THC y los subproductos creados durante la síntesis, pueden ser perjudiciales.
  • La fabricación de productos de Delta-8 THC puede llevarse a cabo en entornos no controlados o antihigiénicos, lo que puede dar lugar a la presencia de contaminantes nocivos u otras sustancias potencialmente dañinas.   

5. Los productos de Delta-8 THC deben mantenerse fuera del alcance de los niños y las mascotas.

Los fabricantes están envasando y etiquetando estos productos de forma que puedan resultar atractivos para los niños (gomitas, chocolates, galletas, dulces, etc.).  Estos productos pueden comprarse en línea, así como en una variedad de establecimientos, incluyendo tiendas de conveniencia y gasolineras, donde puede que no haya límites de edad sobre quién puede comprar estos productos. Como se ha comentado anteriormente, se han producido numerosas alertas de centros de control de envenenamiento que implican a pacientes pediátricos que estuvieron expuestos a productos que contienen Delta-8-THC. Además, los centros de control de envenenamiento de animales han indicado un fuerte aumento general de la exposición accidental de las mascotas a estos productos. Mantenga estos productos fuera del alcance de los niños y las mascotas.

¿Por qué está notificando la FDA al público sobre el Delta-8 THC?

Una combinación de factores ha llevado a la FDA a proporcionar a los consumidores esta información. Estos factores incluyen:

  • Un aumento de los informes de eventos adversos a la FDA y a los centros de control de envenenamientos del país.
  • La comercialización, incluida la comercialización en línea de productos que resulta atractiva para los niños.
  • Preocupación por la contaminación debida a los métodos de fabricación que en algunos casos pueden utilizarse para elaborar productos comercializados de Delta-8 THC. 

La FDA está trabajando activamente con socios federales y estatales para seguir abordando las preocupaciones relacionadas con estos productos y vigilando el mercado en busca de quejas sobre los productos, eventos adversos y otros productos emergentes derivados del cannabis de potencial preocupación. La FDA advertirá a los consumidores sobre problemas de salud pública y seguridad, y tomará medidas, cuando sea necesario, cuando los productos regulados por la FDA infrinjan la ley.

Cómo reportar quejas y casos de exposición accidental o eventos adversos:

Si cree que tiene un efecto secundario grave que supone un peligro inmediato para su salud, llame al 9-1-1 o la sala de emergencias de su localidad. Se alienta a los profesionales de la salud y a los pacientes a que comuniquen las quejas, los casos de exposición accidental y los acontecimientos adversos al programa MedWatch de Información de Seguridad y Reporte de Eventos Adversos de la FDA:

Para más información sobre el Delta-8 THC:  RED DE ALERTA DE SALUD DE LOS CDC (HAN, POR SUS SIGLAS EN INGLÉS) – añada el enlace cuando esté disponible

La Asociación Americana de Centros de Control de Envenenamientos (AAPCC, por sus siglas en inglés) mantiene el Sistema Nacional de Datos sobre Envenenamientos (NPDS, por sus siglas en inglés), que alberga registros de casos no identificados de información recopilada de las personas que llamaron durante la gestión de la exposición, y llamadas de información sobre envenenamientos gestionadas por los centros de control de envenenamientos del país (PCC, por sus siglas en inglés).  Los datos del NPDS no reflejan todo el universo de exposiciones a una sustancia concreta, ya que puede haber exposiciones adicionales que no se reporten a los PCC; por lo tanto, no debe interpretarse que los datos del NPDS representen la incidencia completa de las exposiciones a cualquier sustancia en los EE. UU.  Las exposiciones no representan necesariamente un envenenamiento o sobredosis, y la AAPCC no puede verificar completamente la exactitud de cada informe.  Las conclusiones basadas en los datos del NPDS no reflejan necesariamente las opiniones de la AAPCC.
 

Image
el Delta-8 THC Tiene Graves Riesgos Para la Salud

Communication Type

Short Title
5 Cosas que Debe Saber Sobre el Delta-8 Tetrahidrocannabinol – Delta-8

Source Organization

Short Description
Los productos de Delta-8 THC no están aprobados por la FDA y pueden ponerle en riesgo.

Publish Date
Thu, 09/16/2021 – 18:05

Review Date
Fri, 09/16/2022 – 12:00

Last Reviewed Date
Thu, 09/16/2021 – 12:00

Site Structure

Next Review Date
1 Year

Navigational Page
Off

Bulk Approved
Off

Display Short Description
Off

First Publish Date
Thu, 09/16/2021 – 12:26

Generic Boolean
Off

Language

Number of Related Information to Display
3

Add Subscription Box
On

Description
Haga clic en “Consumer Health Info” y luego marque “Artículos en español”

Email Subscription List

Header
Subscríbase a los Artículos para el Consumidor en español

#CBD #Hemp http://www.fda.gov/consumers/articulos-en-espanol/5-cosas-que-debe-saber-sobre-el-delta-8-tetrahidrocannabinol-delta-8-thc September 16, 2021 4:02 pm

Plastics startup off to fast start after raising $1 million via crowdfunding

Plastics startup off to fast start after raising $1 million via crowdfunding
Plastics startup off to fast start after raising $1 million via crowdfunding

Startup Canadian Industrial Hemp Corporation (CIHC) said has it raised more than $1 million of a $5 million dollar goal on crowdfunding site wefunder.com. Lewes,…

Read More


#CBD #Hemp

Plastics startup off to fast start after raising $1 million via crowdfunding


September 16, 2021 6:53 am

The Feds Can't Outlaw Delta-8 THC!

The Feds Can't Outlaw Delta-8 THC!

A deluge of lab-synthesized CBD isolates, favored by regulators, will devastate hemp CBD commerce by undercutting the need for plant-derived, single-molecule cannabinoids.. But it could also create new opportunities for artisanal cannabis product-makers, who craft full-spectrum THC/CBD mixtures with unique qualities that can never be fully replicated in a lab.

#CBD #Hemp https://www.projectcbd.org/politics/feds-cant-outlaw-delta-8-thc September 16, 2021 1:27 am

The Feds Can't Outlaw Delta-8 THC!

The Feds Can't Outlaw Delta-8 THC!

A deluge of lab-synthesized CBD isolates, favored by regulators, will devastate hemp CBD commerce by undercutting the need for plant-derived, single-molecule cannabinoids.. But it could also create new opportunities for artisanal cannabis product-makers, who craft full-spectrum THC/CBD mixtures with unique qualities that can never be fully replicated in a lab.

#CBD #Hemp https://www.projectcbd.org/politics/feds-cant-outlaw-delta-8-thc September 16, 2021 1:27 am

FDA Issues Warnings on Delta-8 THC Products

FDA Issues Warnings on Delta-8 THC Products

On September 14, the FDA published a consumer update on their website, seeking to educate the public and offer a public health warning on delta-8 tetrahydrocannabinol, otherwise known as delta-8 THC.

For the uninitiated, delta-8 THC is a cannabinoid that can be synthesized from cannabidiol (CBD) derived from hemp. It is an isomer of delta-9 THC, the more commonly known psychoactive cannabinoid found in cannabis. Delta-8 THC does produce psychoactive effects, though not quite as much as its better-known cousin, delta-9 THC.

FDAlogoDue to loopholes in federal and state laws, namely the 2018 Farm Bill specifying that hemp must contain less than 0.3% Delta-9 THC, delta-8 THC is technically legal across the country. It grew in popularity across the United States very quickly over the past year, largely due to online sales.

Following the surge in sales, a number of states including Colorado, Alaska, Arizona, Arkansas, Delaware, Idaho, Iowa, Mississippi, Montana, Rhode Island, Utah and Washington have implemented some form of regulation or outright ban on products containing delta-8 THC. Christopher Hudalla, president and chief scientific officer of ProVerde Laboratories, told Chemical & Engineering News that he has a lot of safety concerns about the whole delta-8 THC craze. Hudalla says he’s more concerned about the processing involved to produce it in large quantities. “These are pretty aggressive synthetic conditions that use strong acids,” Hudalla says. “They might be using strong bases to neutralize. They can use metal catalysts. I hear different people doing it different ways.”

The FDA’s consumer update included this picture at the top of the page

The FDA shares similar concerns. Their fourth point in the consumer update mentions that delta-8 THC products “often involve use of potentially harmful chemicals” in its production. They even claim that some manufacturers might be using unsafe household chemicals to synthesize delta-8 THC. “The final delta-8 THC product may have potentially harmful by-products (contaminants) due to the chemicals used in the process, and there is uncertainty with respect to other potential contaminants that may be present or produced depending on the composition of the starting raw material,” reads the FDA report.

In their consumer update, they note that between December 2020 and July 2021, they received 22 adverse event reports. Of the 22 reports, 14 were hospitalized following ingesting a delta-8 THC product. Notably, those reports included reactions consistent with symptoms from overconsumption of delta-9 THC, such as vomiting, hallucinations, trouble standing, and loss of consciousness.

The chemical structure of Delta 8 THC.

The FDA says that national poison control centers received 661 cases of delta-8 THC products, with 41% being unintentional exposure, 39% involved pediatric patients and 18% required hospitalization.

In the consumer update, they tell the public that delta-8 THC products have not been evaluated by the FDA and that they “may be marketed in ways that put the public health at risk.” This includes marketing it as a hemp product, which it is. Still though, many consumers associate hemp products with somewhat innocuous things, like CBD oil, which is mostly harmless.

The FDA also mentions in the update that delta-8 THC does have psychoactive and intoxicating effects. The FDA says they are notifying the public about the delta-8 THC due to an uptick in adverse event reports, marketing that is appealing to children and concerns regarding manufacturing with unsafe chemicals and contaminants.

The post FDA Issues Warnings on Delta-8 THC Products appeared first on Cannabis Industry Journal.


#CBD #Hemp

FDA Issues Warnings on Delta-8 THC Products


September 15, 2021 9:30 pm

PubMed: Analysis of State Cannabis Laws and Dispensary Staff Recommendations to Adults Purchasing Medical Cannabis

PubMed: Analysis of State Cannabis Laws and Dispensary Staff Recommendations to Adults Purchasing Medical Cannabis

JAMA Netw Open. 2021 Sep 1;4(9):e2124511. doi: 10.1001/jamanetworkopen.2021.24511.

ABSTRACT

IMPORTANCE: Over the last decade, cannabis has become more accessible through the proliferation of dispensaries in states that have legalized its use. Most patients using cannabis for medical purposes report getting advice from dispensaries, yet there has been little exploration of frontline dispensary staff practices.

OBJECTIVE: To describe the practices of frontline dispensary workers who interact with customers purchasing cannabis for medical purposes and assess whether dispensary practices are associated with medicalization of state cannabis laws (degree to which they resemble regulation of prescription or over-the-counter drugs) and statewide adult use.

DESIGN, SETTING, AND PARTICIPANTS: This nationwide cross-sectional survey study was conducted from February 13, 2020, to October 2, 2020, using an online survey tool. Potential respondents were eligible if they reported working in a dispensary that sells tetrahydrocannabinol-containing products and interacting with customers about cannabis purchases.

MAIN OUTCOMES AND MEASURES: Participant responses to questions about formulating customer recommendations and talking to customers about risks.

RESULTS: The 434 survey responses from 351 unique dispensaries were most often completed by individuals who identified as budtenders (40%), managers (32%), and pharmacists (13%). Most respondents reported basing customer recommendations on the customer’s medical condition (74%), the experiences of other customers (70%), the customer’s prior experience with cannabis (67%), and the respondent’s personal experience (63%); fewer respondents relied on clinician input (40%), cost (45%), or inventory (12%). Most respondents routinely advised customers about safe storage and common adverse effects, but few counseled customers about cannabis use disorder, withdrawal, motor vehicle collision risk, or psychotic reactions. A higher state medicalization score was significantly associated with using employer training (odds ratio, 1.41; 95% CI, 1.18-1.67) and physician or clinician input (odds ratio, 1.23; 95% CI, 1.05-1.43) as a basis for recommendation. Medicalization score was not associated with counseling about cannabis risks.

CONCLUSIONS AND RELEVANCE: This survey study provides insight into how frontline dispensary staff base cannabis recommendations and counsel about risks. The findings may have utility for clinicians to counsel patients who purchase cannabis, customers who want to be prepared for a dispensary visit, and policy makers whose decisions affect cannabis laws.

PMID:34524435 | DOI:10.1001/jamanetworkopen.2021.24511

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34524435/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210916065934&v=2.14.5 September 15, 2021 10:00 am

GPS and GCNC Join Forces to Build a Stronger Cannabis Industry

GPS and GCNC Join Forces to Build a Stronger Cannabis Industry

Gateway Proven Strategies (GPS.Global), a team of sustainable cannabis, hemp, and CBD consultants, recently acquired the Global Cannabis Network Collective (GCNC). 

The GCNC, founded by Chris Day and Jillian Reddish, is a growing network of cannabis professionals working to accelerate international cannabis trade.

While Day and Reddish will continue to operate the GCNC, they will also be overseeing GPS executive positions and joining the GPS Board of Directors.

Day and Reddish will assume the titles of Chief Marketing Officer and Senior Vice President for Communications, respectively. 

“The GCNC is known for a culture of C-Suite members who understand the value in knowledge shared across sectors and cultures. That understanding is also an essential ingredient in the collaborative client relationships that GPS is known for. By expanding this ecosystem of cannabis leaders, everybody wins,” said Day.

“The GCNC will continue to operate as it has but this acquisition provides more support and depth of expertise to serve the goals of GCNC members worldwide.”

Prior to founding the GCNC, Day created Project Evolve, which is a marketing think tank for small or emerging businesses to gain marketing leadership skills, business expertise, and hands-on experience within the cannabis space.

On the GCNC’s website, Day said he spent years creating trusted partnerships and now wants to collectively build an industry, supporting other businesses in the process. With the GPS partnership, Day will be doing just that.

This acquisition will open new pathways for GPS to further support the development of cannabis as an economic accelerator.

The company will be working with sizable and modest companies, well-capitalized individuals, capital fund managers, and global governments to minimize risk and responsibly maximize return.


#CBD #Hemp
https://cannatechtoday.com/gps-and-gcnc-join-forces-to-build-a-stronger-cannabis-industry/
September 15, 2021 9:00 am

Biotech processes can drill down on cannabinoids, report suggests

Biotech processes can drill down on cannabinoids, report suggests
Biotech processes can drill down on cannabinoids, report suggests

Biotechnological production processes can unveil pharmacological profiles and potential effects of cannabinoids that are present in cannabis only in small amounts, according to a new…

Read More


#CBD #Hemp

Biotech processes can drill down on cannabinoids, report suggests


September 14, 2021 11:05 am

PubMed: Enhanced Lignanamide Absorption and Antioxidative Effect of Extruded Hempseed (Cannabis sativa L.) Hull in Caco-2 Intestinal Cell Culture

PubMed: Enhanced Lignanamide Absorption and Antioxidative Effect of Extruded Hempseed (Cannabis sativa L.) Hull in Caco-2 Intestinal Cell Culture

J Agric Food Chem. 2021 Sep 14. doi: 10.1021/acs.jafc.1c04500. Online ahead of print.

ABSTRACT

Despite the latest pursuit to discover novel phenolic compounds in hempseed and its biological properties, it remains a mystery whether they can be absorbed in the human body. Extrusion treatment and extraction of the free phenolic fraction significantly (p < 0.05) improved human Caco-2 intestinal cell absorption for hempseed hull lignanamides including cannabisin B (Papp value of 1.35 × 10-5 ± 1.0 × 10-6) as compared to the bound fraction of raw hull (Papp value of 2.82 × 10-6 ± 5.2 × 10-7). Co-supplementation of the flavonoid naringenin (20 μM) further improved these absorption rates. Higher cellular antioxidant activity was observed in the free extraction fractions. Treatment with the free phenolic fraction of extruded hempseed hull (100 mg/mL) alleviated tert-butyl hydroperoxide’s (25 μM) negative effects on cell viability, intracellular malondialdehyde levels, apoptosis induction, glutathione S-transferase, and glutathione levels. RNA-sequencing with the limma method unveiled a total of 2795 differentially expressed genes in 21 day-old Caco-2 intestinal cells, suggesting the changes in cell metabolism after exposure to extruded hempseed hull extract. This study could promote the utilization of extrusion technology to improve the absorption and antioxidant capacities of bioactive phenolics in plant food processing byproducts.

PMID:34520197 | DOI:10.1021/acs.jafc.1c04500

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34520197/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210915065854&v=2.14.5 September 14, 2021 10:00 am

PubMed: The novel heptyl phorolic acid cannabinoids content in different Cannabis sativa L. accessions

PubMed: The novel heptyl phorolic acid cannabinoids content in different Cannabis sativa L. accessions

Talanta. 2021 Dec 1;235:122704. doi: 10.1016/j.talanta.2021.122704. Epub 2021 Jul 15.

ABSTRACT

The recent discovery of the novel heptyl phytocannabinoids cannabidiphorol (CBDP) and Δ9-tetrahydrocannabiphorol (Δ9-THCP) raised a series of questions relating to the presence and abundance of these new unorthodox compounds in cannabis inflorescence or derived products. As fresh inflorescence contains mainly their acid precursors, which are not commercially available, an ad hoc stereoselective synthesis was performed in order to obtain cannabidiphorolic acid (CBDPA) and Δ9-tetrahydrocannabiphorolic acid (THCPA) to be used as analytical standards for quantitative purposes. The present work reports an unprecedented targeted analysis of both pentyl (C5) and heptyl (C7) CBD- and THC-type compounds in forty-nine cannabis samples representing four different chemotypes. Moreover, the ultrahigh performance liquid chromatography coupled to high-resolution mass spectrometry-based method was applied for the putative identification of other heptyl homologs of the most common phytocannabinoid acids, including cannabigerophorolic acid (CBGPA), cannabichromephorolic acid (CBCPA), cannabinophorolic acid (CBNPA), cannabielsophorolic acid (CBEPA), cannabicyclophorolic acid (CBLPA), cannabitriophorolic acid (CBTPA), and cannabiripsophorolic acid (CBRPA).

PMID:34517579 | DOI:10.1016/j.talanta.2021.122704

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34517579/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210914065931&v=2.14.5 September 14, 2021 10:00 am

Kanha CBN Gummies Earn Recognition at 2021 High Times Northern California Cannabis Cup

Kanha CBN Gummies Earn Recognition at 2021 High Times Northern California Cannabis Cup

Each Tranquility gummy is formulated with 5 mg CBN, 5 mg CBD, 5 mg THC, and 1 mg of melatonin, in addition to relaxing terpenes and calming essential oils.

#CBD #Hemp https://www.preparedfoods.com/articles/125990-kanha-cbn-gummies-earn-recognition-at-2021-high-times-northern-california-cannabis-cup September 13, 2021 6:21 pm

Ongoing troubles over licensing lead to another arrest in Portugal

Ongoing troubles over licensing lead to another arrest in Portugal
Ongoing troubles over licensing lead to another arrest in Portugal

Prominent hemp entrepreneur, activist and businessman Hugo Monteiro was arrested on drug charges in Portugal last week amid a lingering, contentious situation between hemp businesses…

Read More


#CBD #Hemp

Ongoing troubles over licensing lead to another arrest in Portugal


September 13, 2021 12:45 pm

PubMed: Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report

PubMed: Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report

Palliat Med. 2021 Sep 11:2692163211045314. doi: 10.1177/02692163211045314. Online ahead of print.

ABSTRACT

BACKGROUND: Neuropathic symptoms have a wide variety of manifestations, ranging from pain to pruritus. Neuropathic pruritus is a type of chronic pruritus related to damaged small fibers. Cannabinoids have evidence to manage neuropathic symptoms. We present a case of refractory neuropathic pruritus that was successfully managed with the use of oral cannabinoids.

CASE PRESENTATION: A 60-year-old male with amyotrophic lateral sclerosis with ongoing pruritus despite the use of standard neuropathic therapies.

POSSIBLE COURSE OF ACTION: Sodium channel and N-methyl-D-aspartate receptor antagonists have evidence for neuropathic symptoms but can cause significant gastrointestinal side effects. Prescription cannabinoids such as nabiximol can be cost prohibitive to use in practice. Synthetic tetrahydrocannabinol products are dose limited by psychoactive side effects.

FORMULATION OF A PLAN: A balanced oral cannabinoid from a licensed producer was preferred as it has evidence for neuropathic symptoms and is generally well tolerated.

OUTCOME: The patient showed improvement to his pruritus score from 7/10 to 3/10. There was initial increased sedation but tolerance developed quickly.

LESSONS LEARNED FROM CASE: Cannabinoids are possibly safe and effective in management of neuropathic pruritus.

VIEW ON RESEARCH PROBLEMS: Additional research is needed to establish efficacy and safety.

PMID:34510973 | DOI:10.1177/02692163211045314

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34510973/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210913065829&v=2.14.5 September 13, 2021 10:00 am

PubMed: A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis

PubMed: A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis

Front Psychiatry. 2021 Aug 26;12:583211. doi: 10.3389/fpsyt.2021.583211. eCollection 2021.

ABSTRACT

“Medicinal cannabis” is defined as the use of cannabis-based products for the treatment of an illness. Investigations of cannabis compounds in psychiatric and neurological illnesses primarily focus on the major cannabinoids, cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC), which are hypothesised to benefit multiple illnesses manifesting cognitive impairment, neurodegeneration and neuro-inflammation, as well as chronic pain, epilepsy and post-traumatic stress disorder, respectively. The cannabis plant contains >500 compounds, including terpenes responsible for the flavour and fragrance profiles of plants. Recently, research has begun providing evidence on the potential use of certain plant-derived terpenes in modern medicine, demonstrating anti-oxidant, anti-inflammatory, and neuroprotective effects of these compounds. This review examined the effects of two key terpenes, pinene and linalool, on parameters relevant to neurological and psychiatric disorders, highlighting gaps in the literature and recommendations for future research into terpene therapeutics. Overall, evidence is mostly limited to preclinical studies and well-designed clinical trials are lacking. Nevertheless, existing data suggests that pinene and linalool are relevant candidates for further investigation as novel medicines for illnesses, including stroke, ischemia, inflammatory and neuropathic pain (including migraine), cognitive impairment (relevant to Alzheimer’s disease and ageing), insomnia, anxiety, and depression. Linalool and pinene influence multiple neurotransmitter, inflammatory and neurotrophic signals as well as behaviour, demonstrating psycho-activity (albeit non-intoxicating). Optimising the phytochemical profile of cannabis chemovars to yield therapeutic levels of beneficial terpenes and cannabinoids, such as linalool, pinene and CBD, could present a unique opportunity to discover novel medicines to treat psychiatric and neurological illnesses; however, further research is needed.

PMID:34512404 | PMC:PMC8426550 | DOI:10.3389/fpsyt.2021.583211

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34512404/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210914065931&v=2.14.5 September 13, 2021 10:00 am

PubMed: Cannabis and Athletic Performance

PubMed: Cannabis and Athletic Performance

Sports Med. 2021 Sep 13. doi: 10.1007/s40279-021-01505-x. Online ahead of print.

ABSTRACT

Cannabis is widely used for both recreational and medicinal purposes on a global scale. There is accumulating interest in the use of cannabis and its constituents for athletic recovery, and in some instances, performance. Amidst speculation of potential beneficial applications, the effects of cannabis and its two most abundant constituents, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), remain largely un-investigated. The purpose of this review is to critically evaluate the literature describing the effects of whole cannabis, THC, and CBD, on athletic performance and recovery. While investigations of whole cannabis and THC have generally shown either null or detrimental effects on exercise performance in strength and aerobic-type activities, studies of sufficient rigor and validity to conclusively declare ergogenic or ergolytic potential in athletes are lacking. The ability of cannabis and THC to perturb cardiovascular homeostasis warrants further investigation regarding mechanisms by which performance may be affected across different exercise modalities and energetic demands. In contrast to cannabis and THC, CBD has largely been scrutinized for its potential to aid in recovery. The beneficial effects of CBD on sleep quality, pain, and mild traumatic brain injury may be of particular interest to certain athletes. However, research in each of these respective areas has yet to be thoroughly investigated in athletic populations. Elucidating the effects of whole cannabis, THC, and CBD is pertinent for both researchers and practitioners given the widespread use of these products, and their potential to interact with athletes’ performance and recovery.

PMID:34515970 | DOI:10.1007/s40279-021-01505-x

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34515970/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210914065931&v=2.14.5 September 13, 2021 10:00 am

PubMed: Tobacco and Cannabis Use During Pregnancy

PubMed: Tobacco and Cannabis Use During Pregnancy

Am J Clin Pathol. 2021 Sep 11:aqab093. doi: 10.1093/ajcp/aqab093. Online ahead of print.

ABSTRACT

OBJECTIVES: Nicotine (NIC) use during pregnancy can influence markers used in biochemical maternal serum screening. This study was designed to determine prevalence of disclosed tobacco smokers in our patient population and to compare disclosed tobacco smoking status with the presence of serum nicotine and a common tetrahydrocannabinol (THC) metabolite.

METHODS: A deidentified dataset of disclosed smoking status for quadruple (Quad) screens was obtained. Residual serum submitted for Quad screens was obtained from frozen storage and analyzed for NIC and THC metabolites.

RESULTS: Of specimens that had corresponding responses to the smoking history question on the patient history form, 7.2% (n = 1,783 of 24,611) specified that the patient was a tobacco smoker. Of the 271 specimens biochemically analyzed for NIC and THC metabolites, disclosed tobacco smokers had the highest prevalence of detectable NIC and THC metabolites. THC product use was most prevalent in patients categorized as probable tobacco smokers based on cotinine concentrations, as well as in younger patients.

CONCLUSIONS: Prevalence and concentration of NIC and THC metabolites vary based on disclosed tobacco smoker status. Biochemical testing may increase sensitivity for the identification of NIC and THC status over self-reporting.

PMID:34508553 | DOI:10.1093/ajcp/aqab093

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34508553/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210912065921&v=2.14.5 September 11, 2021 10:00 am

PubMed: Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101

PubMed: Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101

Molecules. 2021 Sep 2;26(17):5354. doi: 10.3390/molecules26175354.

ABSTRACT

The cannabis-derived molecules, ∆9 tetrahydrocannabinol (THC) and cannabidiol (CBD), are both of considerable therapeutic interest for a variety of purposes, including to reduce pain and anxiety and increase sleep. In addition to their other pharmacological targets, both THC and CBD are competitive inhibitors of the equilibrative nucleoside transporter-1 (ENT-1), a primary inactivation mechanism for adenosine, and thereby increase adenosine signaling. The goal of this study was to examine the role of adenosine A2A receptor activation in the effects of intraperitoneally administered THC alone and in combination with CBD or PECS-101, a 4′-fluorinated derivative of CBD, in the cannabinoid tetrad, elevated plus maze (EPM) and marble bury assays. Comparisons between wild-type (WT) and A2AR knock out (A2AR-KO) mice were made. The cataleptic effects of THC were diminished in A2AR-KO; no other THC behaviors were affected by A2AR deletion. CBD (5 mg/kg) potentiated the cataleptic response to THC (5 mg/kg) in WT but not A2AR-KO. Neither CBD nor THC alone affected EPM behavior; their combination produced a significant increase in open/closed arm time in WT but not A2AR-KO. Both THC and CBD reduced the number of marbles buried in A2AR-KO but not WT mice. Like CBD, PECS-101 potentiated the cataleptic response to THC in WT but not A2AR-KO mice. PECS-101 also reduced exploratory behavior in the EPM in both genotypes. These results support the hypothesis that CBD and PECS-101 can potentiate the cataleptic effects of THC in a manner consistent with increased endogenous adenosine signaling.

PMID:34500787 | DOI:10.3390/molecules26175354

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34500787/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210911065915&v=2.14.5 September 10, 2021 10:00 am

PubMed: Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder

PubMed: Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder

J Autism Dev Disord. 2021 Sep 9. doi: 10.1007/s10803-021-05254-8. Online ahead of print.

ABSTRACT

There is increasing interest in investigating cannabis for behavioral symptoms in individuals with autism spectrum disorder (ASD). The potential role of dysregulated cannabinoid signaling contributing to the pathophysiology of ASD is an area of active investigation. Results from retrospective and uncontrolled trials of cannabis in subjects with ASD have been published, reporting both potential benefits and adverse effects. Here, we describe the clinical course of three young adult males with ASD who developed mania or psychosis after the consistent use of cannabidiol and delta-9-tetrahydrocannabinol. Caution should be utilized with cannabis use in individuals with ASD until large-scale, replicated randomized controlled trials demonstrating efficacy, safety and tolerability have been published.

PMID:34505186 | DOI:10.1007/s10803-021-05254-8

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34505186/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210911065915&v=2.14.5 September 10, 2021 10:00 am

Opponents of California law say they were ‘tricked’ on smokable hemp

Opponents of California law say they were ‘tricked’ on smokable hemp
Opponents of California law say they were ‘tricked’ on smokable hemp

Opponents of a controversial hemp bill that awaits California Gov. Gavin Newsom’s signature say final wording in the measure effectively bans smokable hemp after negotiations…

Read More


#CBD #Hemp

Opponents of California law say they were ‘tricked’ on smokable hemp


September 10, 2021 8:01 am

PubMed: Cannabidiol modulation of oxidative stress and signalling

PubMed: Cannabidiol modulation of oxidative stress and signalling

Neuronal Signal. 2021 Aug 24;5(3):NS20200080. doi: 10.1042/NS20200080. eCollection 2021 Sep.

ABSTRACT

Cannabidiol (CBD), one of the primary non-euphoric components in the Cannabis sativa L. plant, has undergone clinical development over the last number of years as a therapeutic for patients with Lennox-Gastaut syndrome and Dravet syndromes. This phytocannabinoid demonstrates functional and pharmacological diversity, and research data indicate that CBD is a comparable antioxidant to common antioxidants. This review gathers the latest knowledge regarding the impact of CBD on oxidative signalling, with focus on the proclivity of CBD to regulate antioxidants and control the production of reactive oxygen species. CBD is considered an attractive therapeutic agent for neuroimmune disorders, and a body of literature indicates that CBD can regulate redox function at multiple levels, with a range of downstream effects on cells and tissues. However, pro-oxidant capacity of CBD has also been reported, and hence caution must be applied when considering CBD from a therapeutic standpoint. Such pro- and antioxidant functions of CBD may be cell- and model-dependent and may also be influenced by CBD dose, the duration of CBD treatment and the underlying pathology.

PMID:34497718 | PMC:PMC8385185 | DOI:10.1042/NS20200080

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34497718/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210910065944&v=2.14.5 September 9, 2021 10:00 am

Legal Cannabis Stakes a Claim Toward Industrial Sustainability

Legal Cannabis Stakes a Claim Toward Industrial Sustainability

cannabis carbon neutrality

By Oliver Bennett, Special Contributor to New Frontier Data

After a summer of extreme weather events, November’s 2021 United Nations Climate Change Conference (COP26) meeting in Glasgow, Scotland, is likely to instil a sense of urgency in global business to address sustainability. Key goals of the agenda-setting event include how to secure global net-zero carbon emissions by the middle of the century, to hasten 2030 emissions-reductions targets, and protect communities and natural habitats. The meeting will finalise the Paris Agreement Rulebook, a 2015 outline of the aims for a zero-carbon future.

Clearly the event’s eventual takeaways should have significant implications for the cannabis industry, which has found some criticism for poor ecological practices and — at times observing a suboptimal approach to such industry-wide practices as diversity and corporate social responsibility. For now there is nothing to suggest that COP26 will specifically address cannabis: indeed, one British paper disappointingly suggested that the event turned down a hemp group’s bid for engagement.

For their parts, legal cannabis and hemp could, as fast-growing industries, represent beacons in the fight against climate change, with hemp products in particular offering lower carbon-emissions alternative to their industrial alternatives, including building materials, textiles, biodegradable plastics, biofuel, and automotive uses.

As noted by Dr. Michael Obersteiner, director of Oxford University’s Environmental Change Institute, cannabis “might turn out to be a land-saving crop… [which] would spare the expansion of cropland into forests. This will create substantial emission savings.” By example, hemp grows rapidly, aerates soil, and compares favourably to cotton, producing 200%-250% more fibre from the same amount of land. The British Hemp Alliance (BHA) credits hemp for “a range of environmentally friendly and carbon-negative products, while actively contributing to mitigating climate change,” adding that a “thriving domestic hemp industry can kick-start a new green industrial revolution”.

Nevertheless, the cannabis industry as a whole certainly has its sustainability challenges. Chief among such issues facing it is that cannabis cultivation is a big user of electricity in indoor growing, still the sourcing for most legal cannabis, often, requiring up to 2,000 watts of electricity per square meter (i.e., comparable to 50 watts for a cash crop like lettuce). In the U.S., it has been estimated that the industry’s footprint already accounts for more than 1% of electricity consumption, and it is rising. It can also be quite water-intensive (e.g., requiring as much as  6 gallons per plant, some suggest) – with one study concluding that by 2025, total water use in the legal cannabis market is expected to increase by 86%. Even before cannabis was legalized among some U.S. states, water diversion was a critical issue, with more than a billion gallons of water illicitly drained from public water supplies. Water use has been exhaustively addressed in New Frontier Data’s Cannabis H2O: Water Use and Sustainability in Cultivation report, which details how water efficiency is significantly influenced by one’s respective type of cultivation facility and intended annual harvests. The analysis recommends several courses of action as water use becomes ever more critical, including greater industry stewardship at large. It should be stressed that cannabis, as previously discussed in a New Frontier Data blog in March, is already the most water-economical crop among California’s top revenue crops, and represents leadership in responsible water usage. To that end, the cannabis industry should not be punitively singled out by regulators, but incentivized to increase water efficiency by encouraging transparent data reporting and sharing best practices.

Legal cannabis producers share responsibility to make their industry as ecologically friendly and carbon neutral as possible – after all, they too will be subject to extreme weather problems arising from climate change such as flooding, drought, and forest fires. Using passive solar gain and attending to water consumption by utilizing rainwater precipitation, watering at night to prevent evaporation, recapturing water, and maintaining lines and sprinklers are among viable methods to help in the efforts.

“In my opinion, the current cannabis industry is itself undergoing fundamental changes, and moving towards a far more sustainable production and cultivation,” says Harry Wildschut, CEO of Sanoid Isolates – a medical cannabis production facility in Spain acquired by Grow Group. “Sustainability is very much the top of mind, and we talk a lot about the footprint of the cannabis industry. I’m from the Netherlands, and have been exposed to an earlier way of cannabis cultivation: indoors in cellars, with buildings and light which is very expensive, and not very sustainable.”

Sanoid Isolates, says Wildschut, has taken a leap forward by growing under the Andalusian sun and in soil, rather than relying on wasteful indoor cultivation. “Our facilities use hybrid greenhouses, which allow us to grow larger quantities in soil, which means we are not faced with huge electricity consumption.”

He explains that their facilities occupy a large agricultural area. “On one side we have the large Guadalquivir River, and we’re close to the mountains of Andalusia, too. So, we have more than a sufficient supply of natural water, which means that we’re not using drinking water from water companies. As well as this, the greenhouses and irrigation system are fully automated, so we’re minimising our footprint on water usage.” He noted the attendant cost savings to be gained through the reduction of water use.

Indeed, a renewed emphasis on sustainability could well tilt the industry towards more natural growing conditions in warmer climates. “I don’t see any serious supply coming from expensive unsustainable greenhouses in Denmark, the U.K. or northern Germany,” Wildschut said. “At the end of the day, sustainable production is more likely to come from places like Andalusia.” Yet as indoor production continues, vigilance remains important for ways to improve energy usage, such as switching to LED lighting and using chilled water systems for dehumidification.

Should such beneficial factors be handled well, the cannabis industry stands to gain credence for leadership regarding sustainability.

“The industry is taking steps” Wildschut said, while noting that “there’s still sufficient ground to improve the efficacy and efficiency.” As COP26 assembles on 1 November, there is time to consider the partnership role of the legal cannabis industry, and how it can become a purposeful player in the increasingly urgent drive towards a net-zero carbon economy.

The post Legal Cannabis Stakes a Claim Toward Industrial Sustainability appeared first on New Frontier Data.

#CBD #Hemp https://newfrontierdata.com/cannabis-insights/legal-cannabis-stakes-a-claim-toward-industrial-sustainability/ September 8, 2021 11:59 pm

Legal Cannabis Stakes a Claim Toward Industrial Sustainability

Legal Cannabis Stakes a Claim Toward Industrial Sustainability

cannabis carbon neutrality

By Oliver Bennett, Special Contributor to New Frontier Data

After a summer of extreme weather events, November’s 2021 United Nations Climate Change Conference (COP26) meeting in Glasgow, Scotland, is likely to instil a sense of urgency in global business to address sustainability. Key goals of the agenda-setting event include how to secure global net-zero carbon emissions by the middle of the century, to hasten 2030 emissions-reductions targets, and protect communities and natural habitats. The meeting will finalise the Paris Agreement Rulebook, a 2015 outline of the aims for a zero-carbon future.

Clearly the event’s eventual takeaways should have significant implications for the cannabis industry, which has found some criticism for poor ecological practices and — at times observing a suboptimal approach to such industry-wide practices as diversity and corporate social responsibility. For now there is nothing to suggest that COP26 will specifically address cannabis: indeed, one British paper disappointingly suggested that the event turned down a hemp group’s bid for engagement.

For their parts, legal cannabis and hemp could, as fast-growing industries, represent beacons in the fight against climate change, with hemp products in particular offering lower carbon-emissions alternative to their industrial alternatives, including building materials, textiles, biodegradable plastics, biofuel, and automotive uses.

As noted by Dr. Michael Obersteiner, director of Oxford University’s Environmental Change Institute, cannabis “might turn out to be a land-saving crop… [which] would spare the expansion of cropland into forests. This will create substantial emission savings.” By example, hemp grows rapidly, aerates soil, and compares favourably to cotton, producing 200%-250% more fibre from the same amount of land. The British Hemp Alliance (BHA) credits hemp for “a range of environmentally friendly and carbon-negative products, while actively contributing to mitigating climate change,” adding that a “thriving domestic hemp industry can kick-start a new green industrial revolution”.

Nevertheless, the cannabis industry as a whole certainly has its sustainability challenges. Chief among such issues facing it is that cannabis cultivation is a big user of electricity in indoor growing, still the sourcing for most legal cannabis, often, requiring up to 2,000 watts of electricity per square meter (i.e., comparable to 50 watts for a cash crop like lettuce). In the U.S., it has been estimated that the industry’s footprint already accounts for more than 1% of electricity consumption, and it is rising. It can also be quite water-intensive (e.g., requiring as much as  6 gallons per plant, some suggest) – with one study concluding that by 2025, total water use in the legal cannabis market is expected to increase by 86%. Even before cannabis was legalized among some U.S. states, water diversion was a critical issue, with more than a billion gallons of water illicitly drained from public water supplies. Water use has been exhaustively addressed in New Frontier Data’s Cannabis H2O: Water Use and Sustainability in Cultivation report, which details how water efficiency is significantly influenced by one’s respective type of cultivation facility and intended annual harvests. The analysis recommends several courses of action as water use becomes ever more critical, including greater industry stewardship at large. It should be stressed that cannabis, as previously discussed in a New Frontier Data blog in March, is already the most water-economical crop among California’s top revenue crops, and represents leadership in responsible water usage. To that end, the cannabis industry should not be punitively singled out by regulators, but incentivized to increase water efficiency by encouraging transparent data reporting and sharing best practices.

Legal cannabis producers share responsibility to make their industry as ecologically friendly and carbon neutral as possible – after all, they too will be subject to extreme weather problems arising from climate change such as flooding, drought, and forest fires. Using passive solar gain and attending to water consumption by utilizing rainwater precipitation, watering at night to prevent evaporation, recapturing water, and maintaining lines and sprinklers are among viable methods to help in the efforts.

“In my opinion, the current cannabis industry is itself undergoing fundamental changes, and moving towards a far more sustainable production and cultivation,” says Harry Wildschut, CEO of Sanoid Isolates – a medical cannabis production facility in Spain acquired by Grow Group. “Sustainability is very much the top of mind, and we talk a lot about the footprint of the cannabis industry. I’m from the Netherlands, and have been exposed to an earlier way of cannabis cultivation: indoors in cellars, with buildings and light which is very expensive, and not very sustainable.”

Sanoid Isolates, says Wildschut, has taken a leap forward by growing under the Andalusian sun and in soil, rather than relying on wasteful indoor cultivation. “Our facilities use hybrid greenhouses, which allow us to grow larger quantities in soil, which means we are not faced with huge electricity consumption.”

He explains that their facilities occupy a large agricultural area. “On one side we have the large Guadalquivir River, and we’re close to the mountains of Andalusia, too. So, we have more than a sufficient supply of natural water, which means that we’re not using drinking water from water companies. As well as this, the greenhouses and irrigation system are fully automated, so we’re minimising our footprint on water usage.” He noted the attendant cost savings to be gained through the reduction of water use.

Indeed, a renewed emphasis on sustainability could well tilt the industry towards more natural growing conditions in warmer climates. “I don’t see any serious supply coming from expensive unsustainable greenhouses in Denmark, the U.K. or northern Germany,” Wildschut said. “At the end of the day, sustainable production is more likely to come from places like Andalusia.” Yet as indoor production continues, vigilance remains important for ways to improve energy usage, such as switching to LED lighting and using chilled water systems for dehumidification.

Should such beneficial factors be handled well, the cannabis industry stands to gain credence for leadership regarding sustainability.

“The industry is taking steps” Wildschut said, while noting that “there’s still sufficient ground to improve the efficacy and efficiency.” As COP26 assembles on 1 November, there is time to consider the partnership role of the legal cannabis industry, and how it can become a purposeful player in the increasingly urgent drive towards a net-zero carbon economy.

The post Legal Cannabis Stakes a Claim Toward Industrial Sustainability appeared first on New Frontier Data.

#CBD #Hemp https://newfrontierdata.com/cannabis-insights/legal-cannabis-stakes-a-claim-toward-industrial-sustainability/ September 8, 2021 11:59 pm

PubMed: Pharmacokinetic and pharmacodynamic properties of aerosolized ("vaped") THC in adolescent male and female rats

PubMed: Pharmacokinetic and pharmacodynamic properties of aerosolized ("vaped") THC in adolescent male and female rats

Psychopharmacology (Berl). 2021 Sep 8. doi: 10.1007/s00213-021-05976-8. Online ahead of print.

ABSTRACT

RATIONALE: Adolescent exposure to ∆9-tetrahydrocannabinol (THC), the psychotropic constituent of cannabis, might affect brain development, and in rodent models leads to long-term behavioral and physiological alterations. Yet, the basic pharmacology of this drug in adolescent rodents, especially when ingested via ecologically relevant routes like aerosol inhalation, commonly referred to as “vaping,” is still poorly characterized. Moreover, sex differences exist in THC metabolism, kinetics, and behavioral effects, but these have not been rigorously examined after vapor dosing in adolescents.

OBJECTIVES: We investigated the pharmacokinetics and pharmacodynamics of aerosolized THC (30 min inhalation exposure, 25 or 100 mg/ml) in adolescent Wistar rats of both sexes.

METHODS: Liquid chromatography/mass spectrometry analysis of THC and its major metabolites was conducted on blood plasma and brain tissue at 5, 30, 60, and 120 min following a 30-min aerosol dosing session. Effects on activity in a novel environment for 120 min after aerosol, and temperature, were measured in separate rats.

RESULTS: We found sex-dependent differences in the pharmacokinetics of THC and its active (11-OH-THC) and inactive (11-COOH-THC) metabolites in the blood and brain, along with dose- and sex-dependent effects on anxiety-like and exploratory behaviors; namely, greater 11-OH-THC levels accompanied by greater behavioral effects in females at the low dose but similar hypothermic effects in both sexes at the high dose.

CONCLUSIONS: These results provide a benchmark for dosing adolescent rats with aerosolized (or “vaped”) THC, which could facilitate adoption by other labs of this potentially human-relevant THC exposure model to understand cannabis effects on the developing brain.

PMID:34495367 | DOI:10.1007/s00213-021-05976-8

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34495367/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210909065841&v=2.14.5 September 8, 2021 10:00 am

Royal Blend CBD Gummies Reviews – 10 Shocking Reasons To Use It

Royal Blend CBD Gummies Reviews – 10 Shocking Reasons To Use It

Royal Blend CBD Gummies are a clinically-tested product made of natural ingredients to assist consumers in treating their stress, depression, anxiety, mental pain, chronic pain, melancholy, and other diseases of the body. 

The daily consumption of this product will boost the overall mental health of the consumers naturally. 

This product comes in the form of tasty gummies, which consumers will have to chew daily by following all the terms and conditions of the product. 

These chewable gummies are made of a natural extract of pure hemp CBD and other natural components so that users of the product can easily reduce their stress, depression, anxiety, acne, and other mental torments. 

These tasty gummies come in different colors, sizes, and shapes. 

What To Know More Click Here Royal Blend CBD Gummies

What Are Royal Blend CBD Gummies?

This is a scientifically tested formula that is composed of a variety of natural ingredients so that various mental torments of the consumers can be addressed easily and naturally. 

This CBD gummy product will provide various therapeutic benefits to the consumers so they can easily improve overall health and get rid of all kinds of pains and inflammation of the body. 

This CBD gummy is an all-natural product, which is made of natural ingredients with the help of which users can overcome all kinds of mental torments of the body. 

Royal Blend CBD Gummies are made of gelatin and various other natural substances to give a natural boost to the overall health and fitness of consumers.

 Check here Available Discount Price Royal Blend CBD Gummies

What Natural Ingredients Are Used In Making These Royal Blend CBD Gummies?

All the components used in making these CBD gummies are known to be pain-curing, effective, natural, safe, pure, and 100% free from all kinds of adulterated and toxic components. 

With the daily consumption of these CBD gummies, consumers of this product will not get high and they will not be suffering from any psychoactive effects. 

These CBD-based gummies will boost the overall health and fitness of the consumers. 

This CBD gummy product will make sure that consumers do not suffer from any sort of mental pain, stress, depression, acne, high and low blood pressure, hypertension, skin diseases, and so on. 

Royal Blend CBD Gummies are made of natural ingredients that are helpful in treating several mental and physical health ailments of the consumers naturally.

 

What Are The Health Benefits Of Consuming These Royal Blend CBD Gummies?

  • The daily consumption of these CBD-based gummies will surely treat depression, stress, anxiety, mental pain, headache, and other health issues. These CBD gummies will not let consumers go through these mental torments anymore in their life.
  • Royal Blend CBD Gummies are useful for treating insomnia and other sleeping disorders. These tasty gummies will cause sleepless nights and sleeping disorders naturally and easily. 
  • These CBD-infused gummies are prepared with natural and pain-curing ingredients. And consumers can easily deal with all their mental torments. These CBD delicious gummies will boost the overall health of the consumers easily.
  • The consumption of these gummies will make sure that consumers do not suffer from pain and inflammation of the joints. As per the makers of these gummies, with the daily consumption of these gummies, the health of joints and muscles will also improve with no side effects.
  • The daily use of these CBD gummies will enhance the overall health and fitness of the consumers. These CBD gummies will cure the overall mental health of the consumers with no side effects.
  • These CBD gummies cure the problem of high and low blood pressure by maintaining the blood circulation of the body naturally. These CBD gummies will easily address the blood flow of the body. 
  • The metabolism of the body will also be cured and boosted naturally. These CBD gummies will easily take care of the metabolic rate of the body with no side effects. These CBD gummies will also boost the immunity of the body due to which consumers become able to fight stress, depression, viruses, infections, and other health problems.
  • The daily consumption of these CBD gummies will also deal with respiratory diseases such as breathing problems, etc. These CBD-infused gummies will easily take care of the overall health and fitness of the consumers. 
  • As per the makers of these gummies, the daily utilization of this CBD gummy product will deal with cancer and hazardous diseases of the consumers. 

 

What Is The Procedure Of Consuming These Royal Blend CBD Gummies?

To use these CBD-infused gummies, consumers of this product will have to use the product daily and under the guidance of the doctor. With the doctor’s permission, consumers will have to use this CBD gummy product daily and once in the morning and once in the evening by complying with all terms and conditions of the product. 

Royal Blend CBD Gummies will deliver various therapeutic benefits to consumers. 

This CBD gummy product will easily and naturally remove stress, depression, anxiety, high and low blood pressure, acne, and other mental torments of the consumers.

Where To Buy These Royal Blend CBD Gummies?

To buy these Royal Blend CBD Gummies, consumers can make a visit to the official site of the product and from the site, they can easily buy this CBD gummy product with no side effects. 

These CBD-infused gummies will be available at some cheap and affordable prices. On the official site, consumers will have to fill the form by filling in all the required details such as name, address, city, and so on. 

Once the form is filled with all the basic information then, the product will be delivered within a week. 

In case, consumers find any difficulty in filling the form or if they want to know about the product then getting in touch with the customer care of the product would be the most effective and most suitable option.

 Order Now Royal Blend CBD Gummies Official Website

 

Who Is Not Eligible To Consume These Royal Blend CBD Gummies?

  • Royal Blend CBD Gummies are not made to be consumed by people who are below the age of 18. If you are a person who is under the age of 18 then, you are not allowed to use this CBD gummy product.
  • If you are a pregnant lady and breastfeeding mother then the consumption of these CBD gummies will not be good for your health and body. And that’s why do not forget to take the advice of the doctor.
  • If you are suffering from big diseases then consumption of these CBD gummies will not be effective in this case also.
  • If you are addicted to smoking and drinking then the consumption of these gummies will also not be good in this case as well.

The Ultimate Words On Royal Blend CBD Gummies:

With the daily consumption of these gummies, consumers can get rid of all kinds of mental and physical health issues such as stress, depression, anxiety, acne, hypertension, mental pain, and so on. 

This CBD gummy product will easily let consumers improve their overall health and fitness and all kinds of mental torments are cured naturally. 

These little size gummies are useful for alleviating stress, depression, mental pain, acne, and other issues. 

Royal Blend CBD Gummies are made for men and women who are above the age of 18 and comply with all the terms and conditions of the product. 

These CBD-infused gummies will take care of the entire health and lifestyle of the consumers.  


#CBD #Hemp
https://cannatechtoday.com/royal-blend-cbd-gummies-reviews-10-shocking-reasons-to-use-it/
September 7, 2021 11:00 am

PubMed: Differential Interactions of Selected Phytocannabinoids with Human CYP2D6 Polymorphisms

PubMed: Differential Interactions of Selected Phytocannabinoids with Human CYP2D6 Polymorphisms

Biochemistry. 2021 Sep 7. doi: 10.1021/acs.biochem.1c00158. Online ahead of print.

ABSTRACT

Cytochrome P450 2D6 (CYP2D6) is primarily expressed in the liver and in the central nervous system. It is known to be highly polymorphic in nature. It metabolizes several endogenous substrates such as anandamide (AEA). Concomitantly, it is involved in phase 1 metabolism of several antidepressants, antipsychotics, and other drugs. Research in the field of phytocannabinoids (pCBs) has recently accelerated owing to their legalization and increasing medicinal use for pain and inflammation. The primary component of cannabis is THC, which is well-known for its psychotropic effects. Since CYP2D6 is an important brain and liver P450 and is known to be inhibited by CBD, we investigated the interactions of four important highly prevalent CYP2D6 polymorphisms with selected phytocannabinoids (CBD, THC, CBDV, THCV, CBN, CBG, CBC, β-carophyllene) that are rapidly gaining popularity. We show that there is differential binding of CYP2D6*17 to pCBs as compared to WT CYP2D6. We also perform a more detailed comparison of WT and *17 CYP2D6, which reveals the possible regulation of AEA metabolism by CBD. Furthermore, we use molecular dynamics to delineate the mechanism of this binding, inhibition, and regulation. Taken together, we have found that the interactions of CYP2D6 with pCBs vary by polymorphism and by specific pCB class.

PMID:34491040 | DOI:10.1021/acs.biochem.1c00158

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34491040/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210908065847&v=2.14.5 September 7, 2021 10:00 am

PubMed: Comparative effects of combined use of alcohol with cannabis and tobacco on testicular function in rats

PubMed: Comparative effects of combined use of alcohol with cannabis and tobacco on testicular function in rats

Toxicol Res (Camb). 2021 Jun 29;10(4):761-770. doi: 10.1093/toxres/tfab060. eCollection 2021 Aug.

ABSTRACT

Alcoholism has been linked to problems with male reproductive function. The combined effects of alcohol, cannabis, and tobacco were compared in this study. A total of 35 rats were assigned randomly into seven groups A-G: animals in A were administered distilled water. Animals in B-G were either administered alcohol orally (30 ml 40% alcohol) or exposed to smoke from ignited tobacco (exposure to smoke from 0.7 g tobacco for 5 min) or cannabis (exposure to smoke from 0.7 g tobacco and cannabis for 5 min): B (orally administered alcohol), C (exposed to the smoke from tobacco), D (exposed to smoke from cannabis), E (treated with alcohol and exposed to smoke from tobacco), F (treated with alcohol and exposed to smoke from cannabis), G (treated with alcohol and exposed to smokes from tobacco and cannabis). Assays were carried on the testicular homogenate after a 14-day treatment. There was a significant increase in activity of alkaline phosphatase (P ≤ 0.05), concentrations of cholesterol, glutathione reductase, and malondialdehyde in treated rats by the co-administration of alcohol with cannabis and tobacco compared with the control group. The combined treatment also caused degeneration and morphological distortions of testicular cells. The biochemical and histoarchitectural change was due to oxidative damage attributable to the synergistic effects. The high binding energy of tetrahydrocannabinol ligand to prostate acid phosphatase may be a prediction that the ligand can have an inhibitory effect on the function of enzymes in the prostate.

PMID:34484667 | PMC:PMC8403816 | DOI:10.1093/toxres/tfab060

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34484667/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210906065933&v=2.14.5 September 6, 2021 10:00 am

PubMed: Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain

PubMed: Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain

Rev Neurol. 2021 Sep 10;73(S01):S01-S08. doi: 10.33588/rn.73S01.2021250.

ABSTRACT

INTRODUCTION: Cannabidiol (CBD) is one of the main components of the cannabis plant that has demonstrated anti-epileptic seizure effect. Following its clinical development, in September 2019 the European Medicines Agency approved its indication for the adjunctive therapy of epileptic seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS), combined with clobazam (CLB), in patients of 2 years of age and older.

AIM: To establish recommendations on the use of plant-derived highly purified CBD on which Spanish experts have reached consensus for the treatment of epilepsy in patients with DS and LGS based on their clinical experience and the scientific evidence.

DEVELOPMENT: Consensus meeting with the participation of four Spanish neurologists and neuropediatric who are experts in epilepsy secondary to DS and LGS and with clinical experience in the use and management of CBD. They discussed on several topics, including posology (starting dose, dose escalation schema), efficacy (assessment of outcomes and indications for treatment withdrawal), and safety (evaluation, drug-drug interactions, adverse events management).

CONCLUSIONS: In order to optimise CBD treatment, a slow dose escalation (= 4 weeks) is recommended until the maximum recommended dose or the desire effect is reached. It is also recommended that the concomitant antiseizure medications (ASMs) be reduced in case of adverse events due to interactions, and that the treatment continues for at least 6 months if it is well tolerated. The efficacy and safety of CBD must be assessed individually, considering the benefits and risks for individual patients.

PMID:34486101 | DOI:10.33588/rn.73S01.2021250

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34486101/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210907065834&v=2.14.5 September 6, 2021 10:00 am

Leaders in Cannabis Formulations: Part 3 – RealSleep

Leaders in Cannabis Formulations: Part 3 – RealSleep

Sleep health is a large and growing global market. According to Statista, the global market value of the sleep market was $432B in 2019 with an expected CAGR of 6.3% from 2019 to 2024. Supplements are a growing category of popular sleep health products with common ingredients including melatonin, valerian root, and more recently cannabinoids such as CBD and CBN.

RealSleep is a cannabinoid formulation company developing personalized products to improve sleep outcomes. RealSleep’s product strategy has been developed by top scientists and sleep experts, and clinically tested to aid individuals seeking to fall asleep faster, sleep deeper and cut down on sleep disturbances. Their studies have shown that 90% of people taking RealSleep have reported experiencing better sleep immediately

We spoke with Michael Kamins, co-founder and partner of OpenNest Labs and RealSleep, about RealSleep’s innovation in personalized formulations for better sleep. Kamins founded RealSleep as an incubated company under OpenNest Labs, where he is also a founding partner. Michael is the Chief Community Officer of the Wholistic Research and Education Foundation, and just led the world’s largest study on CBD and general health with Wholistic and Radicle Science, where he is also an advisor. Prior to RealSleep, Michael worked in tech where he was an early employee at Musical.ly (now TikTok) building brand partnerships.

Aaron Green: How did you get involved in the cannabis industry?

Michael Kamins, co-founder and partner of OpenNest Labs and RealSleep.

Michael Kamins: I got into the industry professionally about two and a half years ago, but my relationship with the plant goes back to high school. Prior to jumping into this space, I was working primarily in digital media. I was an early employee at Musical.ly, (eventually rebranded as TikTok), leading global music partnerships and growth. I helped grow that business by leveraging the social capital of music artists and celebrities and doing partnerships with record labels. At the end of 2018, I really saw the opportunity in the cannabis space. One of my best friends in Los Angeles, Dr. Jeff Chen, someone I did my MBA with at UCLA, became the founder and executive director of cannabis research at UCLA Medical. Seeing all the clinical research that he was doing and the objective health outcome data coming out of that research was really a huge inspiration to me. I saw a massive whitespace and opportunity to help build that bridge between the medical community and the cannabis marketplace. There’s been almost a century of cannabis prohibition setting back our scientific understanding of the plant. We know more about the rivers and plants in the Amazon than we do about the composition and compounds within the cannabis plant with regards to their wellness benefits.

I met my partners, Tyler Wakstein, Kris Bjornerud and Max Goldstein and we started a cannabis venture studio called OpenNest Labs, which is building out a diversified portfolio of cannabis consumer brands. We are focused on leveraging our collective experience at building ventures and communities and rallying those communities around a brand.

Over the last two and a half years, it’s been super exciting building brands that you see on shelves. We’re still in the early stages right now of building brand loyalty. A lot of cannabis consumers are still going into dispensaries and asking, “what is the cheapest product that I can buy with the highest potency?”

Green: Tell me about RealSleep, how did you come up with the idea and what is the basic concept for the end user?

Kamins: RealSleep comes from the passion that I had developed for medicinal aspects of the cannabis and hemp plant, thinking about not only THC and CBD – which are two major cannabinoids in the plant – but also thinking about the other 120 plus cannabinoids, each with their own unique properties.

It turns out that half the world’s population suffers from one poor night of sleep a week, and sleep issues lead to the highest rate of other comorbidities. We were thinking about the addressable sleep market, with ourselves being a part of that market, and wanting to build products that would help not only ourselves, but the countless other people around the world that suffer from poor sleep too, as it impacts their daily lives.

I’ve had issues with sleep myself. I have a genetic hearing condition called tinnitus. It’s a ringing in your ears that other people can experience environmentally from exposure to loud noises. I’ve had loud ringing in my ears my entire life even in quiet situations, like right before I go to sleep. I’ll often be lying in bed awake for an hour or two unable to sleep with the ringing. Everyone else on the team has had their own sleep issues and realized the profound negative impact of lack of sleep on other areas of health and wellness, whether it be next day energy or immunity.

We felt that by leveraging our access to the medical research community and even running clinical research on our own to validate the efficacy of the product relative to other products on the shelves, we could create a product that was safe and effective. We came across a clinical trial on insomnia and CBD by one of our research partners, the Wholistic Research and Education Foundation. What we saw from a lot of that anecdotal data was that CBD, and hemp in general, really helps to provide restful and restorative sleep.

CBD and CBN are two highly effective compounds for sleep and melatonin is by far the most widely researched and used over the counter sleep aid. We are sourcing clinical research on other ingredients such as valerian root, L-Theanine and GABA, and the list of ingredients goes on. We were interested in formulating a product that incorporates these safe and effective ingredients.

We noticed from our research and our access that sleep is as unique to an individual as their fingerprint. Take brainwave patterns when you are sleeping as an example. No one person’s patterns are the same. You could essentially identify an individual based on those patterns. One solution, or one product, is not going to help everyone. So, we worked with UCLA and the head of their laboratory of sleep and circadian medicine, a gentleman by the name of Dr. Chris Colwell, to understand the science of sleep. He is one of the most renowned sleep researchers in the world and is the head of our scientific advisory board for RealSleep. We’ve done clinical studies with over 900 people and 10,200 nights of sleep and used this data to develop a personalization engine in the form of a quiz that takes 90 seconds and allows us to map ingredients to specific answer selections. From these answers we deliver products that are customized to the individual consumer specific to their unique needs

We’re proud of the journey that we’ve gone on to understand the science and research behind sleep and to develop this personalization engine variations of products that work for each individual and their unique needs.

Green: Tell me how the questionnaire and personalization engine works. I understand the ingredient profile will change based on the customer’s responses?

Kamins: Sleep impacts an individual’s general health and wellness. For me, if I don’t sleep well, my next day is filled with anxiety, and that anxiety leads to worse sleep; it’s a vicious cycle. For other people, it could be a metabolic issue that leads to poor sleep or poor sleep that leads to weight issues. The list of other health issues and diseases linked to poor sleep goes on. So, while we’re looking at combating sleep to prevent other health issues down the road, one person who’s looking to get better sleep to improve one aspect of their life could be different from another person and the area of life they are looking to improve upon.

The quiz is essentially a combination of validated, reliable and flexible measures of patient reported outcomes. We use a combination of gold standard patient reported sleep questionnaires, one of which is called the Pittsburgh Sleep Quality Index, another being the RAND MOS scale, and others. We also work with our scientific advisory board and machine learning experts to advise us on customizing these questions with logic. We then use the responses to generate the appropriate formulations for our customers.

The questions cover everything from very specific questions on sleep, like sleep latency (the time it takes to get the bed) or sleep fragmentation (the number of times you wake up in the middle of the night) sleep duration, sleep quality, and then other areas of health that you’re looking to improve upon. Examples include metabolism, cardiovascular health, skin health, anxiety and stress. So, all these things factor into the different ingredients that we layer into the formulation.

Let’s say you don’t have a problem getting to sleep, but you wake up a lot of times in the middle of the night. Your formulation might be very different from someone who has trouble getting to sleep, but they don’t wake up in the middle of the night. Overall, one of our big goals with the formulation of all these products is that they increase your next day cognitive alertness by giving you that high sleep quality and restorative sleep. We don’t want to make anyone groggy the next day. Because overall, what you’re trying to achieve with sleep is you want to be ready to go the next day and be able to perform at your peak.

Green: So, you mentioned CBD, CBN and melatonin already as ingredients. Are there any other ingredients?

Kamins: Depending on what your answer selections are for the quiz, we will layer in L-Theanine, valerian root, Ashwagandha and even some of the other novel cannabinoids like CBC (cannabichromene). We have about 24 different ingredients that we can layer in, so it just depends. When you look at all the permutations and combinations of formulations and dosages, it’s in the trillions. From a supply chain standpoint, we’ve simplified it in a way that makes it very easy to funnel people into one of many predefined combinations of ingredients and dosage levels.

Our algorithm is an unstructured machine learning algorithm. The more people that take the quiz and the more people that provide feedback on their sleep score makes our programming and our personalization engine smarter.

Green: How does your manufacturing and packaging work?

Kamins: We have a strong relationship with a pharmaceutical partner that we have been growing even before RealSleep. It is a pharmaceutical manufacturing facility underneath a regional health care provider in the state of California. Everything they do is incredible. It’s a state-of-the-art facility and focused on complete transparency and building the products with the highest efficacy and safety profiles. They’re based in LA, and they’ve been such a pleasure to build our supply chain with.

Green: What kind of trends are you looking at in the formulation space?

Kamins: From a cannabinoid side, there’s been a bit more of a look towards some of the novel cannabinoids that have traditionally catered to a niche consumer base that is educated on cannabis. From being inside the industry, it’s very easy for me to talk about all the different cannabinoids, but a lot of people still don’t even know the difference between THC and CBD.

Our goal overall is to build efficacious products and educate people on all the different formulations and the different ingredients going in. Outside of cannabis, this year we’ve seen a large boom in consumer demand for Ashwagandha. There’s just so much hype around it in terms of how it impacts stress and energy and even libido, which is interesting. It’s probably the hottest non-cannabinoid ingredient that we’ve seen. Specific to sleep, the combination of L-Theanine and GABA and how they potentiate each other is impactful. Then there’s valerian root, which has been a big one over the last few years for sleep.

Green: Last question. What are you most interested in learning about?

Kamins: A personal interest of mine over the last few years is understanding from a scientific perspective, each of the cannabis compounds in greater detail. I think part of it is just really the curiosity to know the unknown. We’re at a point in the industry where there are still so many unknowns on the science-side of cannabinoids.

My passion for science has led me to support medical researchers in the space, so much so that I am an advisor and chief community officer to a nonprofit medical research organization called the Wholistic Research and Education Foundation, which to date has funded over six and a half million dollars in human clinical trials with cannabinoid rich therapeutics. One we’re currently conducting at UC San Diego is studying the impact of CBD on autism and other neurological conditions. That’s given me incredible exposure to research in the space. I am also a strategic advisor to a for profit medical research organization called Radicle Science, which is a very swiftly running clinical research for CBD and other cannabis brands in the space.

All in all, I’m driven by the possibilities that come with continuing to unlock the science behind the plant. By doing so, we can innovate products with efficacy and can educate people who are uninformed about the therapeutic benefits of cannabis, which will in turn benefit the industry and society. Striving for research breakthroughs and being transparent about our findings is going to help us destigmatize cannabis and legitimize the industry. 

Green: That concludes the interview. Thanks, Michael!

Kamins: Thanks, Aaron.

The post Leaders in Cannabis Formulations: Part 3 – RealSleep appeared first on Cannabis Industry Journal.


#CBD #Hemp

Leaders in Cannabis Formulations: Part 3 – RealSleep


September 3, 2021 5:39 pm

Leaders in Cannabis Formulations: Part 3 – RealSleep

Leaders in Cannabis Formulations: Part 3 – RealSleep

Sleep health is a large and growing global market. According to Statista, the global market value of the sleep market was $432B in 2019 with an expected CAGR of 6.3% from 2019 to 2024. Supplements are a growing category of popular sleep health products with common ingredients including melatonin, valerian root, and more recently cannabinoids such as CBD and CBN.

RealSleep is a cannabinoid formulation company developing personalized products to improve sleep outcomes. RealSleep’s product strategy has been developed by top scientists and sleep experts, and clinically tested to aid individuals seeking to fall asleep faster, sleep deeper and cut down on sleep disturbances. Their studies have shown that 90% of people taking RealSleep have reported experiencing better sleep immediately

We spoke with Michael Kamins, co-founder and partner of OpenNest Labs and RealSleep, about RealSleep’s innovation in personalized formulations for better sleep. Kamins founded RealSleep as an incubated company under OpenNest Labs, where he is also a founding partner. Michael is the Chief Community Officer of the Wholistic Research and Education Foundation, and just led the world’s largest study on CBD and general health with Wholistic and Radicle Science, where he is also an advisor. Prior to RealSleep, Michael worked in tech where he was an early employee at Musical.ly (now TikTok) building brand partnerships.

Aaron Green: How did you get involved in the cannabis industry?

Michael Kamins, co-founder and partner of OpenNest Labs and RealSleep.

Michael Kamins: I got into the industry professionally about two and a half years ago, but my relationship with the plant goes back to high school. Prior to jumping into this space, I was working primarily in digital media. I was an early employee at Musical.ly, (eventually rebranded as TikTok), leading global music partnerships and growth. I helped grow that business by leveraging the social capital of music artists and celebrities and doing partnerships with record labels. At the end of 2018, I really saw the opportunity in the cannabis space. One of my best friends in Los Angeles, Dr. Jeff Chen, someone I did my MBA with at UCLA, became the founder and executive director of cannabis research at UCLA Medical. Seeing all the clinical research that he was doing and the objective health outcome data coming out of that research was really a huge inspiration to me. I saw a massive whitespace and opportunity to help build that bridge between the medical community and the cannabis marketplace. There’s been almost a century of cannabis prohibition setting back our scientific understanding of the plant. We know more about the rivers and plants in the Amazon than we do about the composition and compounds within the cannabis plant with regards to their wellness benefits.

I met my partners, Tyler Wakstein, Kris Bjornerud and Max Goldstein and we started a cannabis venture studio called OpenNest Labs, which is building out a diversified portfolio of cannabis consumer brands. We are focused on leveraging our collective experience at building ventures and communities and rallying those communities around a brand.

Over the last two and a half years, it’s been super exciting building brands that you see on shelves. We’re still in the early stages right now of building brand loyalty. A lot of cannabis consumers are still going into dispensaries and asking, “what is the cheapest product that I can buy with the highest potency?”

Green: Tell me about RealSleep, how did you come up with the idea and what is the basic concept for the end user?

Kamins: RealSleep comes from the passion that I had developed for medicinal aspects of the cannabis and hemp plant, thinking about not only THC and CBD – which are two major cannabinoids in the plant – but also thinking about the other 120 plus cannabinoids, each with their own unique properties.

It turns out that half the world’s population suffers from one poor night of sleep a week, and sleep issues lead to the highest rate of other comorbidities. We were thinking about the addressable sleep market, with ourselves being a part of that market, and wanting to build products that would help not only ourselves, but the countless other people around the world that suffer from poor sleep too, as it impacts their daily lives.

I’ve had issues with sleep myself. I have a genetic hearing condition called tinnitus. It’s a ringing in your ears that other people can experience environmentally from exposure to loud noises. I’ve had loud ringing in my ears my entire life even in quiet situations, like right before I go to sleep. I’ll often be lying in bed awake for an hour or two unable to sleep with the ringing. Everyone else on the team has had their own sleep issues and realized the profound negative impact of lack of sleep on other areas of health and wellness, whether it be next day energy or immunity.

We felt that by leveraging our access to the medical research community and even running clinical research on our own to validate the efficacy of the product relative to other products on the shelves, we could create a product that was safe and effective. We came across a clinical trial on insomnia and CBD by one of our research partners, the Wholistic Research and Education Foundation. What we saw from a lot of that anecdotal data was that CBD, and hemp in general, really helps to provide restful and restorative sleep.

CBD and CBN are two highly effective compounds for sleep and melatonin is by far the most widely researched and used over the counter sleep aid. We are sourcing clinical research on other ingredients such as valerian root, L-Theanine and GABA, and the list of ingredients goes on. We were interested in formulating a product that incorporates these safe and effective ingredients.

We noticed from our research and our access that sleep is as unique to an individual as their fingerprint. Take brainwave patterns when you are sleeping as an example. No one person’s patterns are the same. You could essentially identify an individual based on those patterns. One solution, or one product, is not going to help everyone. So, we worked with UCLA and the head of their laboratory of sleep and circadian medicine, a gentleman by the name of Dr. Chris Colwell, to understand the science of sleep. He is one of the most renowned sleep researchers in the world and is the head of our scientific advisory board for RealSleep. We’ve done clinical studies with over 900 people and 10,200 nights of sleep and used this data to develop a personalization engine in the form of a quiz that takes 90 seconds and allows us to map ingredients to specific answer selections. From these answers we deliver products that are customized to the individual consumer specific to their unique needs

We’re proud of the journey that we’ve gone on to understand the science and research behind sleep and to develop this personalization engine variations of products that work for each individual and their unique needs.

Green: Tell me how the questionnaire and personalization engine works. I understand the ingredient profile will change based on the customer’s responses?

Kamins: Sleep impacts an individual’s general health and wellness. For me, if I don’t sleep well, my next day is filled with anxiety, and that anxiety leads to worse sleep; it’s a vicious cycle. For other people, it could be a metabolic issue that leads to poor sleep or poor sleep that leads to weight issues. The list of other health issues and diseases linked to poor sleep goes on. So, while we’re looking at combating sleep to prevent other health issues down the road, one person who’s looking to get better sleep to improve one aspect of their life could be different from another person and the area of life they are looking to improve upon.

The quiz is essentially a combination of validated, reliable and flexible measures of patient reported outcomes. We use a combination of gold standard patient reported sleep questionnaires, one of which is called the Pittsburgh Sleep Quality Index, another being the RAND MOS scale, and others. We also work with our scientific advisory board and machine learning experts to advise us on customizing these questions with logic. We then use the responses to generate the appropriate formulations for our customers.

The questions cover everything from very specific questions on sleep, like sleep latency (the time it takes to get the bed) or sleep fragmentation (the number of times you wake up in the middle of the night) sleep duration, sleep quality, and then other areas of health that you’re looking to improve upon. Examples include metabolism, cardiovascular health, skin health, anxiety and stress. So, all these things factor into the different ingredients that we layer into the formulation.

Let’s say you don’t have a problem getting to sleep, but you wake up a lot of times in the middle of the night. Your formulation might be very different from someone who has trouble getting to sleep, but they don’t wake up in the middle of the night. Overall, one of our big goals with the formulation of all these products is that they increase your next day cognitive alertness by giving you that high sleep quality and restorative sleep. We don’t want to make anyone groggy the next day. Because overall, what you’re trying to achieve with sleep is you want to be ready to go the next day and be able to perform at your peak.

Green: So, you mentioned CBD, CBN and melatonin already as ingredients. Are there any other ingredients?

Kamins: Depending on what your answer selections are for the quiz, we will layer in L-Theanine, valerian root, Ashwagandha and even some of the other novel cannabinoids like CBC (cannabichromene). We have about 24 different ingredients that we can layer in, so it just depends. When you look at all the permutations and combinations of formulations and dosages, it’s in the trillions. From a supply chain standpoint, we’ve simplified it in a way that makes it very easy to funnel people into one of many predefined combinations of ingredients and dosage levels.

Our algorithm is an unstructured machine learning algorithm. The more people that take the quiz and the more people that provide feedback on their sleep score makes our programming and our personalization engine smarter.

Green: How does your manufacturing and packaging work?

Kamins: We have a strong relationship with a pharmaceutical partner that we have been growing even before RealSleep. It is a pharmaceutical manufacturing facility underneath a regional health care provider in the state of California. Everything they do is incredible. It’s a state-of-the-art facility and focused on complete transparency and building the products with the highest efficacy and safety profiles. They’re based in LA, and they’ve been such a pleasure to build our supply chain with.

Green: What kind of trends are you looking at in the formulation space?

Kamins: From a cannabinoid side, there’s been a bit more of a look towards some of the novel cannabinoids that have traditionally catered to a niche consumer base that is educated on cannabis. From being inside the industry, it’s very easy for me to talk about all the different cannabinoids, but a lot of people still don’t even know the difference between THC and CBD.

Our goal overall is to build efficacious products and educate people on all the different formulations and the different ingredients going in. Outside of cannabis, this year we’ve seen a large boom in consumer demand for Ashwagandha. There’s just so much hype around it in terms of how it impacts stress and energy and even libido, which is interesting. It’s probably the hottest non-cannabinoid ingredient that we’ve seen. Specific to sleep, the combination of L-Theanine and GABA and how they potentiate each other is impactful. Then there’s valerian root, which has been a big one over the last few years for sleep.

Green: Last question. What are you most interested in learning about?

Kamins: A personal interest of mine over the last few years is understanding from a scientific perspective, each of the cannabis compounds in greater detail. I think part of it is just really the curiosity to know the unknown. We’re at a point in the industry where there are still so many unknowns on the science-side of cannabinoids.

My passion for science has led me to support medical researchers in the space, so much so that I am an advisor and chief community officer to a nonprofit medical research organization called the Wholistic Research and Education Foundation, which to date has funded over six and a half million dollars in human clinical trials with cannabinoid rich therapeutics. One we’re currently conducting at UC San Diego is studying the impact of CBD on autism and other neurological conditions. That’s given me incredible exposure to research in the space. I am also a strategic advisor to a for profit medical research organization called Radicle Science, which is a very swiftly running clinical research for CBD and other cannabis brands in the space.

All in all, I’m driven by the possibilities that come with continuing to unlock the science behind the plant. By doing so, we can innovate products with efficacy and can educate people who are uninformed about the therapeutic benefits of cannabis, which will in turn benefit the industry and society. Striving for research breakthroughs and being transparent about our findings is going to help us destigmatize cannabis and legitimize the industry. 

Green: That concludes the interview. Thanks, Michael!

Kamins: Thanks, Aaron.

The post Leaders in Cannabis Formulations: Part 3 – RealSleep appeared first on Cannabis Industry Journal.


#CBD #Hemp

Leaders in Cannabis Formulations: Part 3 – RealSleep


September 3, 2021 5:39 pm

PubMed: Evaluation of hemp (Cannabis sativa L.) as an industrial crop: a review

PubMed: Evaluation of hemp (Cannabis sativa L.) as an industrial crop: a review

Environ Sci Pollut Res Int. 2021 Sep 2. doi: 10.1007/s11356-021-16264-5. Online ahead of print.

ABSTRACT

Rising human population has increased the utilization of available resources for food, clothes, medicine, and living space, thus menacing natural environment and mounting the gap between available resources, and the skills to meet human desires is necessary. Humans are satisfying their desires by depleting available natural resources. Therefore, multifunctional plants can contribute towards the livelihoods of people, to execute their life requirements without degrading natural resources. Thus, research on multipurpose industrial crops should be of high interest among scientists. Hemp, or industrial hemp, is gaining research interest because of its fastest growth and utilization in commercial products including textile, paper, medicine, food, animal feed, paint, biofuel, biodegradable plastic, and construction material. High biomass production and ability to grow under versatile conditions make hemp, a good candidate species for remediation of polluted soils also. Present review highlights the morphology, adaptability, nutritional constituents, textile use, and medicinal significance of industrial hemp. Moreover, its usage in environmental conservation, building material, and biofuel production has also been discussed.

PMID:34476693 | DOI:10.1007/s11356-021-16264-5

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34476693/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210904065854&v=2.14.5 September 3, 2021 10:00 am

Wisconsin officially ends hemp program; growers will work under feds

Wisconsin officially ends hemp program; growers will work under feds
Wisconsin officially ends hemp program; growers will work under feds

The Wisconsin Department of Agriculture, Trade and Consumer Protection (DATCP) has announced the official end of the state hemp program, leaving farmers to work directly…

Read More


#CBD #Hemp

Wisconsin officially ends hemp program; growers will work under feds


September 3, 2021 5:33 am

Colorado to Bolster Hemp Testing Rules, Rollout Delayed

Colorado to Bolster Hemp Testing Rules, Rollout Delayed

Earlier this year, the Colorado Department of Public Health and Environment (CDPHE) announced a plan to introduce new testing rules for the state’s growing hemp industry. Under the new regulations, hemp products must be tested for residual solvents, heavy metals and pesticides, in addition to making sure they contain less than 0.3% THC.

The CDPHE are planning on a gradual rollout to prevent any supply chain issues or a lab testing bottleneck, similar to what we’ve seen in other states launching new testing requirements in years past, such as Arizona or California. Well, the Colorado rollout appears to be hitting similar snags and because of supply chain issues related to instruments and consumables in laboratories, the implementation of those testing rules is somewhat delayed. What was originally supposed to be implemented over the summer was pushed back to an October 1 deadline, and that deadline has now been pushed back to 2022.

The pesticide testing list to be implemented January 1, 2022

As a result of supply chain shortages and the learning curve to test for such a wide range of pesticides, Colorado is opening hemp testing to out-of-state labs in an effort to stay on schedule with the rollout. Dillon Burns, lab manager at InfiniteCAL, a cannabis testing company with locations in California and Michigan, just completed an audit with the CDPHE in their work to get certified and start conducting hemp testing for businesses in Colorado.

Burns says they’re well-acquainted with the list of pesticides because of how similar the list is to California’s requirements. “For the pesticide testing rules that were supposed to go into effect on August 1st, it’s basically the same list as California just with slightly different action levels,” says Burns. “I would say these action limits are generally stricter – they have much lower LOQs [limits of quantification].”

The pesticide testing list (continued) to be implemented January 1, 2022

Come January 1, 2022, they are expecting an additional 40 pesticides to be required under the new rules. “But currently, it’s still unclear when these regulations will actually go into effect,” says Burns. The full pesticide testing list is currently slated to be implemented on April 1, 2022.

The supply chain issues referenced above have a lot to do with what the state is asking labs to test for. Previously, most of the pesticides tested for under Colorado’s adult use and medical cannabis programs could be analyzed with an LC/MS. A handful of pesticides on the new list do require GC/MS, says Burns. It’s entirely possible that a lot of labs in Colorado just don’t have a GC/MS or are in the process of training staff and developing methods for using the new instrument. “Cleanliness of these instruments is such a priority that it takes time to acquire the right skill set for it,” says Burns.

Dillon Burns, Lab Manager at InfiniteCAL

The new testing rollout isn’t just another compliance hurdle for the cannabis industry; these rules are about protecting public health. Dillon Burns said he’s seen hiccups in California with the amount of new hemp farmers getting into the space. “The hemp products we’ve tested in California often fail for pesticides,” says Burns. It’s a lot easier in most states to get a license for growing hemp than it would be for growing adult use cannabis. “You’ll see a lot more novice growers getting into hemp farming without a background in it. They’ll fail for things they just haven’t considered, like environmental drift. We see a lot of fails in CA. Hemp is bioaccumulating so it presents a lot of problems. If they’re not required to look for it, they weren’t monitoring it.”

When asked how the market might react to the new rules, Burns was confident that Colorado knows what they’re doing. “I don’t anticipate that [a testing bottleneck] happening here. The regulators are reasonable, supportive of the industry and opening it up to out-of-state labs should help in preventing that.”

The post Colorado to Bolster Hemp Testing Rules, Rollout Delayed appeared first on Cannabis Industry Journal.


#CBD #Hemp

Colorado to Bolster Hemp Testing Rules, Rollout Delayed


September 2, 2021 4:22 pm

Weaving Hopes for Reshoring U.S. Hemp Textiles

Weaving Hopes for Reshoring U.S. Hemp Textiles

hemp textiles trade

By Eric Singular, Director, Hemp Business Journal, New Frontier Data

Throughout the past 10,000 years of human civilization, bast fibers derived from the stalks of hemp plants have represented as valuable material in the weaving of textiles. In modern times, hemp yarn’s many uses from sailcloth to apparel have served as rallying cries for returning to widespread industrial use of the versatile, natural, plant-based fiber.

Yet, prior to the 2018 Farm Bill, the plant had for decades been federally prohibited in the United States despite its long, even celebrated history. Early colonists were required to cultivate the plant, founding fathers including George Washington and Thomas Jefferson grew it among the cash crops at their plantations, and even after its being banned in 1937, it was called into service on behalf of the war effort during World War II.

Fast-forward to 2021: Unsurprisingly, during the nearly eight decades of hemp’s prohibition, the textiles industry has evolved dramatically. While dreams of establishing a domestic supply chain capable of bringing to market a completely “Made in the USA” hemp apparel product is very much alive, obstacles abound. The decades after WWII ushered in an era of neoliberal policies. This was spurred by the creation of intergovernmental organizations, like the World Trade Organization, and trade agreements, like the North American Free Trade Agreement (NAFTA), both of which came to fruition in the 1990s. These free trade market forces, paired with a growing population and a greater penchant for consumerism, demanded cheaper labor and an exhaustive supply of raw materials.

This was made possible by the emergence of large textile mills and factories in China and other countries in Asia and Latin America in the mid-1970s. In 1980, about 70% of apparel bought by Americans were buying was still made in the U.S. With the advent of the North American Free Trade Agreement (NAFTA) in the 1990s, it was decided to phase out the Agreement on Textiles and Clothing quotas by 2005, marking the end of trade protections for U.S. textile manufacturers.

Big retail chains began developing vast global supply chains. The goal was to divide each step of production, sourcing the cheapest labor wherever it was offered. According to the Bureau of Labor Statistics, between 1990 and 2011, the U.S. had outsourced nearly 750,000 apparel manufacturing jobs. By 2003, global retailer The Gap had a supply chain spanning 1,200 factories across 42 countries. Today, a reliance on such global supply chains keeps the costs of manufacturing, labor, and production low.

Enter the dilemma of reshoring American manufacturing. Today, hemp fiber processors are trying to re-establish their roots across the United States. In the short term, processors are trying to dial-in the mechanics of decorticating, or separating, hurd from the interior of the industrial hemp stalk. Hurd is the short fiber found in the inner woody core of hemp stalks, typically containing 20-30% lignin. It has a wide variety of nonwoven applications as wood alternatives – including construction and building materials (hempcrete), paper, bioplastics, furniture, animal bedding, flooring, etc.

More profits will come when hemp fiber processors attain the ability to decorticate the long bast fibers of the hemp stalk. Those fibers are high in cellulose and low in lignin, and are used for weaving and spinning fabric for the textile industry. China currently dominates the global hemp fabric industry, along with some competition from Western Europe. The processing technology to accomplish textile-grade hemp fiber is lagging in the U.S.

As cited by the New York Times, textile manufacturing in 2020 worldwide surpassed $1 trillion ($1,000,300,000,000 USD), with expectations to reach nearly $1.042 trillion in 2021. By 2025, that figure is expected to grow to nearly $1.207 trillion.

The U.S. is China’s biggest hemp-fiber customer. With no intention of slowing down, China’s 13th Five-Year Plan sets its sight on producing over 3 million acres of hemp fiber for the global textiles industry by 2030. China’s dominance in textiles is partially driven by its lack of environmental regulations: While farming for fiber withdraws over 3 trillion liters of water, textile dyeing represents one of the most polluting aspects of the global fashion industry.

While the U.S. apparel market is the world’s largest, comprising about 28% of the global total, there remain only a handful of textile mills. Nevertheless, the U.S. plays a vital role in the global cotton market, serving as the world’s leading exporter, recently providing approximately 35% of global cotton exports. According to the USDA, the United States produced nearly 20 million bales of cotton, worth about $7 billion in 2019.

According to the National Council of Textile Organizations, the U.S. industry is the second-largest global exporter of textile-related products, accounting for $25.4 billion in 2020. The U.S. military is the biggest consumer for American-made textiles, sourcing over 8,000 products from domestic manufacturers. Yet, it’s nearly impossible to find an apparel with a “Made in the USA” tag, e.g., while in 1996 there were 2,153 textile and apparel plants in North Carolina, a decade later fewer than 60% (1,282) of those remained.

Still, agribusiness contributes approximately $87 billion to the Tar Heel state’s economy. As Daniel Yohannes, CEO of clean-tech manufacturing Renaissance Fiber explained, “the connection between hemp and textiles was obvious, especially in North Carolina. What we’ve come to understand, though, is that hemp promises two very important things. In a traditional sense, hemp will rebuild some of the lost connection between agriculture and industry that actually built the communities we live in here. At the same time, it will improve the environmental impact of some of the U.S. and the world’s largest and most important supply chains. Both are urgently needed. There almost couldn’t have been a better time for this.”

There is a substantial upside to reshoring: The U.K.’s House of Commons Environmental Audit Committee found that textile production contributes more to climate change than do international aviation and shipping combined. According to the UN Environment Assembly, the fashion industry is responsible for 8% of carbon emissions.

The domestic aim for a low-carbon footprint, has perhaps been best exemplified and supported by outwear manufacturer Patagonia – which notes that hemp currently makes up less than 0.1% of the global fiber market – through its “Bring Hemp Home” Initiative. While Patagonia is a marketing pioneer, it is a niche clothing brand, and comparatively pricey. For consumers to embrace sustainable fabrics with low-carbon footprints, they will need to pay an unwelcomed premium.

In the wake of CBD’s crash, the U.S. hemp industry is learning to build with a confirmed market in mind. For U.S. hemp fiber processors, both the material value and sustainability of hemp’s plant-based fiber are plainly evident. A domestic supply chain means a far lower carbon footprint with respect to transportation, and a localized economy that will likely keep more money in each of the respective links along the U.S. value chain, including farmers and American apparel manufacturers to keep optimism and capital flowing.

Ultimately, the outcomes depend on consumer demand. The average U.S. garment worker makes roughly 38x the wage of one’s Bangladeshi counterpart. In addition, the U.S. textiles industry must abide by strict Environmental Protection Agency (EPA) standards, whose latest rule on textile dyeing aims for a 60% reduction in nationwide organic hazardous air pollutants emissions. It becomes a question of whether the consumer market for environmentally friendly products can balance the reshoring of American manufacturing. With catastrophic climate danger looming larger by the day, how many Americans will pay a premium for sustainability?

The post Weaving Hopes for Reshoring U.S. Hemp Textiles appeared first on New Frontier Data.

#CBD #Hemp https://newfrontierdata.com/cannabis-insights/weaving-hopes-for-reshoring-u-s-hemp-textiles/ September 2, 2021 3:07 pm

Florida ag commissioner backs marijuana legalization to clear way for hemp

Florida ag commissioner backs marijuana legalization to clear way for hemp
Florida ag commissioner backs marijuana legalization to clear way for hemp

A lack of clarity in federal cannabis laws is suppressing growth of the legal hemp industry, according to Florida Agriculture Commissioner Nikki Fried, who this week wrote a…

Read More


#CBD #Hemp

Florida ag commissioner backs marijuana legalization to clear way for hemp


September 2, 2021 10:30 am

Ad valorem excise taxes are not the way to go for marijuana. 

Ad valorem excise taxes are not the way to go for marijuana. 

Ad valorem excise taxes are not the way to go for marijuana.  Ideological adversaries agree on that, if on little else!  The left-leaning Institute for Taxation and Economic Policy warned, in a detailed report, that ad valorem price-based “ad valorem” taxes on marijuana are a recipe for trouble when prices go down – as they do in every jurisdiction where legalization takes hold. https://itep.org/taxing-cannabis/  

More recently, the right-leaning Tax Foundation has joined the warning:  “states risk losing out on forecasted revenue if prices continue to go down.” https://taxfoundation.org/safe-banking-act-state-marijuana-revenues/

We needn’t use ad valorem taxes at all for marijuana.  The bill phases ad valorem taxes out, but keeps them too long, then compounds the error by de facto freezing them.  

The draft sticks precisely to the early 2017 design of the old Blumenauer-Wyden bill, with ad valorem taxes for five years before switching to “specific” (non-ad valorem) taxes, only at that late date taxing flower by weight and concentrates by THC.  See http://thehill.com/blogs/pundits-blog/economy-budget/327694-marijuana-legalization-grows-closer-with-senate-tax

2017 is a long time ago for a drug that was first legalized in 2012; we’ve come a long way in what we know since then.

That five-year delay may have had some possible justification in 2017, but not now.  But even then, ad valorem taxes were outdated.  Sure, no one was taxing anything by THC content then – but several states had already worked out taxing raw plant matter by weight, the state of the art tax system in 2017.  In the intervening four years since the 2017 bill, Canada, legalizing in 2018, moved straight into taxing flower by weight immediately, and concentrates by THC content about a year later.  No five-year delay!  The system up north seems to be humming.  Lots of states tax by weight already, and Canada has the gold standard using both bases, weight and THC.  I don’t know why we don’t just go ahead and copy it — now.

Taxing by price means that when the pre-tax price goes down, taxes do, too. So do after-tax prices.  Low taxes and cheap weed are not on some people’s wish list, but not everyone’s. After legalization, pre-tax prices are bound to wither.  Fully legal marijuana won’t sell for hundreds or even dozens of dollars per ounce, pre-tax.

But price taxes create another problem. In case of “vertical integration” like a farm-to-market operation, the bill shies away from taxing the actual price the consumer pays, so it imagines an artificial — and probably arbitrary — “constructive sale price” in section 5903.   This is the amount one person, who is both retail clerk and farmer, supposedly pays his farmer self as a wholesale price.  Shenanigans galore!  Colorado has this kind of unworkable producer price tax on the books but, finding it doesn’t work, has quietly given up. Colorado taxes producers by weight instead of by the de jure price-based ad valorem method in related party transactions.  Nevada taxes producers by weight instead of the de jure price-based ad valorem tax on its statute books, last I heard – in all transactions.

— Sent to sponsors of U.S. Senate marijuana bill.


#CBD #Hemp
Ad valorem excise taxes are not the way to go for marijuana. 
September 1, 2021 7:03 pm

6 Trends Influencing the Cannabidiol (CBD) Market Forecast Through 2027

6 Trends Influencing the Cannabidiol (CBD) Market Forecast Through 2027

The rise in the number of optimistic regulatory frameworks instigated by various regional governments will positively anchor the forecast for the cannabidiol (CBD) market. The growing awareness regarding the benefits and effects of the product as an alternative treatment method has accelerated its preference among consumers and suppliers. Moreover, the continued advancements in the approval processes by various authorities worldwide have also made way for numerous opportunities supporting CBD market growth.

According to a report by Global Market Insights, Inc, the global CBD market size could exceed $108.8 billion by 2027.

Growing presence in cosmetics

The overall industry share from creams and roll-on products is poised to hit a 35.8% CAGR up to 2027. This is owing to the increasing scope of CBD in cosmetic applications as it is highly effective in treating skin conditions. This, as well as its anti-inflammatory characteristics from a medicinal perspective, are leading to increased demand for CBD products like creams and roll-ons.

Scope in the treatment of mental health

Some of the many infused products on the market today.

CBD market value from anxiety/stress applications exceeded USD 1.5 billion in 2020 due to the growing need for helping mental health. The World Health Organization reported that over 4.5% of the total population in Europe suffers from depression. This escalating anxiety and stress rate has encouraged healthcare practitioners to increasingly make use of CBD-based medications.

Higher demand for oral administration

Demand for oral cannabidiol administration held nearly 45% of the industry proportion in 2020 due to its growing preference considering the gradual relief of pain compared to other disorders. The increasing dependency on the oral administration route for product development by several manufacturers will add positive impetus to market growth.

Medical benefits of cannabis

Annual revenue of the CBD market from the segment of the market dealing with THC (and CBD) products is expected to cross USD 30.1 billion by 2027. This is largely due to its increasing penetration across various countries and regions on account of its legal status. Furthermore, the relatively higher THC content of the compound has led to its growing usage to combat medical conditions, including Alzheimer’s and Parkinson’s disease, among others.

Online distribution to see a considerable footprint

Ads for CBD products online regularly perform very well

The online CBD industry was responsible for more than 46% of the market in 2020. This is mainly due to the numerous advantages of online channels, like on-time delivery and adequate inventory, compared to their offline counterparts. Besides, this distribution platform minimizes the operational costs related to the maintenance of brick and mortar retail.

Australia to lead the regional landscape

Australia dominated the Asia Pacific CBD market by holding over 25% of the market share owing to the expanding geriatric population and the liberal stance of the regulating bodies in the region. The permittance to the medicinal and cosmetic use of CBD products is likely to spur regional adoption. The rising amendments in regulatory scenarios have also triggered awareness regarding the potential benefits of the product in the country. For instance, in April 2020, the Australian government released a new proposal for over-the-counter CBD in a bid to relax its narcotic scheduling whilst making it a Schedule 3 substance.

Providers of various CBD products are actively indulging in numerous growth strategies, like acquisitions and partnerships, to reinforce their market presence. For example, Mota Ventures Corp., in January 2020, acquired Spanish producer and online retailer, Sativida OU in a USD 2.2 million deal. The acquisition expanded the company’s presence in Europe and Latin America.

Although the demand for CBD is likely to experience certain hesitation from consumers in the short term, the market will witness lucrative growth in the long run. However, counterfeit and substandard quality products may potentially restrain industry expansion to some extent.

The post 6 Trends Influencing the Cannabidiol (CBD) Market Forecast Through 2027 appeared first on Cannabis Industry Journal.


#CBD #Hemp

6 Trends Influencing the Cannabidiol (CBD) Market Forecast Through 2027


September 1, 2021 6:21 pm

PubMed: The Role of Cannabis, Cannabidiol and Other Cannabinoids in Chronic Pain. The Perspective of Physicians

PubMed: The Role of Cannabis, Cannabidiol and Other Cannabinoids in Chronic Pain. The Perspective of Physicians

J Neuroimmune Pharmacol. 2021 Aug 31. doi: 10.1007/s11481-021-10010-x. Online ahead of print.

ABSTRACT

Currently, there is a renewed interest in treatments with medical cannabis and cannabinoids. Based on an increasing number of publications over the last decades that permitted new insights into mechanisms, efficacy and safety of cannabinoids, the use of cannabinergic medications is authorised in an increasing number of European and non-European countries. The alleviation of chronic, painful conditions is, since thousands of years, one of the primary reasons for the use of cannabis. Depending on the country, a wide range of medicinal cannabis preparations are available:ranging from defined cultivars of medical cannabis, mainly varying in their THC:CBD ratio, that are inhaled or taken as whole plant extracts,to highly purified single cannabinoids, such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD),or mixtures of two enriched extracts, standardised to a 1:1 ratio of THC:CBD (nabiximols). Although conflicting opinions continue to exist, the majority of reviews in the past concluded that medical cannabis and cannabinoids play a significant role in the management of pain. Surprisingly, systematic studies to date do not support an “entourage effect” of the other plant constituents of cannabis (mainly terpenoids) in treatment of chronic pain. An emerging cannabinoid is CBD which is the only cannabinergic medication available at present that does not cause the typical “cannabis high”; it is not a “controlled substance”. However, despite years of research, there is either no study or no well-conducted, head-to-head, comparison available between different cannabis cultivars, between pure cannabinoids, and between pure cannabinoids and extracts. It remains unanswered which is the optimal treatment approach.

PMID:34467511 | DOI:10.1007/s11481-021-10010-x

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34467511/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210902065949&v=2.14.5 September 1, 2021 10:00 am

PubMed: Effects of cannabidiol in cannabis flower: Implications for harm reduction

PubMed: Effects of cannabidiol in cannabis flower: Implications for harm reduction

Addict Biol. 2021 Aug 31:e13092. doi: 10.1111/adb.13092. Online ahead of print.

ABSTRACT

Using a federally compatible, naturalistic at-home administration procedure, the present study examined the acute effects of three cannabis flower chemovars with different tetrahydrocannabinol (THC) to cannabidiol (CBD) ratios, in order to test whether chemovars with a higher CBD content produce different effects. Participants were randomly assigned to ad libitum administration of one of three chemovars (THC-dominant: 24% THC, 1% CBD; THC+CBD: 9% THC, 10% CBD; CBD-dominant: 1% THC, 23% CBD); 159 regular cannabis users (male = 94, female = 65) were assessed in a mobile pharmacology lab before, immediately after, and 1 h after ad libitum administration of their assigned chemovar. Plasma cannabinoids as well as positive (e.g., high, elation) and negative (e.g., paranoia and anxiety) subjective effects were assessed at each time points. Participants who used the CBD-dominant and THC + CBD chemovars had significantly less THC and more CBD in plasma samples compared to participants who used the THC-dominant chemovar. Further, the THC + CBD chemovar was associated with similar levels of positive subjective effects, but significantly less paranoia and anxiety, as compared to the THC-dominant chemovar. This is one of the first studies to examine the differential effects of various THC to CBD ratios using chemovars that are widely available in state-regulated markets. Individuals using a THC + CBD chemovar had significantly lower plasma THC concentrations and reported less paranoia and anxiety while also reporting similar positive mood effects as compared to individuals using THC only, which is intriguing from a harm reduction perspective. Further research is needed to clarify the harm reduction potential of CBD in cannabis products.

PMID:34467598 | DOI:10.1111/adb.13092

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34467598/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210902065949&v=2.14.5 September 1, 2021 10:00 am

PubMed: Cannabinol and Sleep: Separating Fact from Fiction

PubMed: Cannabinol and Sleep: Separating Fact from Fiction

Cannabis Cannabinoid Res. 2021 Aug 31. doi: 10.1089/can.2021.0006. Online ahead of print.

ABSTRACT

In recent years, marketers of cannabis (i.e., marijuana) products have claimed that cannabinol (CBN) has unique sleep-promoting effects. Despite a plausible mechanism, it is possible that such claims are merely rooted in cannabis lore. The aim of this narrative review was to answer the question: “Is there sufficient clinical evidence to support claims that CBN has sleep-promoting effects?” A systematic search of PubMed/MEDLINE was performed to evaluate the published evidence. The abstracts of 99 human studies were screened for relevance by the author and reviewed for compliance with the inclusion criteria. The characteristics and principal findings were extracted from eight full-text articles that met inclusion criteria for detailed review. Pre-clinical and clinical research investigating the effects of CBN is dated and limited, with the preponderance of human studies occurring in the 1970-1980s with small sample sizes lacking diversity in sociodemographic characteristics. Studies specifically assessing subjective effects associated with sleep, such as sedation or fatigue, are rare. Most importantly, published clinical trials investigating associations between CBN and validated sleep questionnaires and/or formal polysomnography were not identified in this review. In addition, evidence demonstrating that CBN itself elicits cannabis-like effects in humans is mixed, with the majority of available evidence demonstrating a lack of such an effect. Consequently, there is insufficient published evidence to support sleep-related claims. Randomized controlled trials are needed to substantiate claims made by manufacturers of cannabis products containing CBN. These studies should specifically evaluate its effects on sleep through polysomnography, or at minimum, through validated sleep questionnaires, and use dosages significantly higher than those found in currently available cannabis products marketed for sleep (typically ≤5 mg). Individuals seeking cannabis-derived sleep aids should be skeptical of manufacturers’ claims of sleep-promoting effects.

PMID:34468204 | DOI:10.1089/can.2021.0006

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34468204/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210902065949&v=2.14.5 September 1, 2021 10:00 am

PubMed: Evaluation of thermo-chemical conversion temperatures of cannabinoid acids in hemp (Cannabis sativa L.) biomass by pressurized liquid extraction

PubMed: Evaluation of thermo-chemical conversion temperatures of cannabinoid acids in hemp (Cannabis sativa L.) biomass by pressurized liquid extraction

J Cannabis Res. 2021 Aug 31;3(1):40. doi: 10.1186/s42238-021-00098-6.

ABSTRACT

BACKGROUND: Cannabinoids are increasingly becoming compounds of medical interest. However, cannabis plants only produce carboxylated cannabinoids. In order to access the purported medical benefits of these compounds, the carboxylic acid moiety must be removed. This process is typically performed by heating the plant material or extract; however, cannabinoids being thermolabile can readily degrade, evaporate, or convert to undesired metabolites. Pressurized liquid extraction (PLE) operates using a pseudo-closed system under pressure and temperature. While pressure is maintained at 11 MPa, temperature can be varied from ambient to 200 °C.

METHODS: Temperatures were evaluated (80 to 160 °C) using PLE for the thermo-chemical conversion of cannabinoid acids utilizing water as the solvent in the first step of extraction with subsequent extraction with ethanol. Optimum temperatures were established for the conversion of 6 cannabinoid acids to their neutral cannabinoid forms. Cannabinoid acid conversion was monitored by HPLC.

RESULTS: The use of PLE for thermo-chemical decarboxylation has resulted in a rapid decarboxylation process taking merely 6 min. The temperatures established here demonstrate statistically significant maxima and minima of cannabinoids and their parent cannabinoid acids. One-way ANOVA analysis shows where individual cannabinoids are statistically different, but the combination of the maxima and minima provides temperatures for optimum thermo-chemical conversion. CBC, CBD, CBDV, and CBG have an optimum temperature of conversion of 140 °C, while THC was 120 °C for 6 min.

DISCUSSION: Decarboxylation of cannabinoid acids is necessary for conversion to the bioactive neutral form. The pseudo-closed chamber of the PLE makes this an ideal system to rapidly decarboxylate the cannabinoid acids due to pressure and temperature, while minimizing loss typically associated with conventional thermal-decarboxylation. This study established the optimum temperatures for thermo-chemical conversion of the cannabinoid acids in water and provides the groundwork for further development of the technology for industrial scale application.

PMID:34465400 | DOI:10.1186/s42238-021-00098-6

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34465400/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210901065912&v=2.14.5 September 1, 2021 10:00 am

PubMed: Framework for the Design of Cannabis-Mediated Phase I Drug-Drug Interaction Studies

PubMed: Framework for the Design of Cannabis-Mediated Phase I Drug-Drug Interaction Studies

Curr Rev Clin Exp Pharmacol. 2021 Aug 13. doi: 10.2174/2772432816666210813123716. Online ahead of print.

ABSTRACT

Cannabis has become legal in much of the United States similarly to many other countries, for either recreational or medical use. The use of cannabis products is rapidly increasing while the body of knowledge of its myriad of effects still lags. In vitro and clinical data show that cannabis’ main constituents, delta-9-tetrahydrocannabinol and cannabidiol, can affect the pharmacokinetics (PK), safety and pharmacodynamics (PD) of other drugs. Within the context of clinical drug development, the widespread and frequent use of cannabis products has essentially created another special population; that is, the cannabis user. We propose that all clinical drug development programs include a Phase 1 study to assess the drug-drug interaction potential of cannabis as a precipitant on the PK, safety and if applicable, the PD of all new molecular entities (NMEs) in a combination of healthy adult subjects as well as frequent and infrequent cannabis users. This data should be required to inform drug labeling and aid health care providers in treating any patient, as cannabis has quickly become another common concomitant medication and cannabis users, a new special population.

PMID:34455952 | DOI:10.2174/2772432816666210813123716

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34455952/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210830065921&v=2.14.5 August 30, 2021 10:00 am

PubMed: The effects of cannabis and cannabinoids on the endocrine system

PubMed: The effects of cannabis and cannabinoids on the endocrine system

Rev Endocr Metab Disord. 2021 Aug 30. doi: 10.1007/s11154-021-09682-w. Online ahead of print.

ABSTRACT

With the increase in cannabis use due to policy changes and areas of decriminalization, it is important to recognize the potential impact of these substances on endocrine processes. Cannabinoids have many effects by activating the endocannabinoid system. This system plays a role in the normal functioning of nearly every organ and consists of the body’s natural endocannabinoids, the cannabinoid receptors, and the enzymes and processes that regulate endocannabinoids. Exogenous cannabinoids such as Δ9-tetrahydrocannabinol (THC) are known to act through cannabinoid type 1 and 2 receptors, and have been shown to mimic endocannabinoid signaling and affect receptor expression. This review summarizes the known impacts of cannabis on thyroid, adrenal, and gonadal function in addition to glucose control, lipids, and bone metabolism, including: reduced female fertility, increased risk of adverse pregnancy outcomes, reduced sperm counts and function, lower thyroid hormone levels with acute use, blunting of stress response with chronic use, increased risk of prediabetes but lower risk of diabetes, suggested improvement of high density lipoproteins and triglycerides, and modest increase in fracture risk. The known properties of endocannabinoids, animal data, population data, and the possible benefits and concerns of cannabinoid use on hormonal function are discussed. The interconnectivity of the endocrine and endocannabinoid systems suggests opportunities for future therapeutic modalities which are an area of active investigation.

PMID:34460075 | DOI:10.1007/s11154-021-09682-w

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34460075/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210901065912&v=2.14.5 August 30, 2021 10:00 am

Hold Hearings before legalizaing marijuana federally

Hold Hearings before legalizaing marijuana federally

Here’s one of my messages to sponsors of federal marijuana legalization bill:

Dear Senators and Staffers,

On the joint Congressional Committee that devoted four full days of public hearings to liquor taxes alone in December 1933 were a future Supreme Court Justice (Vinson), a future Speaker of the House (McCormack), and a future Vice President (Barkley).  That kind of work might well help Congress today.  The 1933 hearings were hardly a political graveyard for those who took time to listen and study tricky issues.

Those four days covered only taxes, and only liquor – not beer, not wine.  Marijuana legalization needs more work than liquor taxes did in 1933. Unlike with cannabis, we had already had lots of experience taxing liquor.  But Congress studied liquor taxation thoroughly anyway.

Hearings in the Senate Finance Committee on taxes would help, I’d say, as a tax scholar and a former staffer there.  The tax structure in the draft is going to receive severe criticism, only some of it from me, and things have changed dramatically from the Wyden-Blumenauer bill of 2017, whose tax provisions the CAOA basically copies.  Canada has started taxing THC in concentrates, for instance, and New York and Connecticut are going to try to tax it in flower.  These are new developments since 2017 – and warrant a new tax structure.  But what structure?  No one knows. 

There is lot of work for Senators and your staffs to do – and plenty of time to do it in, I suspect, as marijuana legalization will not happen overnight.

In 1933, the Committee heard input from staff, the executive branch, academics, and interested private parties (once known as special interests, now known as stakeholders).  The Ways & Means and Finance Committees reported out a bill in short order, and President Roosevelt signed it in January.  A success story — the result of listening and working.

Here’s the source material, attached. [Newrevenue readers — ask by email for a google drive copy of the large file if you want.]

 Tax on Intoxicating Liquor, Joint Hearings Before the Committee on Ways and Means, House of Representatives and the Committee on Finance, United States Senate, 73d Congress, Interim, 1st and 2d Sessions, Dec. 11-14, 1933, at 309.  


#CBD #Hemp
Hold Hearings before legalizaing marijuana federally
August 29, 2021 9:51 pm

Technical tax comment on federal marijuana bill

Technical tax comment on federal marijuana bill

Comment on the Cannabis Administration and Opportunity Act draft submitted to the Act’s authors:

I don’t understand what (B) is doing in new 26 U.S.C. 5902(a)(2).  

‘‘(2) THC-MEASURABLE CANNABIS PRODUCT.—

The term ‘THC-measurable cannabis product’ means any cannabis product—

‘‘(A) with respect to which the Secretary has made a determination that the amount of tetrahydrocannabinol in such product (or any particular category of products which includes such product) can be measured with a reasonable degree of accuracy—

 ‘‘(i) consistent with good commercial practice, and

 ‘‘(ii) sufficient to protect the revenue and the public, or

 ‘‘(B) which is not cannabis flower and the concentration of tetrahydrocannabinol in which
is significantly higher than the average such concentration in cannabis flower.

+++

 If (A) is satisfied, OK, we know how to measure THC in this product.  Case closed.

If (A) is not satisfied, THC can’t be accurately measured, so at first blush, tax should not be calculated by THC.  

But maybe (B) taxes by THC content something where THC can’t be certifiably accurately measured.  I don’t understand.  (A) alone, without (B), seems to do the job.

(B) seems unnecessary and confusing.  What is (B) supposed to do?  I don’t know.

Thank you.


#CBD #Hemp
Technical tax comment on federal marijuana bill
August 28, 2021 3:43 pm

The profit motive and medical marijuana in North Carolina

The profit motive and medical marijuana in North Carolina

Here are comments on North Carolina SB711 sent to Senators on the Health Committee.

++++

John D. Rockefeller, Jr., was a Baptist teetotaler who opposed alcohol and a Republican businessman who liked the profit motive.  When prohibition was repealed in 1933, Rockefeller didn’t want profit-maximizers retailing liquor.  For health and temperance, he said, let the states themselves sell liquor—and that’s the North Carolina way.  

This bill would let just 10 big companies sell medical cannabis.  If the recreational kind is legalized, those companies will say, “Hooray,” and line up to control the recreational market.  That’s the profit motive.

There’s a more restrictive way than SB711, proven in Canada: Sell medical cannabis only through government retailers—online only, delivered to the patient’s door.  No glitzy storefronts, no marketing to tempt the weak.  No lawsuits claiming cartoons and advertising are protected free speech under the North Carolina Constitution.

Marijuana sellers will say state-run sales are a nonstarter because marijuana is federally illegal, but that’s a diversion.  The federal government simply doesn’t care.  The State of Louisiana has been openly growing and selling marijuana for years – with impunity.  The federal government hasn’t batted an eye.

How about the voters?  In a 2013 North Carolina poll, state marijuana sales beat private sales by 3-to-1.  The full poll with cross-tabs is at https://newtax.files.wordpress.com/2013/03/nc-marijuana-polling-march-2013.pdf.

Sure, if state sales are inept and bureaucratic, the illegal market will step up.  But the kind of licensing proposed in SB711 creates a host of problems.  Medicine will be delayed as folks who didn’t get licenses go to court to protest.  Out-of-state interests will go to court to say the bill’s residence restrictions are unconstitutional.  Winning licensees will go to court to say the bill’s advertising rules improperly restrict free speech under the North Carolina Constitution.  Winning licensees may “flip” valuable licenses for huge sums – and shareholders in winning corporate licensees may “flip” their ownership interests to new shareholders – all for huge windfalls.  And naturally enough, winning licensees will aim to maximize sales and profits.

State sales are no easy answer, but they can be safe, quiet, and restrictive.  The profit motive has its place, but for marijuana, maybe North Carolina can restrict it.

+++

Thank you for this opportunity, and for listening to me and others.  


#CBD #Hemp
The profit motive and medical marijuana in North Carolina
August 28, 2021 2:25 pm

PubMed: Pharmacokinetic Investigation of Commercially Available Edible Marijuana Products in Humans: Potential Influence of Body Composition and Influence on Glucose Control

PubMed: Pharmacokinetic Investigation of Commercially Available Edible Marijuana Products in Humans: Potential Influence of Body Composition and Influence on Glucose Control

Pharmaceuticals (Basel). 2021 Aug 20;14(8):817. doi: 10.3390/ph14080817.

ABSTRACT

The purpose of the study was to describe and compare the pharmacokinetics of five commercial edible marijuana products, determine the influence of body composition on pharmacokinetics, and, in light of epidemiology suggesting marijuana may offer diabetes protection, explore the influence of edible marijuana on glucose tolerance. Seven regular users of marijuana self-administered five edible products in a randomized crossover design; each product contained 10 mg of delta-9-tetrahydrocannabinol (THC). Thirty minutes following marijuana ingestion, participants imbibed a 75 g glucose beverage. Time-to-peak plasma THC concentration ranged between 35 and 90 min; maximal plasma THC concentration (Cmax) ranged between 3.2 and 5.5 ng/mL. Differences between products in plasma THC concentration during the first 20-30 min were detected (p = 0.019). Relations were identified between body composition and pharmacokinetic parameters for some products; however, none of these body composition characteristics were consistently related to pharmacokinetics across all five of the products. Edible marijuana had no effect on oral glucose tolerance compared with a marijuana-free control (Matsuda Index; p > 0.395). Commercially available edible marijuana products evoke different plasma THC concentrations shortly after ingestion, but do not appear to influence acute glucose regulation. These data may allow recreational marijuana users to make informed decisions pertaining to rates of edible marijuana ingestion and avoid overdose.

PMID:34451914 | DOI:10.3390/ph14080817

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34451914/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210829065850&v=2.14.5 August 28, 2021 10:00 am

PubMed: Evidence for adverse effects of cannabidiol (CBD) products and their non-conformity on the European food market – response to the European Industrial Hemp Association

PubMed: Evidence for adverse effects of cannabidiol (CBD) products and their non-conformity on the European food market – response to the European Industrial Hemp Association

F1000Res. 2020 Aug 26;9:1051. doi: 10.12688/f1000research.26045.2. eCollection 2020.

ABSTRACT

An interesting and valuable discussion has arisen from our recent article (Lachenmeier et al., 2020) and we are pleased to have the opportunity to expand on the various points we made. Equally important, we wish to correct several important misunderstandings that were made by Kruse and Beitzke (2020) on behalf of the European Industrial Hemp Association (EIHA) that possibly contributed to their concerns about the validity of our data, toxicological assessment and conclusions regarding regulatory status of cannabidiol (CBD) products. First and foremost, our study did only assess the risk of psychotropic Δ 9-tetrahydrocannabinol (THC) without inclusion of non-psychotropic Δ 9-tetrahydrocannabinolic acid (THCA). Secondly, as this article will discuss in more detail, there is ample evidence for adverse effects of CBD products, not only in paediatric patients, but also in adult users of over-the-counter CBD products (including inadvertent “high” effects). Thirdly, the exposure and risk assessment was conducted using up-to-date guidelines according to the European Food Safety Authority (EFSA) and the German Federal Institute for Risk Assessment (BfR). And finally, the current legal situation in the European Union, without approval of any hemp extract-containing product according to the Novel Food regulation, actually allows blanket statements that all such products are illegal on the market, and this indeed would imply a general ban on the use and marketing of such products as food or food ingredients until such an approval has been granted. We hope that this reassures the F1000Research readership regarding the validity of our results and conclusions. We are pleased, though, that the EIHA has acknowledged the fact that there are non-compliant CBD products available, but according to our data these are a substantial fraction of the market.

PMID:33082934 | PMC:PMC7542252 | DOI:10.12688/f1000research.26045.2

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/33082934/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210828065943&v=2.14.5 August 27, 2021 10:00 am

PubMed: Cannabinoids Accumulation in Hemp (Cannabis sativa L.) Plants under LED Light Spectra and Their Discrete Role as a Stress Marker

PubMed: Cannabinoids Accumulation in Hemp (Cannabis sativa L.) Plants under LED Light Spectra and Their Discrete Role as a Stress Marker

Biology (Basel). 2021 Jul 24;10(8):710. doi: 10.3390/biology10080710.

ABSTRACT

Hemp adaptability through physiological and biochemical changes was studied under 10 LED light spectra and natural light in a controlled aeroponic system. Light treatments were imposed on 25 days aged seedlings for 16 h daily (300 µmol m-2 s-1) for 20 days. Plant accumulated highest Cannabidiol (CBD) in R7:B2:G1 light treatment, with relatively higher photosynthetic rate and lower reactive oxygen species, total phenol content, total flavonoid content, DPPH radical scavenging capacity, and antioxidant enzymatic activities. Tetrahydrocannabinol (THC) also accumulated at a higher level in white, R8:B2, and R7:B2:G1 light with less evidence of stress-modulated substances. These results indicated that CBD and THC have no or little relation with light-mediated abiotic stress in hemp plants. On the contrary, Tetrahydrocannabinolic acid (THCA) was accumulated higher in R6:B2:G1:FR1 and R5:B2:W2:FR1 light treatment along with lower photosynthetic rate and higher reactive oxygen species, total phenol content, total flavonoid content, DPPH radical scavenging capacity, and antioxidant enzymatic activities. However, Cannabidiolic acid (CBDA) was accumulated higher in R6:B2:G1:FR1 light treatment with higher stress-modulated substances and lower physiological traits. CBDA was also accumulated higher in R8:B2 and R7:B2:G1 light treatments with less evidence of stress-modulated substances. Besides, Greenlight influenced CBD and CBDA synthesis where FR and UV-A (along with green) play a positive and negative role in this process. Overall, the results indicated that the treatment R7:B2:G1 enhanced the medicinal cannabinoids most, and the role of THCA as a stress marker is more decisive in the hemp plant than in other cannabinoids under attributed light-mediated stress.

PMID:34439943 | DOI:10.3390/biology10080710

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34439943/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210827065926&v=2.14.5 August 27, 2021 10:00 am

ACS Laboratory Launches Tested Safe Certified Seal Program

ACS Laboratory Launches Tested Safe Certified Seal Program

ACS Laboratory, a cannabis and hemp testing lab based outside of Tampa Bay, Florida, announced the launch of their “Tested Safe Certified Seal” program. The program is designed to help raise standards and put more consumer trust in safe, tested products.

The “Tested Safe Certified Seal” on a hemp oil product

ACS Laboratory is an ISO 17025-accredited and DEA-licensed cannabis testing company founded in 2008. Last year they were certified by the Florida Department of Health to perform cannabis testing for state-licensed cannabis companies. In addition, the company acquired Botanica Testing, Inc. in 2020, adding more than 500 hemp and CBD clients to their portfolio. They now perform hemp testing for clients in more than 44 states.

The “Tested Safe Certified Seal” program allows companies to adorn their products with the trademarked seal following testing, informing consumers that their product has met safety standards and a full panel of compliance tests. “Unlike a mandated QR code that links to a Certificate of Analysis (COA) with detailed test results, the Seal shows visual proof at a glance that consumers can trust a brand,” reads the press release.

The program is also endorsed by the American Cannabinoid Association (ACA). “It is exciting to see our industry legally providing cannabis and cannabis-derived products on a commercial scale,” says Matthew Guenther, founder of the ACA. “As with any consumer product, safety and quality control remain our absolute priority.”

To earn the seal, companies send their products to the ACS lab for a full panel of safety and potency tests. ACS has a scope of services that includes: potency testing for 21 cannabinoids, 38 terpene profiles, 42 residual solvents, screening for 105 pesticides, moisture content, water activity, microbiology panels, heavy metals screening, flavonoid testing for 16 profiles, micronutrient testing, mycotoxins, Vitamin E acetate, shelf life & stability, plant regulators (PGRS), PAH testing and Pharmacokinetic Studies (PK) aka human trials.

The post ACS Laboratory Launches Tested Safe Certified Seal Program appeared first on Cannabis Industry Journal.


#CBD #Hemp

ACS Laboratory Launches Tested Safe Certified Seal Program


August 26, 2021 2:21 pm

ACS Laboratory Launches Tested Safe Certified Seal Program

ACS Laboratory Launches Tested Safe Certified Seal Program

ACS Laboratory, a cannabis and hemp testing lab based outside of Tampa Bay, Florida, announced the launch of their “Tested Safe Certified Seal” program. The program is designed to help raise standards and put more consumer trust in safe, tested products.

The “Tested Safe Certified Seal” on a hemp oil product

ACS Laboratory is an ISO 17025-accredited and DEA-licensed cannabis testing company founded in 2008. Last year they were certified by the Florida Department of Health to perform cannabis testing for state-licensed cannabis companies. In addition, the company acquired Botanica Testing, Inc. in 2020, adding more than 500 hemp and CBD clients to their portfolio. They now perform hemp testing for clients in more than 44 states.

The “Tested Safe Certified Seal” program allows companies to adorn their products with the trademarked seal following testing, informing consumers that their product has met safety standards and a full panel of compliance tests. “Unlike a mandated QR code that links to a Certificate of Analysis (COA) with detailed test results, the Seal shows visual proof at a glance that consumers can trust a brand,” reads the press release.

The program is also endorsed by the American Cannabinoid Association (ACA). “It is exciting to see our industry legally providing cannabis and cannabis-derived products on a commercial scale,” says Matthew Guenther, founder of the ACA. “As with any consumer product, safety and quality control remain our absolute priority.”

To earn the seal, companies send their products to the ACS lab for a full panel of safety and potency tests. ACS has a scope of services that includes: potency testing for 21 cannabinoids, 38 terpene profiles, 42 residual solvents, screening for 105 pesticides, moisture content, water activity, microbiology panels, heavy metals screening, flavonoid testing for 16 profiles, micronutrient testing, mycotoxins, Vitamin E acetate, shelf life & stability, plant regulators (PGRS), PAH testing and Pharmacokinetic Studies (PK) aka human trials.

The post ACS Laboratory Launches Tested Safe Certified Seal Program appeared first on Cannabis Industry Journal.


#CBD #Hemp

ACS Laboratory Launches Tested Safe Certified Seal Program


August 26, 2021 2:21 pm

CBD Use Associated With Improved Emotional Wellness

CBD Use Associated With Improved Emotional Wellness

We are living in the midst of some truly hard times. Due to the ongoing pandemic and many other factors, emotional wellness is something that many people struggle with.

It was estimated that roughly one out of every seven people globally struggled with mental health as of 2017, and it’s likely a safe bet that the problem has only gotten worse.

Emotional wellness is a subset of overall mental health, and is often described as a person’s ability to successfully navigate the stresses that come with life, and to be able to adapt to change during difficult times.

Depression has increased during the pandemic all over the world, as have anxiety and emotional exhaustion, and people are looking for ways to reduce that depression

According to the results of a new study, CBD may be able to help.

CBD And Emotional Wellness

A team of researchers in Brazil recently conducted a clinical trial to explore CBD’s relationship with depression, emotional exhaustion, and anxiety.

The clinical trial conducted by researchers with the University of São Paulo in Brazil involved a cohort of 120 ‘frontline health care professionals’ half of which were administered 300mgs of CBD daily and the other half having not used CBD.

“This randomized clinical trial found that the efficacy and safety of daily treatment with CBD, 300 mg, for 4 weeks combined with standard care was superior to standard care alone for reducing the symptoms of emotional exhaustion, anxiety, and depression among frontline health care professionals working with patients with COVID-19,” the study’s authors stated.

“Cannabidiol may act as an effective agent for the reduction of burnout symptoms among a population with important mental health needs worldwide.” the researchers concluded.

Talk To Your Doctor

It is worth noting that 5 of the cohort subjects that participated in the previously cited study had to drop out of the study due to adverse effects of the CBD products that were used.

That fact should serve as a reminder to people that they should always check with a medical professional prior to incorporating CBD into their treatment regimens, and cease use of CBD if complications arise.

With that being said, CBD helps far more people than it hurts, and there will always be someone that is allergic to just about anything, including certain cannabinoids.

Do your research, evaluate your own situation, and talk to a medical professional to make sure that CBD, or any other cannabinoid, is right for you.


#CBD #Hemp
https://cannatechtoday.com/cbd-use-associated-with-improved-emotional-wellness/
August 25, 2021 11:00 am

PubMed: Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications

PubMed: Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications

Cannabis Cannabinoid Res. 2021 Aug 24. doi: 10.1089/can.2020.0154. Online ahead of print.

ABSTRACT

Objective: The objective of this study was to evaluate the safety and efficacy of medications commonly used in autism spectrum disorder (ASD) and compare this to what current research has shown regarding medical cannabis use in this population. Methods: Searches were performed to collect information surrounding currently used medications and their safety and efficacy profiles, biologic plausibility of cannabis use for symptoms of ASD, and studies detailing cannabis’ safety and efficacy profile for use in the ASD population. Results were used to compare medications to cannabis as a proposed treatment. Results: The heterogeneity of ASD produces great difficulties in finding appropriate treatment, leading to many medication changes or treatment trials throughout a patient’s life. Commonly prescribed medications display varying levels of efficacy, safety, and tolerability between patients and symptoms targeted. Some of the most common side effects cited are also considered the most troubling symptoms associated with ASD; aggression, anxiety, irritability, and a negative effect on cognition, leading many patients to discontinue use as the side effects outweigh benefits. Recent case reports and retrospective studies have displayed the potential efficacy, safety, and tolerability of cannabidiol (CBD)-rich medical cannabis use for treating both core symptoms of ASD and many comorbid symptoms such as irritability and sleep problems. Studies have also identified circulating endocannabinoids as a possible biomarker for ASD, providing another possible method of diagnosis. Conclusions: Currently, there are no approved medications for the core symptoms of ASD and only two medications Food and Drug Administration approved for associated irritability. Prescribed medications for symptoms associated with ASD display varying levels of efficacy, safety, and tolerability among the heterogeneous ASD population. At the time of this study there are no published placebo-controlled trials of medical cannabis for ASD and the observational studies have limitations. CBD-rich medical cannabis seems to be an effective, tolerable, and relatively safe option for many symptoms associated with ASD, however, the long-term safety is unknown at this time.

PMID:34432543 | DOI:10.1089/can.2020.0154

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34432543/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210826065930&v=2.14.5 August 25, 2021 10:00 am

Growing a Competitive Advantage from Cultivation to Consumption

Growing a Competitive Advantage from Cultivation to Consumption

There are an increasing number of publicly-traded companies in the evolving North American cannabis sector, all vying for attention.

Yet for this industry to grow, it must embrace the principles of Environmental, Social, and Corporate Governance (ESG) Frameworks and navigate the risks and opportunities inherent in ESG issues.  

Corporations embrace ESG standards for a variety of reasons including access to capital, enhanced risk mitigation and value creation, greater social “license to operate,” customer acquisition, and employee retention.

Greater recognition of the competitive advantage linked to this approach is increasingly making ESG a business fundamental for companies across industry sectors. 

The risks of climate change have brought environmental management to the forefront as a business imperative.

For the cannabis industry, energy and water stewardship are two critical environmental issues all companies must be actively managing.

Estimated at approximately 40% of operational expenses, the energy required for plant cultivation, temperature control, and product manufacturing makes energy management a vital cost consideration.

As global temperatures and the frequency of severe weather events rise, so will the risks associated with energy stewardship and resilience.

Similarly, global water scarcity and its material impact on a wide range of industries make water stewardship a vital component to controlling costs and ensuring business continuity in the future.

Cannabis companies must implement a systematic approach to environmental management and resource stewardship across the value chain, from seed to storefront. 

As the multi-industrial applications for cannabis and hemp become better understood, the range of social risks and opportunities increase.

From a human capital perspective, companies will need employees with a broad range of skill sets and backgrounds to capitalize on the range of potential opportunities.

Developing a clear talent acquisition and retention strategy will become increasingly important.

Similarly, engagement and collaboration across stakeholder groups provide a range of opportunities.

From advancing economic inclusion for marginalized populations to revitalizing distressed rural farming communities, focused stakeholder engagement can mitigate reputational challenges while addressing operational needs and product commercialization.

Cannabis companies need a methodical and consistent approach to governance, especially given the rapid evolution of the industry and its regulatory landscape. A focus on governance prioritizes long-term business continuity amongst managing these risks. To manage the complexity inherent in engaging ESG issues across an enterprise, the composition of the board and management team, and their associated experiences, credentials, and effectiveness, can have a profound impact on ensuring ESG becomes a source of competitive advantage. 

Regennabis and Summit Strategy Group have partnered to provide a range of services that address the most pressing risks and opportunities facing the cannabis industry and the changing business landscape at large. The approach is based on a series of specific steps that all companies should follow when developing an effective ESG program; fig. 1 highlights some of the most critical: (see Fig 1. ESG Framework: a 5-Step Process). ϖ

To learn more, please contact [email protected].  

Fig 1

1. Understanding why ESG is critical to commercial success

• Identify the relevancy of ESG trends to your business model, industry, and stakeholder groups.

• Assess the competitive landscape and expectations from your key stakeholder groups.

2. Mapping an ESG journey that leads to desired business outcomes  

• A materiality assessment uncovers ESG threats that present financial risk to the business and opportunities to strengthen engagement with stakeholders.   

• Assess and understand what you are already doing to address these issues and clearly articulate your desired objectives moving forward.

• Create a shared vision of success and engage the stakeholders most relevant to this success to participate in the process.

3. Gauge how you are being perceived

• Evaluate how you are being assessed on ESG performance.

• What is your current reputation with stakeholders?  What are the potential risks associated with these stakeholders?

• Assess what is working well with your current reputation, what could be developed to support both perceptions of investment risk and ESG maturity, and the actions that must be taken and communicated to your key stakeholder groups.  

4. Develop an ESG strategy 

• Integrate material ESG issues into corporate strategy and risk management, ensuring clear targets and performance indicators are established, and the internal systems are in place to track that progress.

• Embed the ESG strategy into daily operations and stand up an internal governance structure to oversee enterprise implementation.

5. Communicate and Disclose

• Determine your priority audiences and the most important stakeholders to your business.

• Determine the right messages and methods for communicating this progress that speaks to the relevant issues and in the language known to your stakeholders.  Identify and align around the disclosure frameworks and communications cadence preferable to your key stakeholders.

• Communications, specifically with credible disclosure frameworks like SASB and TCFD, ensures the ESG strategy and accompanying narrative is clear, credible, and accurate, which in turn fortifies stakeholder trust and positively impacts corporate reputation and valuation.


#CBD #Hemp
https://cannatechtoday.com/growing-a-competitive-advantage-from-cultivation-to-consumption/
August 24, 2021 11:00 am

Growing a Competitive Advantage from Cultivation to Consumption

Growing a Competitive Advantage from Cultivation to Consumption

There are an increasing number of publicly-traded companies in the evolving North American cannabis sector, all vying for attention.

Yet for this industry to grow, it must embrace the principles of Environmental, Social, and Corporate Governance (ESG) Frameworks and navigate the risks and opportunities inherent in ESG issues.  

Corporations embrace ESG standards for a variety of reasons including access to capital, enhanced risk mitigation and value creation, greater social “license to operate,” customer acquisition, and employee retention.

Greater recognition of the competitive advantage linked to this approach is increasingly making ESG a business fundamental for companies across industry sectors. 

The risks of climate change have brought environmental management to the forefront as a business imperative.

For the cannabis industry, energy and water stewardship are two critical environmental issues all companies must be actively managing.

Estimated at approximately 40% of operational expenses, the energy required for plant cultivation, temperature control, and product manufacturing makes energy management a vital cost consideration.

As global temperatures and the frequency of severe weather events rise, so will the risks associated with energy stewardship and resilience.

Similarly, global water scarcity and its material impact on a wide range of industries make water stewardship a vital component to controlling costs and ensuring business continuity in the future.

Cannabis companies must implement a systematic approach to environmental management and resource stewardship across the value chain, from seed to storefront. 

As the multi-industrial applications for cannabis and hemp become better understood, the range of social risks and opportunities increase.

From a human capital perspective, companies will need employees with a broad range of skill sets and backgrounds to capitalize on the range of potential opportunities.

Developing a clear talent acquisition and retention strategy will become increasingly important.

Similarly, engagement and collaboration across stakeholder groups provide a range of opportunities.

From advancing economic inclusion for marginalized populations to revitalizing distressed rural farming communities, focused stakeholder engagement can mitigate reputational challenges while addressing operational needs and product commercialization.

Cannabis companies need a methodical and consistent approach to governance, especially given the rapid evolution of the industry and its regulatory landscape. A focus on governance prioritizes long-term business continuity amongst managing these risks. To manage the complexity inherent in engaging ESG issues across an enterprise, the composition of the board and management team, and their associated experiences, credentials, and effectiveness, can have a profound impact on ensuring ESG becomes a source of competitive advantage. 

Regennabis and Summit Strategy Group have partnered to provide a range of services that address the most pressing risks and opportunities facing the cannabis industry and the changing business landscape at large. The approach is based on a series of specific steps that all companies should follow when developing an effective ESG program; fig. 1 highlights some of the most critical: (see Fig 1. ESG Framework: a 5-Step Process). ϖ

To learn more, please contact [email protected].  

Fig 1

1. Understanding why ESG is critical to commercial success

• Identify the relevancy of ESG trends to your business model, industry, and stakeholder groups.

• Assess the competitive landscape and expectations from your key stakeholder groups.

2. Mapping an ESG journey that leads to desired business outcomes  

• A materiality assessment uncovers ESG threats that present financial risk to the business and opportunities to strengthen engagement with stakeholders.   

• Assess and understand what you are already doing to address these issues and clearly articulate your desired objectives moving forward.

• Create a shared vision of success and engage the stakeholders most relevant to this success to participate in the process.

3. Gauge how you are being perceived

• Evaluate how you are being assessed on ESG performance.

• What is your current reputation with stakeholders?  What are the potential risks associated with these stakeholders?

• Assess what is working well with your current reputation, what could be developed to support both perceptions of investment risk and ESG maturity, and the actions that must be taken and communicated to your key stakeholder groups.  

4. Develop an ESG strategy 

• Integrate material ESG issues into corporate strategy and risk management, ensuring clear targets and performance indicators are established, and the internal systems are in place to track that progress.

• Embed the ESG strategy into daily operations and stand up an internal governance structure to oversee enterprise implementation.

5. Communicate and Disclose

• Determine your priority audiences and the most important stakeholders to your business.

• Determine the right messages and methods for communicating this progress that speaks to the relevant issues and in the language known to your stakeholders.  Identify and align around the disclosure frameworks and communications cadence preferable to your key stakeholders.

• Communications, specifically with credible disclosure frameworks like SASB and TCFD, ensures the ESG strategy and accompanying narrative is clear, credible, and accurate, which in turn fortifies stakeholder trust and positively impacts corporate reputation and valuation.


#CBD #Hemp
https://cannatechtoday.com/growing-a-competitive-advantage-from-cultivation-to-consumption/
August 24, 2021 11:00 am

3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth

3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth

CBD demonstrated promising results in a recent case study on 35 people in the ‘Hair and Scalp’ center in Clearwater, Florida. After six months, the hair in the temporal area increased by 74.1% in men, and 55.2% in women. For the vertex, the findings show an increase of hair growth of 120.1% for men and 64.9% for women. 

Androgenetic alopecia (AGA) is a condition characterized by follicular miniaturization in a patterned hair loss occurring due to systemic androgen and genetic factors. It starts immediately after puberty, but the age of onset is usually 30s and 40s. According to research, 50% of Caucasian men and 19% of Caucasian women are confronted with hair loss, while its severity is lower in Asian and black people. Men and women have different patterns of hair loss – in men, it results in baldness at the top of the head, and in women, it usually occurs as diffuse thinning, while the frontal hair is preserved. Considering that the human population is heading towards eight billion, there is quite a number of bald heads in the world.

CBD could be a promising novel treatment for AGA, but a previous study has shown that the effects of CBD on human hair are strictly dose-dependent. Missing the exact dose, as always, could lead to the opposite effect – hair loss.

Research published in Cannabis, a publication of the Research Society on Marijuana gives some new clues about this important dosage. A study on 35 subjects (28 males, seven females) with androgenetic alopecia (AGA) using topical hemp extract with 3-4 mg of CBD once daily has shown a 93.5% increase in hair after six months. The topical extract in question has been made of high CBD Cannabis Sativa flower ultra-pulverized into a fine powder that contained 10.78% CBD, and 0.21% THC. The results revealed that men did slightly better than women, and the vertex area did better than the temporal areas.

How does it work in the body?

As the new study conducted by Gregory L. Smith and John Satino explains, CBD works through the endocannabinoid system (ECS) and shows some novel effects on hair follicle elongation and hair matrix keratinocytes activated through ECS receptors. Stimulating CB1 receptors, which are well expressed in the hair follicle cells, leads to decreased hair loss. Rodent studies have shown that the receptors targeted for hair loss are TRPV1. The phytocannabinoids such as THC and CBD message TRPV1 receptors. It is postulated that CBD has therapeutic effects through TRPV1 receptors, and THC has been shown to dose-dependently inhibit hair shaft elongation, decrease proliferation of hair matrix keratinocytes and induce intraepithelial apoptosis and premature hair follicle regression. The research shows that THC and other CB1 agonists can be used to manage unwanted hair growth, and CB1 antagonists, such as CBD and tetrahydrocannabivarin (THCV) or cannabidivarin (CBDV) can be used to promote hair growth.

CBD for hair loss: The lucky 35

The study is a case series of adults presenting to a ‘Hair and Scalp’ center in Clearwater Florida. Adult subjects, not currently using minoxidil or finasteride were offered the opportunity to receive the hemp oil extract free of charge through Facebook advertising. The first thirty-five subjects who responded were selected. The females were ages 46-76 (average age 61) and the males 28-72 (average age 43).

The subjects were given a topical extract in a 2 oz (around 60 ml) jar once a month and advised to apply a thin layer once each morning to the areas of baldness. The subjects were advised that they could use blow dryers, conditioners, and other hair preparations. The 2 oz topical was replaced as needed at monthly visits throughout the six-month trial. The amount used varied significantly based on the area of the scalp to be treated. None of the subjects used more than 2 oz in any one-month period. The chalk-like green powder produced from the hemp flowers was infused into a lanolin base paste and natural Emu oil carrier. Each 2 oz jar contained 1000 mg of the powder or 108 mg of CBD.

The hair counts in the temporal area increased an average of 74.1% in men, and 55.2% in women. In the vertex area, the hair counts increased an average of 120.1% for men, and 64.9% for women. One-third of the patients reported some slightly increased hair discharge during the first month of treatment, this was no longer was noted at the two-month visit. Otherwise, there were no reported adverse effects.

Although the mechanism of therapeutic effects is not entirely clear, this case study supports significant hair regrowth benefits in both men and women with AGA, the scientists conclude. Definitive research is planned.

The post 3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth appeared first on ilesol.


#CBD #Hemp

3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth


August 22, 2021 1:32 pm

3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth

3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth

CBD demonstrated promising results in a recent case study on 35 people in the ‘Hair and Scalp’ center in Clearwater, Florida. After six months, the hair in the temporal area increased by 74.1% in men, and 55.2% in women. For the vertex, the findings show an increase of hair growth of 120.1% for men and 64.9% for women. 

Androgenetic alopecia (AGA) is a condition characterized by follicular miniaturization in a patterned hair loss occurring due to systemic androgen and genetic factors. It starts immediately after puberty, but the age of onset is usually 30s and 40s. According to research, 50% of Caucasian men and 19% of Caucasian women are confronted with hair loss, while its severity is lower in Asian and black people. Men and women have different patterns of hair loss – in men, it results in baldness at the top of the head, and in women, it usually occurs as diffuse thinning, while the frontal hair is preserved. Considering that the human population is heading towards eight billion, there is quite a number of bald heads in the world.

CBD could be a promising novel treatment for AGA, but a previous study has shown that the effects of CBD on human hair are strictly dose-dependent. Missing the exact dose, as always, could lead to the opposite effect – hair loss.

Research published in Cannabis, a publication of the Research Society on Marijuana gives some new clues about this important dosage. A study on 35 subjects (28 males, seven females) with androgenetic alopecia (AGA) using topical hemp extract with 3-4 mg of CBD once daily has shown a 93.5% increase in hair after six months. The topical extract in question has been made of high CBD Cannabis Sativa flower ultra-pulverized into a fine powder that contained 10.78% CBD, and 0.21% THC. The results revealed that men did slightly better than women, and the vertex area did better than the temporal areas.

How does it work in the body?

As the new study conducted by Gregory L. Smith and John Satino explains, CBD works through the endocannabinoid system (ECS) and shows some novel effects on hair follicle elongation and hair matrix keratinocytes activated through ECS receptors. Stimulating CB1 receptors, which are well expressed in the hair follicle cells, leads to decreased hair loss. Rodent studies have shown that the receptors targeted for hair loss are TRPV1. The phytocannabinoids such as THC and CBD message TRPV1 receptors. It is postulated that CBD has therapeutic effects through TRPV1 receptors, and THC has been shown to dose-dependently inhibit hair shaft elongation, decrease proliferation of hair matrix keratinocytes and induce intraepithelial apoptosis and premature hair follicle regression. The research shows that THC and other CB1 agonists can be used to manage unwanted hair growth, and CB1 antagonists, such as CBD and tetrahydrocannabivarin (THCV) or cannabidivarin (CBDV) can be used to promote hair growth.

CBD for hair loss: The lucky 35

The study is a case series of adults presenting to a ‘Hair and Scalp’ center in Clearwater Florida. Adult subjects, not currently using minoxidil or finasteride were offered the opportunity to receive the hemp oil extract free of charge through Facebook advertising. The first thirty-five subjects who responded were selected. The females were ages 46-76 (average age 61) and the males 28-72 (average age 43).

The subjects were given a topical extract in a 2 oz (around 60 ml) jar once a month and advised to apply a thin layer once each morning to the areas of baldness. The subjects were advised that they could use blow dryers, conditioners, and other hair preparations. The 2 oz topical was replaced as needed at monthly visits throughout the six-month trial. The amount used varied significantly based on the area of the scalp to be treated. None of the subjects used more than 2 oz in any one-month period. The chalk-like green powder produced from the hemp flowers was infused into a lanolin base paste and natural Emu oil carrier. Each 2 oz jar contained 1000 mg of the powder or 108 mg of CBD.

The hair counts in the temporal area increased an average of 74.1% in men, and 55.2% in women. In the vertex area, the hair counts increased an average of 120.1% for men, and 64.9% for women. One-third of the patients reported some slightly increased hair discharge during the first month of treatment, this was no longer was noted at the two-month visit. Otherwise, there were no reported adverse effects.

Although the mechanism of therapeutic effects is not entirely clear, this case study supports significant hair regrowth benefits in both men and women with AGA, the scientists conclude. Definitive research is planned.

The post 3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth appeared first on ilesol.


#CBD #Hemp

3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth


August 22, 2021 1:32 pm

3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth

3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth

CBD demonstrated promising results in a recent case study on 35 people in the ‘Hair and Scalp’ center in Clearwater, Florida. After six months, the hair in the temporal area increased by 74.1% in men, and 55.2% in women. For the vertex, the findings show an increase of hair growth of 120.1% for men and 64.9% for women. 

Androgenetic alopecia (AGA) is a condition characterized by follicular miniaturization in a patterned hair loss occurring due to systemic androgen and genetic factors. It starts immediately after puberty, but the age of onset is usually 30s and 40s. According to research, 50% of Caucasian men and 19% of Caucasian women are confronted with hair loss, while its severity is lower in Asian and black people. Men and women have different patterns of hair loss – in men, it results in baldness at the top of the head, and in women, it usually occurs as diffuse thinning, while the frontal hair is preserved. Considering that the human population is heading towards eight billion, there is quite a number of bald heads in the world.

CBD could be a promising novel treatment for AGA, but a previous study has shown that the effects of CBD on human hair are strictly dose-dependent. Missing the exact dose, as always, could lead to the opposite effect – hair loss.

Research published in Cannabis, a publication of the Research Society on Marijuana gives some new clues about this important dosage. A study on 35 subjects (28 males, seven females) with androgenetic alopecia (AGA) using topical hemp extract with 3-4 mg of CBD once daily has shown a 93.5% increase in hair after six months. The topical extract in question has been made of high CBD Cannabis Sativa flower ultra-pulverized into a fine powder that contained 10.78% CBD, and 0.21% THC. The results revealed that men did slightly better than women, and the vertex area did better than the temporal areas.

How does it work in the body?

As the new study conducted by Gregory L. Smith and John Satino explains, CBD works through the endocannabinoid system (ECS) and shows some novel effects on hair follicle elongation and hair matrix keratinocytes activated through ECS receptors. Stimulating CB1 receptors, which are well expressed in the hair follicle cells, leads to decreased hair loss. Rodent studies have shown that the receptors targeted for hair loss are TRPV1. The phytocannabinoids such as THC and CBD message TRPV1 receptors. It is postulated that CBD has therapeutic effects through TRPV1 receptors, and THC has been shown to dose-dependently inhibit hair shaft elongation, decrease proliferation of hair matrix keratinocytes and induce intraepithelial apoptosis and premature hair follicle regression. The research shows that THC and other CB1 agonists can be used to manage unwanted hair growth, and CB1 antagonists, such as CBD and tetrahydrocannabivarin (THCV) or cannabidivarin (CBDV) can be used to promote hair growth.

CBD for hair loss: The lucky 35

The study is a case series of adults presenting to a ‘Hair and Scalp’ center in Clearwater Florida. Adult subjects, not currently using minoxidil or finasteride were offered the opportunity to receive the hemp oil extract free of charge through Facebook advertising. The first thirty-five subjects who responded were selected. The females were ages 46-76 (average age 61) and the males 28-72 (average age 43).

The subjects were given a topical extract in a 2 oz (around 60 ml) jar once a month and advised to apply a thin layer once each morning to the areas of baldness. The subjects were advised that they could use blow dryers, conditioners, and other hair preparations. The 2 oz topical was replaced as needed at monthly visits throughout the six-month trial. The amount used varied significantly based on the area of the scalp to be treated. None of the subjects used more than 2 oz in any one-month period. The chalk-like green powder produced from the hemp flowers was infused into a lanolin base paste and natural Emu oil carrier. Each 2 oz jar contained 1000 mg of the powder or 108 mg of CBD.

The hair counts in the temporal area increased an average of 74.1% in men, and 55.2% in women. In the vertex area, the hair counts increased an average of 120.1% for men, and 64.9% for women. One-third of the patients reported some slightly increased hair discharge during the first month of treatment, this was no longer was noted at the two-month visit. Otherwise, there were no reported adverse effects.

Although the mechanism of therapeutic effects is not entirely clear, this case study supports significant hair regrowth benefits in both men and women with AGA, the scientists conclude. Definitive research is planned.

The post 3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth appeared first on ilesol.


#CBD #Hemp

3-4 Mg of CBD Once a Day Brings 93.5% Increase in Hair Growth


August 22, 2021 1:32 pm

PubMed: Cellular distribution of cannabinoid-related receptors TRPV1, PPAR-gamma, GPR55 and GPR3 in the equine cervical dorsal root ganglia

PubMed: Cellular distribution of cannabinoid-related receptors TRPV1, PPAR-gamma, GPR55 and GPR3 in the equine cervical dorsal root ganglia

Equine Vet J. 2021 Aug 21. doi: 10.1111/evj.13499. Online ahead of print.

ABSTRACT

BACKGROUND: The activation of cannabinoid and cannabinoid-related receptors by endogenous, plant-derived or synthetic cannabinoids may exert beneficial effects on pain perception. Of the cannabinoids contained in Cannabis sativa, cannabidiol (CBD) does not produce psychotropic effects and seems to represent a molecule having great therapeutic potential. Cannabidiol acts on a great number of cannabinoid and cannabinoid-related G-protein coupled receptors and ionotropic receptors which have, to date, been understudied in veterinary medicine particularly in equine medicine.

OBJECTIVES: To localise the cellular distribution of four putative cannabinoid-related receptors in the equine cervical dorsal root ganglia (DRG).

STUDY DESIGN: A qualitative and quantitative immunohistochemical study.

METHODS: The cervical (C6-C8) DRG of six slaughtered horses were obtained from a local slaughterhouse. The tissues were fixed and processed for immunohistochemistry, and the resulting cryosections were used to investigate immunoreactivity for the following putative CBD receptors: Transient receptor potential vanilloid type 1 (TRPV1), nuclear peroxisome proliferator-activated receptor gamma (PPARγ), and G protein-coupled receptors 55 (GPR55) and 3 (GPR3).

RESULTS: Large percentages of neuronal cell bodies showed immunoreactivity for TRPV1 (80±20%), PPARγ (100%), GPR55 (64±15%), and GPR3 (63±11%). The satellite glial cells (SGCs) were immunoreactive for TRPV1, PPARγ and GPR55. In addition, GPR55 immunoreactivity was expressed by DRG interneuronal macrophages. In addition, microglia cells were observed surrounding the neuron-SGC complex.

MAIN LIMITATIONS: The limited number of horses included in the study.

CONCLUSIONS: Cannabinoid-related receptors were distributed in the sensory neurons (TRPV1, PPARγ, GPR55 and GPR3), SGCs (TRPV1, PPARγ and GPR55), macrophages (GPR55) and other interneuronal cells (PPARγ and GPR55) of the equine DRG. Given the key role of DRG cellular elements and cannabinoid receptors in the pathophysiology of pain, the present findings provided an anatomical basis for additional studies aimed at exploring the therapeutic uses of non-psychotropic cannabinoid agonists for the management of pain in horses.

PMID:34418142 | DOI:10.1111/evj.13499

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34418142/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210822065913&v=2.14.5 August 21, 2021 10:00 am

Quick Hits: This Week in Cannabis News

Quick Hits: This Week in Cannabis News

Seizures 

Humboldt County, a region infamously synonymous with the Shangri-la of cannabis cultivation, was caught in the crosshairs when law enforcement seized over 64,000 unregulated marijuana plants. 

According to a news release from the Humboldt County Sheriff’s Office, deputies from their Marijuana Enforcement Team (MET) conducted multiple investigations during the week of August 9-12 into illegal cannabis cultivation in watersheds determined to be critical spawning streams for various salmon, trout, and other types of fish. 

MET investigated numerous parcels during the service of the search warrants in the South Fork Trinity River, East Branch, Steelhead Creek, Mad River, Van Duzen, and Little Larrabee Creek/Van Duzen watersheds. 

None of the parcels investigated possessed the required county permit and state license to cultivate cannabis commercially.

In total, deputies eradicated over 64,000 illegally grown cannabis plants and documented approximately 79 environmental violations, including 42 water diversion violations, 24 depositing trash into waterway violations, and 13 water pollution violations. 

During the service of the search warrants, environmental scientists and law enforcement found and documented severe damage to the watersheds. 

Environmental scientists found numerous deceased wildlife and located Coastal Giant Salamander larvae in a water diversion pool.

Full story from the Times-Standard.  

Cannabis Grants 

In other Humboldt County news, Isabella Vanderheiden of the Times-Standard reports that Humboldt County announced more than $2 million in grant funding through Project Trellis, the county’s cannabis micro-grant, marketing, and local equity program. 

The grants are designated to assist the local cannabis community with entering into the commercial cannabis marketplace. 

Those eligible can apply for up to $10,000 “per service” per Humboldt County’s eligibility requirements for Project Trellis.

Applicants may download an application for the grant funding at the county’s website and send the application to [email protected].

Potential applicants may request a hard copy by contacting Project Trellis at +1 (707)-445-7745. 

Hard copies can be mailed or delivered to the County of Humboldt CAO’s Office of Economic Development, Attn: Project Trellis, 825 Fifth Street No. 112, Eureka, CA 95501.

Applications must be received or postmarked no later than 5 p.m. on September 17.

M & A 

Ayr Wellness, a vertically integrated cannabis multi-state operator (MSO), or dispensary chain, has entered into a binding letter of intent (LOI) to acquire Cultivauna, the owner of the Levia branded cannabis-infused seltzers and water-soluble tinctures. 

Both companies expect the acquisition to close by the fourth quarter (Q4) of 2021, with a purchase price of $20 million. 

Ayr intends to purchase 100% of the equity interests of Cultivauna, LLC. 

The transaction terms include $20 million in upfront consideration, comprising up to $10 million in cash with the remainder in stock. 

Ayr will provide an earn-out payment of up to an additional $40 million in shares based on achieving revenue targets in 2022 and 2023.

“Ayr Wellness is excited to join the rapidly-growing infused beverage segment through our Levia acquisition. We believe the opportunity to unlock a new consumer base through the beverage market is endless, and we look forward to continuing to make cannabis more approachable and sessionable through our high-quality products,” said Jonathan Sandelman, CEO of Ayr. 

Levia is currently available in Massachusetts in three flavors: “Achieve” Raspberry Lime (Sativa), “Celebrate” Lemon Lime (Hybrid), and “Dream” Jam Berry (Indica)

Each flavor is available in 12-ounce skinny cans that contain 5mg of THC

Levia is also available in water soluble tinctures in the same formulations.

Even though cannabis beverages have been hyped for years as the next exploding marketplace trend, beginning with Constellation Brands’ – makers of Corona beer– acquisition of Canadian cannabis company Canopy Growth, the market still hasn’t taken off according to various analysts’ predictions. 

While the category is growing, with unique brands including House of Saka, and Cannacraft’s Gem + Jane, the category as a whole, has yet to rival alcohol or cannabis flower for significant market share. 

Prohibition of Interstate cannabis commerce and the lack of state-by-state bottling plant manufacturing contracts currently hinder national launches of cannabevs. 

The market might see an explosion in this category once national distribution becomes available. 

In 2019, shrewd cannabis company Caliva acquired plant-based beverage company, Zola, to preeminently access its established beverage-to-supermarket distribution network and expand into the cannabis and hemp-based CBD (hCBD) beverage market.

Cannabis Trade Shows

The Cannabis Edibles Expo (CEE), presented by the Beverage Trade Network, is an excellent place to check out emerging cannabevs and infused confectionaries. 

Taking place in San Francisco on November 12, 2021, at the South San Francisco Conference Center, and in Chicago on November 16, 2021, at the Midwest Conference Center, the CEE gives MSOs and local dispensary buyers the chance to connect with established and emerging edibles brands. 


#CBD #Hemp
https://cannatechtoday.com/quick-hits-this-week-in-cannabis-news/
August 20, 2021 11:00 am

PubMed: Dioecious hemp (Cannabis sativa L.) plants do not express significant sexually dimorphic morphology in the seedling stage

PubMed: Dioecious hemp (Cannabis sativa L.) plants do not express significant sexually dimorphic morphology in the seedling stage

Sci Rep. 2021 Aug 19;11(1):16825. doi: 10.1038/s41598-021-96311-w.

ABSTRACT

Some economically important crop species are dioecious, producing pollen and ovules on distinct, unisexual, individuals. On-the-spot diagnosis of sex is important to breeders and farmers for crop improvement and maximizing yield, yet diagnostic tools at the seedling stage are understudied and lack a scientific basis. Understanding sexual dimorphism in juvenile plants may provide key ecological, evolutionary and economic insights into dioecious plant species in addition to improving the process of crop cultivation. To address this gap in the literature, we asked: can we reliably differentiate males, females, and co-sexual individuals based on seedling morphology in Cannabis sativa, and do the traits used to distinguish sex at this stage vary between genotypes? To answer these questions, we collected data on phenotypic traits of 112 C. sativa plants (50 female, 52 male, 10 co-sexuals) from two hemp cultivars (CFX-1, CFX-2) during the second week of vegetative growth and used ANOVAs to compare morphology among sexes. We found males grew significantly longer hypocotyls than females by week 2, but this difference depended on the cultivar investigated. Preliminary evidence suggests that co-sexual plants may be distinguished from male and female plants using short hypocotyl length and seedling height, although this relationship requires more study since sample sizes of co-sexual plants were small. In one of the cultivars, two-week old male plants tend to produce longer hypocotyls than other plants, which may help to identify these plants prior to anthesis. We call for increased research effort on co-sexual plants, given their heavy economic cost in industrial contexts and rare mention in the literature. Our preliminary data suggests that short hypocotyl length may be an indicator of co-sexuality. These results are the first steps towards developing diagnostic tools for predicting sex using vegetative morphology in dioecious species and understanding how sexual dimorphism influences phenotype preceding sexual maturity.

PMID:34413374 | DOI:10.1038/s41598-021-96311-w

#CBD #Hemp https://pubmed.ncbi.nlm.nih.gov/34413374/?utm_source=Chrome&utm_medium=rss&utm_campaign=None&utm_content=1jYCQzi_o_qLYr-oQfnMhShgOXkvGma3vcnBGJtrBhuJMOvEVJ&fc=None&ff=20210821065909&v=2.14.5 August 20, 2021 10:00 am